Cationic lipids and methods of use thereof

Novel cationic lipids and lipid particles enhance the delivery and activity of nucleic acids, addressing issues of nuclease susceptibility and toxicity, achieving efficient intracellular delivery and improved therapeutic efficacy.

JP2024161074AInactive Publication Date: 2024-11-15ARBUTUS BIOPHARMA CORPORAT ION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024141914
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2010-09-17
Filing Date
2024-08-23
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current nucleic acid delivery systems face challenges such as susceptibility to nuclease digestion, limited intracellular access, systemic toxicity, and inefficient delivery of therapeutic nucleic acids, particularly interfering RNA constructs like siRNA and miRNA, which require chemically modified linkers for stability but may reduce activity.

Method used

Development of novel cationic lipids and lipid particles, such as SNALPs, that encapsulate nucleic acids efficiently, providing protection from degradation, enhancing intracellular delivery, and reducing systemic toxicity, while maintaining therapeutic efficacy.

Benefits of technology

The novel cationic lipids and lipid particles improve the delivery and activity of nucleic acids, enabling effective gene silencing and protein downregulation with reduced toxicity, thus increasing the therapeutic index compared to previous compositions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161074000001
    Figure 2024161074000001
  • Figure 2024161074000002
    Figure 2024161074000002
  • Figure 2024161074000003
    Figure 2024161074000003
Patent Text Reader

Abstract

To provide: novel cationic (amino) lipids and lipid particles comprising these lipids, which are advantageous for the in vivo delivery of effective components, such as nucleic acids; nucleic acid-lipid particle compositions suitable for in vivo therapeutic use; methods for producing these compositions; and methods for introducing effective components, such as nucleic acids, and therapeutic agents into cells by using these compositions, e.g., for the treatment of various disease conditions.SOLUTION: This invention relates to cationic lipids expressed by formula I or its salt. (R1 and R2 are each independently H or C1-C6 alkyl, or the like; R3 is not present, or is H or C1-C6 alkyl, and provides a quaternary amine; R4 and R5 are each independently C10-C24 alkyl, or the like; X is O, S, C(O), C(O)O, or the like; Y is not present, or is optionally substituted C1-C6 alkyl, or the like).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 61 / 334,104, filed May 12, 2010, and U.S. Provisional Patent Application No. 61 / 384,050, filed September 17, 2010, the disclosures of which are incorporated by reference in their entireties herein for all purposes. [Background technology]

[0002] 2. Background of the Invention Therapeutic nucleic acids include, for example, small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, ribozymes, plasmids, and immunostimulatory nucleic acids. These nucleic acids act by a variety of mechanisms. In the case of interfering RNA molecules, such as siRNA and miRNA, these nucleic acids can downregulate the intracellular levels of specific proteins through a process called RNA interference (RNAi). After introducing the interfering RNA into the cytoplasm, these double-stranded RNA constructs can bind to a protein called RISC. The sense strand of the interfering RNA is released from the RISC complex, providing a template within the RISC that can recognize and bind to mRNAs that have a sequence complementary to that of the bound interfering RNA. Upon binding to the complementary mRNA, the RISC complex cleaves the mRNA and releases the cleaved strand. RNAi can provide downregulation of specific proteins by targeting the specific destruction of the corresponding mRNA that codes for protein synthesis.

[0003] Because interference RNA constructs can be synthesized to have any nucleotide sequence against target protein, the therapeutic application of RNAi is extremely broad.To date, siRNA constructs have shown the ability to specifically down-regulate target protein in both in vitro and in vivo models.In addition, siRNA constructs are currently being evaluated in clinical trials.

[0004] However, two problems currently facing interfering RNA constructs are, first, their susceptibility to nuclease digestion in plasma, and, second, their limited ability to access intracellular compartments where they can bind to RISC when administered systemically as free interfering RNA molecules. These double-stranded constructs can be stabilized by the incorporation of chemically modified nucleotide linkers, such as phosphothioate groups, within the molecule. However, such chemically modified linkers provide only limited protection from nuclease digestion and may reduce the activity of the construct. Intracellular delivery of interfering RNA can be facilitated by the use of carrier systems such as polymers, cationic liposomes, or by covalent attachment of cholesterol moieties to the molecule. However, improved delivery systems are needed to increase the potency of interfering RNA molecules such as siRNAs and miRNAs, and to alleviate or eliminate the requirement for chemically modified nucleotide linkers.

[0005] Additionally, there remain issues with the limited ability of therapeutic nucleic acids such as interfering RNA to cross cell membranes (see Vlassov et al., Biochim. Biophys. Acta, 1197:95-1082 (1994)), as well as issues associated with systemic toxicity such as complement-mediated anaphylaxis, altered coagulation properties, and cytopenias (Galbraith et al., Antisense Nucl. Acid Drug Des., 4:201-206 (1994)).

[0006] In an attempt to improve efficacy, researchers have also used lipid-based carrier systems to deliver chemically modified or unmodified therapeutic nucleic acids. Zelphati et al. (J. Contr. Rel., 41:99-119 (1996)) describe the use of anionic (conventional) liposomes, pH-sensitive liposomes, immunoliposomes, fusogenic liposomes, and cationic lipid / antisense aggregates. Similarly, siRNA has been systemically administered in cationic liposomes, and these nucleic acid-lipid particles have been reported to provide improved downregulation of target proteins in mammals, including non-human primates (Zimmermann et al., Nature, 441: 111-114 (2006)).

[0007] Despite this progress, there is still a need in the art for improved lipid-therapeutic nucleic acid compositions suitable for general therapeutic use. Preferably, these compositions encapsulate nucleic acids with high efficiency, have a high drug:lipid ratio, protect the encapsulated nucleic acid from degradation and clearance in serum, are suitable for systemic delivery, and provide intracellular delivery of the encapsulated nucleic acid. In addition, these nucleic acid-lipid particles should be well tolerated and provide a sufficient therapeutic index so that treatment of a patient with an effective dose of nucleic acid is not associated with significant toxicity and / or risk to the patient. The present invention provides such compositions, methods for making the compositions, and methods for using the compositions to introduce nucleic acids into cells for the treatment of disease. [Prior art documents] [Non-patent literature]

[0008] [Non-Patent Document 1] Vlassov et al., Biochim. Biophys. Acta, 1197:95-1082 (1994) [Non-Patent Document 2] Galbraith et al., Antisense Nucl. Acid Drug Des., 4:201-206 (1994) [Non-Patent Document 3] Zelphati et al., J. Contr. Rel., 41:99-119 (1996) [Non-Patent Document 4] Zimmermann et al., Nature, 441: 111-114 (2006) Summary of the Invention

[0009] BRIEF SUMMARY OF THE INVETION The present invention provides novel cationic (amino) lipids and lipid particles comprising these lipids that are advantageous for in vivo delivery of active ingredients or therapeutic agents, such as nucleic acids, as well as lipid particles, such as nucleic acid-lipid particle compositions, suitable for in vivo therapeutic applications. The present invention also provides methods for producing these lipid compositions, and methods for using these lipid compositions to introduce active ingredients or therapeutic agents, such as nucleic acids, into cells, for example, for the treatment of various diseases.

[0010] In one aspect, the present invention provides a cationic lipid of formula I having the structure: providing TIFF2024161074000001.tif29128, wherein: R 1 and R 2 are the same or different and are independently hydrogen (H) or an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; or R 1 and R 2 may be taken together to form an optionally substituted heterocycle; R 3 is absent or is hydrogen (H) or C1-C6 alkyl to provide a quaternary amine; R 4 and R 5 are the same or different and independently, optionally substituted C 10-C 24 Alkyl, C 10 -C 24 Alkenyl, C 10 -C 24 Alkynyl, or C 10 -C 24 is acyl; X is O, S, N(R 6 ), C(O), C(O)O, OC(O), C(O)N(R 6 ), N(R 6 )C(O),OC(O)N(R 6 ), N(R 6 )C(O)O, C(O)S, C(S)O, S(O), S(O)(O), C(S), or an optionally substituted heterocycle, where R 6 is hydrogen (H) or optionally substituted C1-C 10 Alkyl, C2-C 10 Alkenyl, or C2-C 10 alkynyl; and Y is absent or optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0011] In one embodiment, R 1 and R 2 are independently selected from the group consisting of methyl and ethyl groups, i.e., R 1 and R 2 Either both are methyl groups or R 1 and R 2 are both ethyl groups, or R 1 and R 2 is a combination of one methyl group and one ethyl group. 1 and R 2are taken together to form an optionally substituted heterocycle having 2-5 carbon atoms (e.g., 2, 3, 4, or 5 carbon atoms, or 2-5, 2-4, 2-3, 3-5, 3-4, or 4-5 carbon atoms) and 1-3 heteroatoms (e.g., 1, 2, or 3 heteroatoms, or 1-3, 1-2, or 2-3 heteroatoms) selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof. 1 and R 2 taken together form an optionally substituted diazole (eg, an optionally substituted imidazole) or an optionally substituted triazole.

[0012] In yet another embodiment, X is O, C(O)O, C(O)N(R 6 ), N(R 6 )C(O)O, or C(O)S. In some cases, R 6 is hydrogen (H), an optionally substituted methyl group, an optionally substituted ethyl group, or an optionally substituted C3-C 10 An alkyl group, an alkenyl group, or an alkynyl group (e.g., an optionally substituted C3, C4, C5, C6, C7, C8, C9, or C 10 In a further embodiment, X is an optionally substituted heterocycle having 2-5 carbon atoms (e.g., 2, 3, 4, or 5 carbon atoms, or 2-5, 2-4, 2-3, 3-5, 3-4, or 4-5 carbon atoms) and 1-3 heteroatoms (e.g., 1, 2, or 3 heteroatoms, or 1-3, 1-2, or 2-3 heteroatoms) selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof. In some cases, X is an optionally substituted diazole (e.g., an optionally substituted imidazole) or an optionally substituted triazole. In other embodiments, Y is (CH2) nwhere n is 0, 1, 2, 3, 4, 5, or 6. In certain embodiments, n is 2, 3, or 4 (e.g., n is 2 to 4, 2 to 3, or 3 to 4).

[0013] In one embodiment, optionally independently substituted R 4 and R 5 At least one of (e.g., R 4 and R 5 In certain embodiments, both R 4 and R 5 is independently selected from the group consisting of a dodecenyl moiety, a tetradecenyl (e.g., myristoleyl) moiety, a hexadecenyl (e.g., palmitoleyl) moiety, an octadecenyl (e.g., oleyl) moiety, and an icosenyl moiety. 4 Or R 5 One of the groups is an oleyl component or R 4 and R 5 In some embodiments, both of R 4 or R 5 One of the side chains contains one site of unsaturation as described herein, and the other side chain contains at least two or three sites of unsaturation.

[0014] In another embodiment, optionally independently substituted R 4 and R 5 At least one of (e.g., R 4 and R 5 In certain embodiments, both R 4 and R 5 is independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, and an icosadienyl moiety. In certain instances, the octadecadienyl moiety is a linoleyl moiety. In preferred embodiments, R 4 Or R 5 One of the two is a linoleyl component or R 4 and R 5In some embodiments, both of R 4 or R 5 In another embodiment, X is C(O)O, Y is (CH2)2 or (CH2)3, and R 4 and R 5 When both are linoleyl components, R 1 and R 2 Both cannot be methyl groups.

[0015] In yet another embodiment, optionally independently substituted R 4 and R 5 At least one of (e.g., R 4 and R 5 In certain embodiments, R 4 and R 5 is independently selected from the group consisting of dodecatrienyl, tetradecatrienyl, hexadecatrienyl, octadecatrienyl, and icosatrienyl moieties. In certain instances, the octadecatrienyl moiety is a linolenyl moiety or a γ-linolenyl moiety. In preferred embodiments, R 4 Or R 5 is a linolenyl or γ-linolenyl moiety, or R 4 and R 5 are linolenyl or γ-linolenyl moieties. 4 or R 5 One of the side chains contains three sites of unsaturation as described herein, and the other side chain contains at least four sites of unsaturation.

[0016] In a further embodiment, R 4 and R 5 At least one of (e.g., R 4 and R 5 Both of these are replaced by C 12 -C 24 In certain embodiments, substituted C 12-C 24 Alkyl is a C alkyl group having at least 1 to 6 C1-C6 alkyl substituents. 12 -C 24 In some cases, R 4 Or R 5 one of the groups is a phytanyl component or R 4 and R 5 In some embodiments, both of R 4 or R 5 One of them is the substituted C 12 -C 24 The other side chain contains at least 1, 2, or 3 sites of unsaturation as described herein.

[0017] In still yet another embodiment, R 4 or R 5 One of the groups includes at least one optionally substituted cyclic alkyl group. In certain embodiments, the optionally substituted cyclic alkyl group includes an optionally substituted saturated cyclic alkyl group, an optionally substituted unsaturated cyclic alkyl group, or a combination thereof. In some cases, the optionally substituted saturated cyclic alkyl group includes an optionally substituted C alkyl group, such as, for example, a cyclopropyl group. 3-8 In certain other cases, the optionally substituted unsaturated cyclic alkyl group is an optionally substituted C 3-8 In some embodiments, R 4 or R 5 one of which contains at least one optionally substituted cyclic alkyl group, and the other has a side chain which is optionally substituted as described herein. 10 -C 24 Alkyl, C 10 -C 24 Alkenyl, C 10 -C 24 Alkynyl, or C 10 -C 24 acyl groups (eg, side chains containing at least 1, 2, or 3 sites of unsaturation).

[0018] In some embodiments, R 4 and R 5 Each of the at least one, two, or three unsaturation sites present in one or both of 4 and R 5 In some cases, R 4 and R 5 may have any combination of double bonds in the cis and / or trans configuration at one or more positions in the side chain (e.g., C 18 C containing cis and / or trans double bonds in the 9-position, in the 6- and 9-position, in the 3-, 6-, and 9-position, in the 6-, 9-, and 12-position, or in the 7- and 9-position of the alkyl group 18 R is an alkyl group. 4 and R 5 It will be understood that the at least one, two, or three unsaturation sites present in one or both of the formulas may also be characterized by either the chemical symbol "E" and / or the chemical symbol "Z."

[0019] In certain embodiments, the cationic lipid of formula I is selected from the group consisting of compounds 4, 8, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and 45 described herein.

[0020] In a further aspect, the present invention provides lipid particles comprising one or more of the above cationic lipids of formula I or salts thereof. In some embodiments, the lipid particles further comprise one or more non-cationic lipids, such as neutral lipids. In some other embodiments, the lipid particles further comprise one or more conjugated lipids that can reduce or inhibit particle aggregation. In a further embodiment, the lipid particles further comprise one or more active ingredients or therapeutic agents.

[0021] In some embodiments, the non-cationic lipid component of the lipid particle may comprise a phospholipid, cholesterol (or cholesterol derivative), or a mixture thereof. In a particular embodiment, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. In some embodiments, the bound lipid component of the lipid particle comprises a polyethylene glycol (PEG)-lipid conjugate. In some cases, the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof. In other embodiments, the lipid conjugate comprises a polyoxazoline (POZ)-lipid conjugate, such as a POZ-DAA conjugate.

[0022] In some embodiments, the active ingredient or therapeutic agent comprises nucleic acid.In some cases, the nucleic acid comprises interfering RNA molecule, and the interfering RNA molecule comprises any double-stranded RNA that can mediate RNAi, such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, pre-miRNA, or mixture thereof.In some other cases, the nucleic acid comprises single-stranded or double-stranded DNA, RNA, or DNA / RNA hybrid, such as antisense oligonucleotide, ribozyme, plasmid, immunostimulatory oligonucleotide, or mixture thereof.

[0023] In other embodiments, the active ingredient or therapeutic agent is fully encapsulated within the lipid portion of the lipid particle such that the active ingredient or therapeutic agent in the lipid particle is resistant in aqueous solution to enzymatic degradation, e.g., by nucleases or proteases, hi further embodiments, the lipid particle is substantially non-toxic to mammals, such as humans.

[0024] In a preferred embodiment, the present invention provides serum-stable nucleic acid-lipid particles (SNALPs) comprising: (a) one or more nucleic acids, such as an interfering RNA molecule; (b) one or more cationic lipids of formula I, or salts thereof; (c) one or more non-cationic lipids; and (d) one or more binding lipids that inhibit aggregation of the particles.

[0025] In some embodiments, the invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I, or salts thereof, comprising about 50 mol% to about 85 mol% of the total lipid present in the particle; (c) one or more non-cationic lipids, comprising about 13 mol% to about 49.5 mol% of the total lipid present in the particle; and (d) one or more bound lipids that inhibit particle aggregation, comprising about 0.5 mol% to about 2 mol% of the total lipid present in the particle.

[0026] In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 50 mol% to about 65 mol% of the total lipid present in the particle; (c) one or more non-cationic lipids comprising a mixture of one or more phospholipids and cholesterol or a derivative thereof, wherein the one or more phospholipids constitute about 4 mol% to about 10 mol% of the total lipid present in the particle, and the cholesterol or a derivative thereof constitutes about 30 mol% to about 40 mol% of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 0.5 mol% to about 2 mol% of the total lipid present in the particle. The nucleic acid-lipid particle of this embodiment is generally referred to herein as a "1:57" formulation.

[0027] In some cases, the 1:57 formulation comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 52 mol% to about 62 mol% of the total lipids present in the particle; (c) a mixture of one or more phospholipids and cholesterol or a derivative thereof, which constitutes about 36 mol% to about 47 mol% of the total lipids present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 1 mol% to about 2 mol% of the total lipids present in the particle. In a particular embodiment, the 1:57 formulation is a four-component system comprising about 1.4 mol% of the PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol% of the cationic lipid of formula I or salt thereof, about 7.1 mol% of DPPC (or DSPC), and about 34.3 mol% of cholesterol (or a derivative thereof).

[0028] In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 56.5 mol% to about 66.5 mol% of the total lipids present in the particle; (c) cholesterol and / or one or more derivatives thereof, which constitute about 31.5 mol% to about 42.5 mol% of the total lipids present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 1 mol% to about 2 mol% of the total lipids present in the particle. The nucleic acid-lipid particle of this embodiment is generally referred to herein as a "1:62" formulation. In a particular embodiment, the 1:62 formulation is a three-component system that does not include phospholipids and includes about 1.5 mol% of PEG-lipid conjugates (e.g., PEG2000-C-DMA), about 61.5 mol% of cationic lipids of formula I or salts thereof, and about 36.9 mol% of cholesterol (or derivatives thereof).

[0029] Further aspects regarding the 1:57 and 1:62 formulations are described in WO 09 / 127060 and U.S. Patent Application Publication No. 20110071208, the disclosures of which are incorporated by reference herein in their entireties for all purposes.

[0030] In other embodiments, the invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I, or salts thereof, comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids, comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more bound lipids that inhibit particle aggregation, comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.

[0031] In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 30 mol% to about 50 mol% of the total lipids present in the particle; (c) a mixture of one or more phospholipids and cholesterol or derivatives thereof, which constitutes about 47 mol% to about 69 mol% of the total lipids present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 1 mol% to about 3 mol% of the total lipids present in the particle. The nucleic acid-lipid particle of this embodiment is generally referred to herein as a "2:40" formulation. In a particular embodiment, the 2:40 formulation is a four-component system comprising about 2 mol% of the PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 40 mol% of the cationic lipid of formula I or salts thereof, about 10 mol% of DPPC (or DSPC), and about 48 mol% of cholesterol (or derivatives thereof).

[0032] In a further embodiment, the invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I, or salts thereof, comprising from about 50 mol% to about 65 mol% of the total lipid present in the particle; (c) one or more non-cationic lipids, comprising from about 25 mol% to about 45 mol% of the total lipid present in the particle; and (d) one or more bound lipids that inhibit particle aggregation, comprising from about 5 mol% to about 10 mol% of the total lipid present in the particle.

[0033] In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 50 mol% to about 60 mol% of the total lipids present in the particle; (c) a mixture of one or more phospholipids and cholesterol or a derivative thereof, which constitutes about 35 mol% to about 45 mol% of the total lipids present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 5 mol% to about 10 mol% of the total lipids present in the particle. The nucleic acid-lipid particle of this embodiment is generally referred to herein as a "7:54" formulation. In some cases, the non-cationic lipid mixture in the 7:54 formulation comprises: (i) about 5 mol% to about 10 mol% of the phospholipids of the total lipids present in the particle; and (ii) about 25 mol% to about 35 mol% of the total lipids present in the particle. In one particular embodiment, the 7:54 formulation is a four-component system comprising about 7 mol% PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol% cationic lipid of formula I or a salt thereof, about 7 mol% DPPC (or DSPC), and about 32 mol% cholesterol (or a derivative thereof).

[0034] In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of formula I or salts thereof, which constitute about 55 mol% to about 65 mol% of the total lipids present in the particle; (c) cholesterol and / or one or more derivatives thereof, which constitute about 30 mol% to about 40 mol% of the total lipids present in the particle; and (d) one or more PEG-lipid conjugates, which constitute about 5 mol% to about 10 mol% of the total lipids present in the particle. The nucleic acid-lipid particle of this embodiment is generally referred to herein as a "7:58" formulation. In a particular embodiment, the 7:58 formulation is a three-component system that does not contain phospholipids and contains about 7 mol% of PEG-lipid conjugates (e.g., PEG750-C-DMA), about 58 mol% of cationic lipids of formula I or salts thereof, and about 35 mol% of cholesterol (or derivatives thereof).

[0035] Further aspects regarding the 7:54 and 7:58 formulations are described in U.S. Patent Application Publication No. 20110076335, the disclosure of which is incorporated by reference herein in its entirety for all purposes.

[0036] The present invention also provides pharmaceutical compositions comprising a lipid particle, such as a nucleic acid-lipid particle (eg, SNALP), and a pharma- ceutically acceptable carrier.

[0037] In another aspect, the invention provides a method for introducing one or more therapeutic agents, such as a nucleic acid, into a cell, comprising contacting the cell with a lipid particle (e.g., SNALP) described herein. In one embodiment, the cell is in a mammal, and the mammal is a human.

[0038] In yet another aspect, the present invention provides a method for in vivo delivery of one or more therapeutic agents, such as nucleic acids, comprising administering to a mammal a lipid particle (e.g., SNALP) as described herein. In some embodiments, the lipid particle (e.g., SNALP) is administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal. In certain embodiments, the lipid particle (e.g., SNALP) is administered systemically by enteral or parenteral routes of administration. In a preferred embodiment, the mammal is a human.

[0039] In a further aspect, the present invention provides a method for treating a disease or disorder in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of lipid particles (e.g., SNALP) comprising one or more therapeutic agents, such as nucleic acids.Non-limiting examples of diseases or disorders include viral infections, liver diseases or disorders, and cancer.Preferably, the mammal is a human.

[0040] In some embodiments, the present invention provides a method for treating liver disease or disorder by administering nucleic acid such as interference RNA (e.g. siRNA) in nucleic acid-lipid particle (e.g. SNALP) alone or in combination with hyperlipidemia drug.Examples of lipid disease and disorder include, but are not limited to, dyslipidemia (e.g. hyperlipidemia such as elevated triglyceride level (hypertriglyceridemia) and / or elevated cholesterol level (hypercholesterolemia)), atherosclerosis, coronary heart disease, coronary artery disease, atherosclerotic cardiovascular disease (CVD), fatty liver disease (steatosis), abnormal lipid metabolism, abnormal cholesterol metabolism, diabetes (including type 2 diabetes), obesity, cardiovascular disease, and other disorders related to abnormal metabolism.Non-limiting examples of hyperlipidemia drug include statins, fibrates, ezetimibe, thiazolidinedione, niacin, beta-blockers, nitroglycerin, calcium antagonists, and fish oil.

[0041] In a particular embodiment, the present invention provides a method for lowering or reducing cholesterol in a mammal (e.g., a human) in need of such a reduction (e.g., a mammal with elevated blood cholesterol levels), comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more interfering RNAs (e.g., siRNAs) that target one or more genes associated with metabolic diseases and disorders. In another particular embodiment, the present invention provides a method for lowering or reducing triglyceride levels in a mammal (e.g., a human) in need of such a reduction (e.g., a mammal with elevated blood triglyceride levels), comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) comprising one or more interfering RNAs (e.g., siRNAs) that target one or more genes associated with metabolic diseases and disorders. These methods can be carried out in vitro using standard tissue culture techniques, or in vivo by administering interfering RNAs (e.g., siRNAs) using any means known in the art. In a preferred embodiment, the interfering RNA (eg, siRNA) is delivered to liver cells (eg, hepatocytes) in a mammal, such as a human.

[0042] Further aspects relating to treating liver diseases or disorders with lipid particles are described, for example, in International Publication No. 2010 / 083615 and U.S. Patent Application Publication No. 20060134189, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0043] In another embodiment, the present invention provides a method for treating cell proliferation disorders such as cancer by administering nucleic acid such as interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP) alone or in combination with chemotherapeutic drugs.The method can be carried out in vitro using standard tissue culture techniques, or in vivo by administering interfering RNA (e.g., siRNA) using any means known in the art.In a preferred embodiment, interfering RNA (e.g., siRNA) is delivered alone or in combination with chemotherapeutic drugs to cancer cells in mammals such as humans.Nucleic acid-lipid particles and / or chemotherapeutic drugs can also be co-administered with conventional hormonal agents, immunotherapeutic agents, and / or radiotherapeutic agents.

[0044] Further aspects relating to treating cell proliferation disorders with lipid particles are described, for example, in International Publication No. WO 09 / 082817, U.S. Patent Application Publication No. 20090149403, International Publication No. WO 09 / 129319, and International Publication No. 2011 / 038160, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0045] In a further aspect, the present invention provides a method for preventing or treating viral infections, such as arenavirus (e.g., Lassa virus) infections or filovirus (e.g., Ebola virus, Marburg virus, etc.) infections that cause hemorrhagic fever, or hepatitis virus (e.g., Hepatitis C virus) infections that cause acute or chronic hepatitis, by administering nucleic acid, such as interfering RNA (e.g., siRNA), in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with administration of conventional agents used to treat or ameliorate viral conditions or any symptoms associated therewith.The method can be carried out in vitro using standard tissue culture techniques, or in vivo by administering interfering RNA using any means known in the art. In some preferred embodiments, the interfering RNA (e.g., siRNA) is delivered to cells, tissues, or organs of a mammal, such as a human, infected with and / or susceptible to hemorrhagic fever virus, such as reticuloendothelial cells (e.g., monocytes, macrophages, etc.), endothelial cells, liver cells (e.g., hepatocytes), fibroblasts, and / or platelet cells. In some other preferred embodiments, the interfering RNA (e.g., siRNA) is delivered to cells, tissues, or organs of a mammal, such as a human, infected with and / or susceptible to hepatitis virus, such as liver cells (e.g., hepatocytes).

[0046] Further aspects relating to the use of lipid particles to prevent or treat viral infections are described, for example, in U.S. Patent Application Publication No. 20070218122, U.S. Patent Application Publication No. 20070135370, International Publication Nos. 2011 / 011447, 2010 / 105372, and U.S. Patent Application No. 13 / 077,856, filed March 31, 2011, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0047] The lipid particles of the invention comprising one or more cationic lipids of formula I or salts thereof (e.g., SNALPs) are particularly advantageous and suitable for use in administering nucleic acids, such as interfering RNA, to a subject (e.g., a mammal such as a human) because they are stable in the circulation, are of the necessary size for pharmacodynamic behavior to provide access to extravascular sites, and are accessible to target cell populations.

[0048] Other objects, features and advantages of the present invention will become apparent to those skilled in the art from the following detailed description.

[0049] BRIEF DESCRIPTION OF THE DRAWINGS none DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] Detailed Description of the Invention I. Introduction The present invention is based in part on the discovery of novel cationic (amino) lipids that provide benefits when used in lipid particles for the in vivo delivery of active ingredients or therapeutic agents, such as nucleic acids, to mammalian cells.In particular, the present invention provides nucleic acid-lipid particle compositions that include one or more novel cationic lipids described herein, which provide increased activity of nucleic acids (e.g., interfering RNA) and improved in vivo tolerability of the compositions, thereby leading to a significant increase in therapeutic index compared to previously described nucleic acid-lipid particle compositions.

[0051] In certain embodiments, the present invention provides novel cationic lipids that allow the formulation of improved compositions for the in vitro and in vivo delivery of interference RNA such as siRNA.It is shown herein that these improved lipid particle compositions are effective for downregulating (e.g. silencing) the protein level and / or mRNA level of target gene.Furthermore, it is shown herein that the activity of these improved lipid particle compositions depends on the presence of the novel cationic lipids of the present invention.

[0052] The lipid particles and compositions of the present invention can be used for various purposes, for example, to deliver encapsulated or bound (e.g., complexed) therapeutic agents, such as nucleic acids, to cells, both in vitro and in vivo.Thus, the present invention further provides a method for treating disease or disorder in a subject in need of such treatment by contacting the subject with lipid particles that encapsulate or bind to a suitable therapeutic agent, wherein the lipid particles comprise one or more of the novel cationic lipids described herein.

[0053] The lipid particles of the present invention described herein are particularly useful for the delivery of nucleic acid, including, for example, interfering RNA molecules such as siRNA.Therefore, the lipid particles and compositions of the present invention can be used to reduce the expression of target genes and proteins both in vitro and in vivo by contacting cells with lipid particles comprising one or more novel cationic lipids described herein, wherein the lipid particles encapsulate or are combined with nucleic acids that reduce the expression of target genes (e.g., siRNA).Alternatively, the lipid particles and compositions of the present invention can be used to increase the expression of desired proteins both in vitro and in vivo by contacting cells with lipid particles comprising one or more novel cationic lipids described herein, wherein the lipid particles encapsulate or are combined with nucleic acids that increase the expression of desired proteins (e.g., the plasmid that codes for desired proteins).

[0054] Various exemplary embodiments of the cationic lipids of the present invention, lipid particles and compositions comprising same, and their use to deliver active ingredients or therapeutic agents, such as nucleic acids, and to regulate gene and protein expression, are described in further detail below.

[0055] II. Definition As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0056] The term "interfering RNA" or "RNAi" or "interfering RNA sequence" as used herein includes single-stranded RNA (e.g. mature miRNA, ssRNAi oligonucleotide, ssDNAi oligonucleotide), double-stranded RNA (i.e. double-stranded RNA such as siRNA, dicer substrate dsRNA, shRNA, aiRNA, or pre-miRNA), DNA-RNA hybrid (e.g. see WO 2004 / 078941), or DNA-DNA hybrid (e.g. see WO 2004 / 104199), which can reduce or inhibit the expression of a target gene or sequence (e.g. by mediating the degradation of the mRNA complementary to the interfering RNA sequence or by inhibiting translation) when the interfering RNA is in the same cell as the target gene or sequence. Thus, interfering RNA refers to a single-stranded RNA that is complementary to a target mRNA sequence, or a double-stranded RNA formed by two complementary strands or one self-complementary strand. The interfering RNA may have substantial or complete identity to the target gene or sequence, or may contain mismatched regions (i.e., mismatch motifs). The sequence of the interfering RNA may correspond to the full-length target gene or a subsequence thereof. Preferably, the interfering RNA molecule is chemically synthesized. The disclosures of each of the above patent documents are incorporated herein by reference in their entirety for all purposes.

[0057] Interfering RNA includes "small interfering RNA" or "siRNA", e.g., an interfering RNA that is about 15-60, 15-50, or 15-40 (duplex) nucleotides in length, more typically about 15-30, 15-25, or 19-25 (duplex) nucleotides in length, and preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length (e.g., double-stranded siRNAs). Each complementary sequence of is about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 nucleotides long, preferably about 20-24, 21-22, or 21-23 nucleotides long, and the double-stranded siRNA is about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 base pairs long, preferably about 18-22, 19-20, or 19-21 base pairs long). The siRNA duplex may include a 3' overhang of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and a 5' phosphate terminus. Examples of siRNA include, but are not limited to, double-stranded polynucleotide molecules assembled from two separate strand molecules, where one strand is sense strand and the other is complementary antisense strand; double-stranded polynucleotide molecules assembled from single strand molecules, where the sense and antisense regions are linked by nucleic acid-based or non-nucleic acid-based linker; double-stranded polynucleotide molecules with hairpin-type secondary structure with self-complementary sense and antisense regions; and circular single-stranded polynucleotide molecules with stems with two or more loop structures and self-complementary sense and antisense regions, where the circular polynucleotides can be processed in vivo or in vitro to produce active double-stranded siRNA molecules.The term "siRNA" used herein includes RNA-RNA duplexes and DNA-RNA hybrids (see, for example, WO2004 / 078941).

[0058] Preferably, the siRNA is chemically synthesized. siRNA can also be produced by cleaving longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with RNase III or Dicer from E. coli. These enzymes process dsRNA into biologically active siRNAs (see, e.g., Yang et al., Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al., Proc. Natl. Acad. Sci. USA, 99:14236 (2002); Byrom et al., Ambion TechNotes, 10(1):4-6 (2003); Kawasaki et al., Nucleic Acids Res., 31:981-987 (2003); Knight et al., Science, 293:2269-2271 (2001); and Robertson et al., J. Biol. Chem., 243:82 (1968)). Preferably, the dsRNA is at least 50 nucleotides long to about 100, 200, 300, 400, or 500 nucleotides long. The dsRNA can be 1000, 1500, 2000, 5000 nucleotides long or longer. The dsRNA can encode an entire gene transcript or a portion of a gene transcript. In some cases, the siRNA can be encoded by a plasmid (e.g., transcribed as a sequence that automatically folds into a duplex with a hairpin loop).

[0059] The term "mismatch motif" or "mismatch region" as used herein refers to a portion of an interfering RNA (e.g., siRNA) sequence that does not have 100% complementarity to its target sequence. An interfering RNA may have at least 1, 2, 3, 4, 5, 6 or more mismatch regions. The mismatch regions may be contiguous or separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides. A mismatch motif or mismatch region may comprise one nucleotide, or may comprise 2, 3, 4, 5 or more nucleotides.

[0060] The phrase "inhibit expression of a target gene" refers to the ability of a nucleic acid, such as an interfering RNA (e.g., siRNA), to silence, reduce, or inhibit expression of a target gene. To examine the degree of gene silencing, a test sample (e.g., a sample of cultured cells expressing a target gene) or a test mammal (e.g., a mammal, such as a human, or an animal model, such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model) is contacted with a nucleic acid, such as an interfering RNA (e.g., siRNA), that silences, reduces, or inhibits expression of a target gene. The expression of the target gene in the test sample or test animal is compared with the expression of the target gene in a control sample (e.g., a sample of cultured cells expressing a target gene) or a control mammal (e.g., a mammal, such as a human, or an animal model, such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model) that is not contacted or administered with a nucleic acid (e.g., an interfering RNA). The expression of the target gene in the control sample or control mammal can be assigned a value of 100%. In certain aspects, silencing, inhibition, or reduction of expression of the target gene is achieved when the expression level of the target gene in a test sample or test mammal is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0% of the expression level of the target gene in a control sample or control mammal. In other words, the nucleic acid (e.g., interfering RNA) can silence, reduce or inhibit expression of the target gene in a test sample or test mammal by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to the expression level of the target gene in a control sample or control mammal that has not been contacted with or administered the nucleic acid (e.g., interfering RNA).Suitable assays for measuring the expression level of a target gene include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, for example, dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, and phenotypic assays known to those of skill in the art.

[0061] An "effective amount" or "therapeutically effective amount" of an active agent or therapeutic agent, such as a therapeutic nucleic acid (e.g., an interfering RNA, such as siRNA), is an amount sufficient to produce a desired effect, such as inhibition of the expression of a target sequence, compared to the normal expression level detected in the absence of the nucleic acid (e.g., an interfering RNA). Inhibition of the expression of a target gene or target sequence is achieved when the value obtained using a nucleic acid, such as an interfering RNA (e.g., siRNA), is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0% of the control. Suitable assays for measuring the expression of a target gene or target sequence include, for example, testing protein or RNA levels using techniques known to those skilled in the art, such as dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, and phenotypic assays known to those skilled in the art.

[0062] "Reduce", "reduce", "reduce" or "reduce" an immune response by a nucleic acid such as an interfering RNA (e.g., siRNA) is intended to mean a detectable decrease in the immune response to a given nucleic acid (e.g., a modified interfering RNA). In some examples, the amount of reduction in the immune response by a nucleic acid such as a modified interfering RNA can be measured relative to the level of the immune response in the presence of an unmodified interfering RNA. As a non-limiting example, the detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more lower than the immune response detected in the presence of an unmodified interfering RNA. A reduced immune response to a nucleic acid (e.g., an interfering RNA) is typically measured by a reduction in in vitro production of a cytokine (e.g., IFNγ, IFNα, TNFα, IL-6, IL-8, or IL-12) by responder cells, or a reduction in the production of cytokines in the serum of a mammalian subject following administration of the nucleic acid (e.g., an interfering RNA).

[0063] The term "responder cell" as used herein refers to a cell, preferably a mammalian cell, that generates a detectable immune response when contacted with an immunostimulatory nucleic acid, such as an unmodified interfering RNA (e.g., an unmodified siRNA). Examples of responder cells include, but are not limited to, dendritic cells, macrophages, peripheral blood mononuclear cells (PBMCs), spleen cells, and the like. Detectable immune responses include, for example, the production of cytokines or growth factors, such as TNF-α, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, TGF, and combinations thereof. Detectable immune responses also include, for example, the induction of interferon-inducible protein 1 (IFIT1) mRNA with tetratricopeptide repeats.

[0064] The term "nucleic acid" as used herein refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides, in either single-stranded or double-stranded form, including DNA, RNA, and hybrids thereof. DNA can be in the form of, for example, antisense molecules, plasmid DNA, DNA-DNA duplexes, pre-condensed DNA, PCR products, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. RNA can be in the form of small interfering RNA (siRNA), dicer substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include synthetic, natural, and non-natural nucleic acids that contain known nucleotide analogs or modified backbone residues or linkages that have similar binding properties to the reference nucleic acid. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs).Unless specifically limited, this term encompasses nucleic acids that contain known analogs of natural nucleotides that have similar binding properties to the reference nucleic acid.Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses not only the sequence specified, but also its conservatively modified variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences. Specifically, degenerate codon substitutions can be achieved by producing sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)).A "nucleotide" contains the sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate group. "Base" includes purines and pyrimidines, which further include the naturally occurring compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, as well as synthetic derivatives of purines and pyrimidines, including but not limited to modifications that place new reactive groups, such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkyl halides.

[0065] The term "gene" refers to a nucleic acid (eg, DNA or RNA) sequence that comprises a partial or full-length coding sequence necessary for the production of a polypeptide or precursor polypeptide.

[0066] As used herein, "gene product" refers to a gene product such as an RNA transcript or a polypeptide.

[0067] The term "lipid" refers to a group of organic compounds, including but not limited to fatty acid esters, that are insoluble in water but soluble in many organic solvents. They are commonly divided into at least three classes: (1) "simple lipids," which include fats, oils, and waxes; (2) "complex lipids," which include phospholipids and glycolipids; and (3) "derived lipids," such as steroids.

[0068] The term "lipid particle" includes lipid formulations that can be used to deliver active or therapeutic agents such as nucleic acid (e.g., interfering RNA) to target sites of interest (e.g., cells, tissues, organs, tumors, etc.).In a preferred embodiment, the lipid particle of the present invention is a nucleic acid-lipid particle that is typically formed from cationic lipid, non-cationic lipid, and optional binding lipid that inhibits particle aggregation.In another preferred embodiment, active or therapeutic agents such as nucleic acid (e.g., interfering RNA) can be protected from enzymatic degradation by being encapsulated in the lipid portion of the particle.

[0069] The term "SNALP" as used herein refers to a stable nucleic acid-lipid particle. SNALP is a particle made of lipid (e.g., cationic lipid, non-cationic lipid, and any binding lipid that inhibits particle aggregation), and nucleic acid (e.g., interfering RNA) is completely encapsulated within the lipid. In some cases, SNALP can show extended circulation life after intravenous (iv) injection, can accumulate at distant sites (e.g., sites physically separated from the administration site), and can mediate the silencing of target gene expression at these distant sites, making them extremely useful for systemic application. As shown in WO 00 / 03683, nucleic acid can be complexed with a condensing agent and encapsulated within SNALP, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0070] The lipid particles of the present invention (e.g., SNALP) typically have a diameter of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 to about 90 nm, about 80 nm to about 90 nm, about 70 nm to about 80 nm The nucleic acid has an average diameter of about 30nm, 35nm, 40nm, 45nm, 50nm, 55nm, 60nm, 65nm, 70nm, 75nm, 80nm, 85nm, 90nm, 95nm, 100nm, 105nm, 110nm, 115nm, 120nm, 125nm, 130nm, 135nm, 140nm, 145nm, or 150nm, and is substantially non-toxic.In addition, when present in the lipid particles of the present invention, the nucleic acid is resistant to degradation by nucleases in aqueous solution.Nucleic acid-lipid particles and their preparation methods are disclosed, for example, in US Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0071] As used herein, "encapsulated lipid" can refer to a lipid particle that provides an active or therapeutic agent, such as a nucleic acid (e.g., an interfering RNA such as siRNA), that is fully encapsulated, partially encapsulated, or both. In preferred embodiments, the nucleic acid (e.g., an interfering RNA) is fully encapsulated in the lipid particle (e.g., to form a SNALP or other nucleic acid-lipid particle).

[0072] The term "lipid conjugate" refers to a bound lipid that inhibits lipid particle aggregation. Such lipid conjugates include, but are not limited to, PEG-lipid conjugates, such as PEG coupled with dialkyloxypropyl (e.g., PEG-DAA conjugates), PEG coupled with diacylglycerol (e.g., PEG-DAG conjugates), PEG coupled with cholesterol, PEG coupled with phosphatidylethanolamine, and PEG coupled with ceramide (e.g., see U.S. Pat. No. 5,885,613), cationic PEG lipids, polyoxazoline (POZ)-lipid conjugates (e.g., POZ-DAA conjugates; see U.S. Pat. App. No. 13 / 006,277, filed Jan. 13, 2011), polyamide oligomers (e.g., ATTA-lipid conjugates), and mixtures thereof. Additional examples of POZ-lipid conjugates are described in WO 2010 / 006282. PEG or POZ can be directly bound to lipid or can be linked to lipid via linker moiety.Any suitable linker moiety can be used for coupling PEG or POZ to lipid, including non-ester-containing linker moiety and ester-containing linker moiety.In some preferred embodiments, non-ester-containing linker moiety such as amide or carbamate is used.The disclosures of each of the above patent documents are incorporated herein by reference in their entirety for all purposes.

[0073] The term "amphiphilic lipid" refers in part to any suitable material in which the hydrophobic portion of the lipid material is oriented toward the hydrophobic phase, while the hydrophilic portion is oriented toward the aqueous phase. The hydrophilic character comes from the presence of polar or charged groups, such as carbohydrate, phosphate, carboxyl, sulfate, amino, sulfhydryl, nitro, hydroxyl, and other equivalent groups. Hydrophobicity can be imparted by the inclusion of non-polar groups, including but not limited to long chain saturated and unsaturated aliphatic hydrocarbon groups, and such groups substituted with one or more aromatic, alicyclic, or heterocyclic groups. Examples of amphiphilic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.

[0074] Representative examples of phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine.Other compounds that lack phosphorus, such as sphingolipids, glycosphingolipid families, diacylglycerols, and β-acyloxyacids, are also included in the group designated as amphipathic lipids.In addition, the above amphipathic lipids can be mixed with other lipids, including triglycerides and sterols.

[0075] The term "neutral lipid" refers to any of several lipid species that exist in either an uncharged form or a neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerol.

[0076] The term "non-cationic lipid" refers to any amphipathic lipid and any other neutral or anionic lipid.

[0077] The term "anionic lipid" refers to any lipid that has a negative charge at physiological pH. These lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine, lysylphosphatidylglycerol, palmitoyloleoylphosphatidylglycerol (POPG), and other anionic modifying groups combined with neutral lipids.

[0078] The term "hydrophobic lipid" refers to compounds having apolar groups, including, but not limited to, saturated and unsaturated long chain aliphatic hydrocarbon groups, which may be substituted with one or more aromatic, alicyclic, or heterocyclic groups. Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N-dialkylamino, 1,2-diacyloxy-3-aminopropane, and 1,2-dialkyl-3-aminopropane.

[0079] The term "fusogenic" refers to the ability of a lipid particle, such as a SNALP, to fuse with a membrane of a cell. The membrane can be either the plasma membrane or a membrane surrounding an organelle, such as an endosome, nucleus, etc.

[0080] As used herein, the term "aqueous solution" refers to a composition that comprises, in whole or in part, water.

[0081] As used herein, the term "organic lipid solution" refers to a composition that comprises, in whole or in part, an organic solvent having lipids.

[0082] As used herein, a "distant site" refers to a physically isolated site, including sites distributed widely throughout the organism, including but not limited to adjacent capillary beds.

[0083] "Serum stability" in the context of nucleic acid-lipid particles such as SNALP means that the particles are not significantly degraded after exposure to serum or nuclease assays that can significantly degrade free DNA or RNA. Suitable assays include, for example, standard serum assays, DNAse assays, or RNAse assays.

[0084] "Systemic delivery" as used herein refers to delivery of lipid particles that results in broad biodistribution of active agents, such as interfering RNA (e.g., siRNA) in vivo. Some administration techniques may lead to systemic delivery of an agent, while others do not. Systemic delivery means that a useful amount, preferably a therapeutic amount, of the agent is exposed to most of the body. To achieve broad biodistribution, the agent generally requires a blood lifespan that does not undergo rapid degradation and clearance (such as by first-pass organs (liver, lung, etc.) or rapid non-specific cell binding) before reaching disease sites distal to the administration site. Systemic delivery of lipid particles can be performed by any means known in the art, including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.

[0085] As used herein, "localized delivery" refers to the direct delivery of an active agent, such as an interfering RNA (e.g., siRNA), to a target site in the body. For example, the agent can be locally delivered by direct injection to a disease site, such as a tumor, or other target site, such as an inflammation site, or to a target organ, such as the liver, heart, pancreas, kidney, etc.

[0086] The term "mammal" refers to any mammalian species, such as humans, mice, rats, dogs, cats, hamsters, guinea pigs, rabbits, farm animals, and the like.

[0087] The term "cancer" refers to any member of a class of diseases characterized by uncontrolled proliferation of abnormal cells. The term includes all known cancers and tumor conditions, whether characterized as malignant, benign, soft tissue or solid, and all stages and grades of cancer, including pre-metastatic and post-metastatic cancers. Examples of different types of cancer include, but are not limited to, liver cancer, lung cancer, colon cancer, rectal cancer, anal cancer, bile duct cancer, small intestine cancer, stomach cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, appendix cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, kidney cancer (e.g., renal cell carcinoma), cancer of the central nervous system, glioblastoma, skin cancer, lymphoma, choriocarcinoma, head and neck cancer, osteogenic sarcoma, and blood cancer. Non-limiting examples of specific types of liver cancer include hepatocellular carcinoma (HCC), secondary liver cancer (e.g., those resulting from metastasis of some other types of non-hepatic cancer cells), and hepatoblastoma. As used herein, a "tumor" includes one or more cancer cells.

[0088] III. Novel cationic lipids The present invention provides, inter alia, novel cationic (amino) lipids that can be advantageously used in the lipid particles described herein for in vitro and / or in vivo delivery of therapeutic agents, such as nucleic acids, to cells. The novel cationic lipids of the present invention have the structure shown in Formula I herein, including the (R) and / or (S) enantiomers thereof.

[0089] In some embodiments, the lipids of the present invention comprise racemic mixtures. In other embodiments, the lipids of the present invention comprise mixtures of one or more diastereomers. In some embodiments, the lipids of the present invention are enriched in one enantiomer, such that the lipids of the present invention comprise at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% enantiomeric excess. In some other embodiments, the lipids of the present invention are enriched in one diastereomer, such that the lipids of the present invention comprise at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% diastereomeric excess. In some further embodiments, the lipids of the present invention are chirally pure (e.g., comprise a single optical isomer). In further embodiments, the lipids of the present invention are enriched in one optical isomer (e.g., an optically active isomer) such that the lipids contain at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% isomeric excess. The present invention provides for the synthesis of cationic lipids of formula I as racemic mixtures or in optically pure form.

[0090] The terms "cationic lipid" and "amino lipid" are used interchangeably herein to include lipids and their salts having one, two, three or more fatty acid or aliphatic alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group). Cationic lipids are typically selected from the group consisting of lipids having a pH-titratable amino head group and a pH-titratable amino head group, and their salts. a It is protonated (i.e. positively charged) at a pH below pK a The cationic lipids of the present invention are also sometimes referred to as titratable cationic lipids.

[0091] The term "salt" includes any anionic / cationic complex, such as a complex formed between a cationic lipid disclosed herein and one or more anions. Non-limiting examples of anions include inorganic and organic anions, such as hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylamide, carboxylate ... Cationic lipid salts include aryl acid salt, fumarate acid salt, maleate acid salt, itaconate acid salt, glycolate acid salt, gluconate acid salt, malate acid salt, mandelate acid salt, tiglate acid salt, ascorbate acid salt, salicylate acid salt, polymethacrylate acid salt, perchlorate acid salt, chlorate acid salt, chlorite acid salt, hypochlorite acid salt, bromate acid salt, hypobromite acid salt, iodate acid salt, alkylsulfonate acid salt, arylsulfonate acid salt, arsenate acid salt, arsenite acid salt, chromate acid salt, dichromate acid salt, cyanide acid salt, cyanate acid salt, thiocyanate acid salt, hydroxide acid salt, peroxide acid salt, permanganate acid salt, and mixtures thereof.In certain embodiments, the salt of cationic lipid disclosed herein is a crystalline salt.

[0092] The term "alkyl" includes straight or branched, non-cyclic or cyclic, saturated aliphatic hydrocarbons containing 1 to 24 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like, while saturated branched alkyls include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include, but are not limited to, the C cyclic alkyls described herein. 3-8Cycloalkyls include, but are not limited to, cycloalkyls as described herein, while unsaturated cyclic alkyls include, but are not limited to, C 3-8 Cycloalkenyl is included.

[0093] The term "heteroalkyl" includes linear or branched, acyclic or cyclic saturated aliphatic hydrocarbons, as defined above, having from about 1 to about 5 heteroatoms (i.e., 1, 2, 3, 4, or 5 heteroatoms), such as, for example, O, N, Si, and / or S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. Heteroalkyl groups can be attached to the remainder of the molecule via a carbon atom or a heteroatom.

[0094] The term "cyclic alkyl" includes any of the substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups described below.

[0095] The term "cycloalkyl" includes substituted or unsubstituted cyclic alkyl groups having from about 3 to about 8 carbon atoms (i.e., 3, 4, 5, 6, 7, or 8 carbon atoms) as ring vertices. Preferred cycloalkyl groups include cycloalkyl groups having from about 3 to about 6 carbon atoms as ring vertices. 3-8 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, methyl-cyclopropyl, dimethyl-cyclopropyl, cyclobutyl, methyl-cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, methyl-cyclohexyl, dimethyl-cyclohexyl, cycloheptyl, and cyclooctyl, as well as other substituted C 3-8 Cycloalkyl groups are included.

[0096] The term "heterocycloalkyl" includes substituted or unsubstituted cyclic alkyl groups, as defined above, having from about 1 to about 3 ring members selected from the group consisting of O, N, Si and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. Heterocycloalkyl groups can be attached to the remainder of the molecule via a carbon atom or a heteroatom.

[0097] The term "cycloalkenyl" includes substituted or unsubstituted cyclic alkenyl groups having about 3 to about 8 carbon atoms (i.e., 3, 4, 5, 6, 7, or 8 carbon atoms) as ring vertices. Preferred cycloalkenyl groups are those having about 3 to about 6 carbon atoms as ring vertices. 3-8 Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, methyl-cyclopropenyl, dimethyl-cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl, as well as other substituted C 3-8 Cycloalkenyl groups are included.

[0098] The term "heterocycloalkenyl" includes substituted or unsubstituted cyclic alkenyl groups, as defined above, having from about 1 to about 3 ring members selected from the group consisting of O, N, Si and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. Heterocycloalkenyl groups can be attached to the remainder of the molecule via a carbon atom or a heteroatom.

[0099] The term "alkoxy" includes groups of the formula: alkyl-O-, where "alkyl" is defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

[0100] The term "alkenyl" includes alkyl as defined above containing at least one double bond between adjacent carbon atoms. Alkenyl includes both cis and trans isomers. Representative straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like. Representative cyclic alkenyls are described above.

[0101] The term "alkynyl" includes any alkyl or alkenyl as defined above that additionally contains at least one triple bond between adjacent carbon atoms. Representative straight chain and branched alkynyls include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1 butynyl, and the like.

[0102] The term "aryl" includes polyunsaturated (typically aromatic) hydrocarbon groups that may be a single ring or multiple rings (up to three rings) fused or covalently linked together, and may bear one or more substituents, such as, for example, halogen, trifluoromethyl, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitro, etc. Non-limiting examples of unsubstituted aryl groups include phenyl, naphthyl, and biphenyl. Non-limiting examples of substituted aryl groups include phenyl, chlorophenyl, trifluoromethylphenyl, chlorofluorophenyl, and aminophenyl.

[0103] The terms "alkylthio", "alkylsulfonyl", "alkylsulfinyl" and "arylsulfonyl" include groups of the formula: -SR i , -S(O)2-R i , -S(O)-R iand -S(O)R j [In the formula, R i is an alkyl group as defined above, and R j is an aryl group as defined above.

[0104] The terms "alkenyloxy" and "alkynyloxy" include groups of the formula: -OR i [In the formula, R i are each an alkenyl or alkynyl group.

[0105] The terms "alkenylthio" and "alkynylthio" include groups of the formula: -SR k [In the formula, R k are each an alkenyl or alkynyl group.

[0106] The term "alkoxycarbonyl" includes a radical of the formula: -C(O)OR i [In the formula, R i is an alkyl group as defined above, where the total number of carbon atoms refers to the combined alkyl and carbonyl moieties.

[0107] The term "acyl" includes any alkyl, alkenyl, or alkynyl group where the carbon at the point of attachment is substituted with an oxo group, as defined below. The following are non-limiting examples of acyl groups: -C(=O)alkyl, -C(=O)alkenyl, and -C(=O)alkynyl.

[0108] The term "heterocycle" includes 5- to 7-membered monocyclic heterocycles or 7- to 10-membered bicyclic heterocycles that are either saturated, unsaturated, or aromatic and contain one, two, three, or more heteroatoms independently selected from nitrogen (N), oxygen (O), and sulfur (S), where the nitrogen and sulfur heteroatoms are optionally oxidized, the nitrogen heteroatom is optionally quaternized, and heterocycles include bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle can be attached via any heteroatom or carbon atom. Heterocycles include, but are not limited to, heteroaryl, as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

[0109] The term "heteroaryl" includes aromatic 5- to 10-membered heterocycles containing one, two, three, or more heteroatoms selected from nitrogen (N), oxygen (O), and sulfur (S). Heteroaryls may be substituted on one or more carbon atoms with substituents such as halogen, alkyl, alkoxy, cyano, haloalkyl (e.g., trifluoromethyl), heterocyclyl (e.g., morpholinyl or pyrrolidinyl), and the like. Non-limiting examples of heteroaryls include pyridinyl and furanyl.

[0110] The term "halogen" includes fluoro, chloro, bromo, and iodo.

[0111] The terms "optionally substituted alkyl", "optionally substituted cyclic alkyl", "optionally substituted alkenyl", "optionally substituted alkynyl", "optionally substituted acyl", and "optionally substituted heterocycle" mean that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an "oxo" substituent (=O), two hydrogen atoms are replaced. Non-limiting examples of substituents include oxo, halogen, heterocycle, -CN, -OR x , -NR x R y , -NR x C(=O)R y , -NR x SO2R y , -C(=O)R x , -C(=O)OR x , -C(=O)NR x R y , -SO n R x , and -SO n NR x R y [In the formula, n is 0, 1, or 2; x and R y are the same or different and are independently hydrogen, alkyl, or heterocycle, and each of the alkyl and heterocycle substituents may further comprise one or more of oxo, halogen, -OH, -CN, alkyl, -OR x , heterocycle, -NR x R y , -NR x C(=O)R y , -NR x SO2R y , -C(=O)R x , -C(=O)OR x , -C(=O)NR x R y , -SO n R x , and -SO n NR x R yThe term "optionally substituted" used before a list of substituents means that each substituent in the list may be optionally substituted as described herein.

[0112] In one aspect, the present invention provides a cationic lipid of formula I having the structure: providing TIFF2024161074000002.tif30128, wherein: R 1 and R 2 are the same or different and are independently hydrogen (H) or an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; or R 1 and R 2 may be taken together to form an optionally substituted heterocycle; R 3 is absent or is hydrogen (H) or C1-C6 alkyl to provide a quaternary amine; R 4 and R 5 are the same or different and independently, optionally substituted C 10 -C 24 Alkyl, C 10 -C 24 Alkenyl, C 10 -C 24 Alkynyl, or C 10 -C 24 is acyl; X is O, S, N(R 6 ), C(O), C(O)O, OC(O), C(O)N(R 6 ), N(R 6 )C(O),OC(O)N(R 6 ), N(R 6 )C(O)O, C(O)S, C(S)O, S(O), S(O)(O), C(S), or an optionally substituted heterocycle, where R 6 is hydrogen (H) or optionally substituted C1-C 10 Alkyl, C2-C 10 Alkenyl, or C2-C 10alkynyl; and Y is absent or optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0113] In some embodiments, R 1 and R 2 each independently represents hydrogen (H) or optionally substituted C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C2-C3 alkyl, C2-C4 alkyl, C2-C5 alkyl, C2-C6 alkyl, C3-C4 alkyl, C3-C5 alkyl, C3-C6 alkyl, C4-C5 alkyl, C4-C6 alkyl, C5-C6 alkyl, C2-C3 alkenyl, C2-C4 alkenyl, C2-C5 alkynyl, In certain embodiments, R is C2-C6 alkenyl, C3-C4 alkenyl, C3-C5 alkenyl, C3-C6 alkenyl, C4-C5 alkenyl, C4-C6 alkenyl, C5-C6 alkenyl, C2-C3 alkynyl, C2-C4 alkynyl, C2-C5 alkynyl, C2-C6 alkynyl, C3-C4 alkynyl, C3-C5 alkynyl, C3-C6 alkynyl, C4-C5 alkynyl, C4-C6 alkynyl, or C5-C6 alkynyl. 1 and R 2 are both methyl groups, both ethyl groups, or a combination of one methyl group and one ethyl group. In some cases, the pH is adjusted to the pK a When it is higher than 3 does not exist and the pH is equal to the pK a When less than R 3 is hydrogen (H). In certain other cases, R 3 is optionally substituted C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C2-C3 alkyl, C2-C4 alkyl, C2-C5 alkyl, C2-C6 alkyl, C3-C4 alkyl, C3-C5 alkyl, C3-C6 alkyl, C4-C5 alkyl, C4-C6 alkyl, or C5-C6 alkyl to provide a quaternary amine.

[0114] In one embodiment, R 1 and R 2 taken together form an optionally substituted heterocycle containing 1, 2, 3, 4, 5, 6, or more carbon atoms and 1, 2, 3, 4, or more heteroatoms, such as nitrogen (N), oxygen (O), sulfur (S), and combinations thereof. In some embodiments, the optionally substituted heterocycle contains 2-5 carbon atoms and 1-3 heteroatoms, such as nitrogen (N), oxygen (O), and / or sulfur (S). In some embodiments, the heterocycle includes optionally substituted imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole), pyrazole, thiazole, pyrrole, furan, oxazole, isoxazole, oxazoline, oxazolidine, oxadiazole, tetrazole, and the like. In certain cases, an optionally substituted heterocyclic ring contains five carbon atoms and one nitrogen atom, where the heterocyclic ring is optionally substituted at the ortho, meta, and / or para positions with substituents such as hydroxyl (-OH) groups. In certain cases, the heterocyclic ring contains an optionally substituted imidazole group.

[0115] In other embodiments, R 6 is hydrogen (H) or optionally substituted C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C2-C3 alkyl, C2-C4 alkyl, C2-C5 alkyl, C2-C6 alkyl, C2-C7 alkyl, C2-C8 alkyl, C2-C9 alkyl, C2-C 10 Alkyl, C3-C4 alkyl, C3-C5 alkyl, C3-C6 alkyl, C3-C7 alkyl, C3-C8 alkyl, C3-C9 alkyl, C3-C 10 Alkyl, C4-C5 alkyl, C4-C6 alkyl, C4-C7 alkyl, C4-C8 alkyl, C4-C9 alkyl, C4-C 10Alkyl, C5-C6 alkyl, C5-C7 alkyl, C5-C8 alkyl, C5-C9 alkyl, C5-C 10 Alkyl, C6-C7 alkyl, C6-C8 alkyl, C6-C9 alkyl, C6-C 10 Alkyl, C7-C8 alkyl, C7-C9 alkyl, C7-C 10 Alkyl, C8-C9 alkyl, C8-C 10 Alkyl, C9-C 10 Alkyl, C2-C3 alkenyl, C2-C4 alkenyl, C2-C5 alkenyl, C2-C6 alkenyl, C2-C7 alkenyl, C2-C8 alkenyl, C2-C9 alkenyl, C3-C4 alkenyl, C3-C5 alkenyl, C3-C6 alkenyl, C3-C7 alkenyl, C3-C8 alkenyl, C3-C9 alkenyl, C3-C 10 Alkenyl, C4-C5 alkenyl, C4-C6 alkenyl, C4-C7 alkenyl, C4-C8 alkenyl, C4-C9 alkenyl, C4-C 10 Alkenyl, C5-C6 alkenyl, C5-C7 alkenyl, C5-C8 alkenyl, C5-C9 alkenyl, C5-C 10 Alkenyl, C6-C7 alkenyl, C6-C8 alkenyl, C6-C9 alkenyl, C6-C 10 Alkenyl, C7-C8 alkenyl, C7-C9 alkenyl, C7-C 10 Alkenyl, C8-C9 alkenyl, C8-C 10 Alkenyl, C9-C 10 Alkenyl, C2-C3 alkynyl, C2-C4 alkynyl, C2-C5 alkynyl, C2-C6 alkynyl, C2-C7 alkynyl, C2-C8 alkynyl, C2-C9 alkynyl, C3-C4 alkynyl, C3-C5 alkynyl, C3-C6 alkynyl, C3-C7 alkynyl, C3-C8 alkynyl, C3-C9 alkynyl, C3-C 10 Alkynyl, C4-C5 alkynyl, C4-C6 alkynyl, C4-C7 alkynyl, C4-C8 alkynyl, C4-C9 alkynyl, C4-C 10 Alkynyl, C5-C6 alkynyl, C5-C7 alkynyl, C5-C8 alkynyl, C5-C9 alkynyl, C5-C 10Alkynyl, C6-C7 alkynyl, C6-C8 alkynyl, C6-C9 alkynyl, C6-C 10 Alkynyl, C7-C8 alkynyl, C7-C9 alkynyl, C7-C 10 Alkynyl, C8-C9 alkynyl, C8-C 10 Alkynyl or C9-C 10 In one particular embodiment, R 6 are hydrogen (H), C1 alkyl (methyl) groups, and C2, C3, C4, C5, C6, C7, C8, C9, and C 10 The aryl, aryl and aryl groups are selected from the group consisting of alkyl, alkenyl, and alkynyl groups.

[0116] In one particular embodiment, X is C(O)O. In another particular embodiment, X is O. In some embodiments, X is C(O)N(R 6 ), N(R 6 )C(O)O, or C(O)S. In a particular embodiment, X is N(R 6 )C(O)O, R 6 is hydrogen (H), a methyl group, or C2, C3, C4, C5, C6, C7, C8, C9, or C 10 In certain other embodiments, X is an optionally substituted heterocycle. In certain embodiments, the heterocycle contains 1, 2, 3, 4, 5, 6, or more carbon atoms and 1, 2, 3, 4, or more heteroatoms, such as nitrogen (N), oxygen (O), sulfur (S), and combinations thereof. In some embodiments, the optionally substituted heterocycle contains 2-5 carbon atoms and 1-3 heteroatoms, such as nitrogen (N), oxygen (O), and / or sulfur (S). In certain embodiments, the heterocycle includes optionally substituted imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole), pyrazole, thiazole, pyrrole, furan, oxazole, isoxazole, oxazoline, oxazolidine, oxadiazole, tetrazole, and the like. In certain cases, X is C(O)O, Y is (CH2)2 or (CH2)3, and R 4 and R5 If both are linoleyl components, R 1 and R 2 Both cannot be methyl groups.

[0117] In one embodiment, R 4 and R 5 At least one or both of the groups may be optionally substituted C 12 -C 24 , C 12 -C 22 , C 12 -C 20 , C 14 -C 24 , C 14 -C 22 , C 14 -C 20 , C 16 -C 24 , C 16 -C 22 , or C 16 -C 20 Alkyl, alkenyl, alkynyl, or acyl groups (i.e., C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , or C 24 In another embodiment, R 4 and R 5At least one or both of independently contain at least 1, 2, 3, 4, 5, or 6 sites of unsaturation (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 sites of unsaturation), or a substituted alkyl or acyl group. In certain cases, the unsaturated side chain comprises a dodecenyl moiety, a tetradecenyl moiety (e.g., myristoleyl), a hexadecenyl moiety (e.g., palmitoleyl), an octadecenyl moiety (e.g., oleyl), an icosenyl moiety, a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradecatrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, or an acyl derivative thereof (e.g., oleoyl, linoleoyl, linolenoyl, γ-linolenoyl, etc.). In certain embodiments, R 4 and R 5 are linoleyl moieties. In other cases, the octadecatrienyl moiety is a linolenyl moiety or a γ-linolenyl moiety. In certain embodiments, R 4 and R 5 Both of R and R are linolenyl or γ-linolenyl moieties. 4 and R 5 In embodiments where one or both of the above independently comprise a branched alkyl or acyl group (e.g., a substituted alkyl or acyl group), the branched alkyl or acyl group is a C alkyl group having at least 1-6 (e.g., 1, 2, 3, 4, 5, 6, or more) C1-C6 alkyl substituents. 12 -C 24 In certain embodiments, the branched alkyl or acyl group can include a C alkyl or acyl group having 1 to 6 (e.g., 1, 2, 3, 4, 5, 6) C1-C4 alkyl (e.g., methyl, ethyl, propyl, or butyl) substituents. 12 -C 20 or C 14 -C 22In some embodiments, the branched alkyl group comprises a phytanyl (3,7,11,15-tetramethyl-hexadecanyl) moiety and the branched acyl group comprises a phytanoyl (3,7,11,15-tetramethyl-hexadecanoyl) moiety. In certain embodiments, R 4 and R 5 and R are both phytanyl moieties. 4 and R 5 At least one or both of the groups may be an oxo (=O) substituent, -OR x R is independently substituted with one, two, three, four, or more substituents, such as, x are independently hydrogen or an alkyl group. In some cases, oxo (=O) or -OR x (e.g. -OH) substituents are R 4 and R 5 R in either or both of 4 or R 5 to the rest of the compound.

[0118] In some embodiments, R 4 and R 5 The 1, 2, 3, 4, 5, 6, or more sites of unsaturation present in one or both of the alkyl and alkylene groups correspond in each case to a cis double bond, a trans double bond, or a combination thereof, at a particular position in one or both of the unsaturated side chains. For unsaturated side chains in which the double bond is located between a hydrogen atom and an alkyl or alkylene chain, the chemical symbol "E" refers to a trans double bond configuration and the chemical symbol "Z" refers to a cis double bond configuration. As non-limiting examples, R 4 and R 5 may have any combination of double bonds in the cis and / or trans configuration at one or more positions in the side chain (e.g., C 18 C containing cis and / or trans double bonds at the 9 position, at the 6 and 9 positions, at the 3, 6 and 9 positions, at the 6, 9 and 12 positions, or at the 7 and 9 positions of the alkyl group 18 Similarly, non-limiting examples include R4 and R 5 may have any combination of double bonds (e.g., C 18 C having double bonds "Z" and / or "E" at the 9 position, at the 6 and 9 positions, at the 3, 6, and 9 positions, at the 6, 9, and 12 positions, or at the 7 and 9 positions of the alkyl group 18 It is an alkyl group.

[0119] In other embodiments, R 4 or R 5 In some cases, R 4 or R 5 one of which is independently an optionally substituted C 12 -C 24 , C 12 -C 22 , C 12 -C 20 , C 14 -C 24 , C 14 -C 22 , C 14 -C 20 , C 16 -C 24 , C 16 -C 22 , or C 16 -C 20 Alkyl, alkenyl, alkynyl, or acyl groups (i.e., C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , or C 24alkyl, alkenyl, alkynyl, or acyl groups of the formula 4 or R 5 the other contains at least 1, 2, 3, 4, 5, or 6 optionally substituted cyclic alkyl groups (for example, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 2 to 3, 2 to 4, 2 to 5, or 2 to 6 optionally substituted cyclic alkyl groups).

[0120] In certain embodiments, R 4 and R 5 The one or more optionally substituted cyclic alkyl groups present on either side of the cyclic alkyl group are independently selected from the group consisting of optionally substituted saturated cyclic alkyl groups, optionally substituted unsaturated cyclic alkyl groups, and combinations thereof. In some cases, the optionally substituted saturated cyclic alkyl group is an optionally substituted C 3-8 In a preferred embodiment, the optionally substituted saturated cyclic alkyl group includes a cyclopropyl group, which may contain one or more substituents and / or heteroatoms. In other cases, the optionally substituted unsaturated cyclic alkyl group includes an optionally substituted C 3-8 Includes cycloalkenyl groups (eg, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like).

[0121] In some embodiments, R 4 or R 5 One of R contains at least 1, 2, 3, 4, 5, or 6 unsaturated sites (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 unsaturated sites) or a substituted alkyl or acyl group, and the other side chain contains at least 1, 2, 3, 4, 5, or 6 optionally substituted cyclic alkyl groups (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 optionally substituted cyclic alkyl groups). 4 or R5 In embodiments where one of R contains at least 1, 2, 3, 4, 5, or 6 sites of unsaturation, the unsaturated side chain may include a myristoleyl moiety, a palmitoleyl moiety, an oleyl moiety, a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradecatrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, or an acyl derivative thereof (e.g., linoleoyl, linolenoyl, γ-linolenoyl, etc.). In some cases, the octadecadienyl moiety is a linoleyl moiety. In other cases, the octadecatrienyl moiety is a linolenyl moiety or a γ-linolenyl moiety. R 4 or R 5 In embodiments where one of the groups comprises a branched alkyl or acyl group (e.g., a substituted alkyl or acyl group), the branched alkyl or acyl group is a C alkyl group having at least 1-6 (e.g., 1, 2, 3, 4, 5, 6, or more) C1-C6 alkyl substituents. 12 -C 24 In certain embodiments, the branched alkyl or acyl group can include a C alkyl or acyl group having 1 to 6 (e.g., 1, 2, 3, 4, 5, 6) C1-C4 alkyl (e.g., methyl, ethyl, propyl, or butyl) substituents. 12 -C 20 or C 14 -C 22 In some embodiments, the branched alkyl group comprises a phytanyl moiety and the branched acyl group comprises a phytanoyl moiety.

[0122] In a preferred embodiment, R 4 or R 5 The optionally substituted cyclic alkyl group present in one of R is located at the unsaturated site in the corresponding unsaturated side chain. 4 or R 5 one of which is a C containing 1, 2 or 3 optionally substituted cyclic alkyl groups 18An alkyl group, where an optionally substituted cyclic alkyl group (e.g., an independently selected cyclopropyl group) is located at one or more (e.g., all) of the sites of unsaturation present in the corresponding linoleyl, linolenyl, or γ-linolenyl moiety.

[0123] In an alternative embodiment of the cationic lipid of formula I, R 4 and R 5 are different and independently optionally substituted C-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, or C1-C 24 In certain embodiments, R 4 or R 5 In one embodiment, R 4 and R 5 are different and independently optionally substituted C4-C 20 Alkyl, C4-C 20 Alkenyl, C4-C 20 Alkynyl, or C4-C 20 In some cases, R 4 is an optionally substituted C 12 -C 24 Alkyl, C 12 -C 24 Alkenyl, C 12 -C 24 Alkynyl, or C 12 -C 24 Acyl and R 5 is an optionally substituted C4-C 10 Alkyl, C4-C 10 Alkenyl, C4-C 10 Alkynyl, or C4-C 10 In other cases, R 4 is an optionally substituted C 12 -C 20Or C 14 -C 22 Alkyl, C 12 -C 20 Or C 14 -C 22 Alkenyl, C 12 -C 20 Or C 14 -C 22 Alkynyl, or C 12 -C 20 Or C 14 -C 22 Acyl and R 5 is an optionally substituted C4-C8 or C6 alkyl, C4-C8 or C6 alkenyl, C4-C8 or C6 alkynyl, or C4-C8 or C6 acyl. 4 is an optionally substituted C4-C 10 Alkyl, C4-C 10 Alkenyl, C4-C 10 Alkynyl, or C4-C 10 Acyl and R 5 is an optionally substituted C 12 -C 24 Alkyl, C 12 -C 24 Alkenyl, C 12 -C 24 Alkynyl, or C 12 -C 24 In certain other cases, R 4 is an optionally substituted C4-C8 or C6 alkyl, C4-C8 or C6 alkenyl, C4-C8 or C6 alkynyl, or C4-C8 or C6 acyl, and R 5 is an optionally substituted C 12 -C 20 Or C 14 -C 22 Alkyl, C 12 -C 20 Or C 14 -C 22 Alkenyl, C 12 -C 20 Or C 14 -C 22 Alkynyl, or C 12-C 20 Or C 14 -C 22 In certain embodiments, the one or more optionally substituted cyclic alkyl groups are R 4 or R 5 If it is present in either one of the above, then

[0124] In some groups of embodiments of the cationic lipid of formula I, R 4 and R 5 are the same or different and are independently selected from the group consisting of: TIFF2024161074000003.tif241159.

[0125] In some embodiments, Y is optionally substituted C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C2-C3 alkyl, C2-C4 alkyl, C2-C5 alkyl, C2-C6 alkyl, C3-C4 alkyl, C3-C5 alkyl, C3-C6 alkyl, C4-C5 alkyl, C4-C6 alkyl, C5-C6 alkyl, C2-C3 alkenyl, C2-C4 alkenyl, C2-C5 alkenyl , C2-C6 alkenyl, C3-C4 alkenyl, C3-C5 alkenyl, C3-C6 alkenyl, C4-C5 alkenyl, C4-C6 alkenyl, C5-C6 alkenyl, C2-C3 alkynyl, C2-C4 alkynyl, C2-C5 alkynyl, C2-C6 alkynyl, C3-C4 alkynyl, C3-C5 alkynyl, C3-C6 alkynyl, C4-C5 alkynyl, C4-C6 alkynyl, or C5-C6 alkynyl. In one particular embodiment, Y is (CH2) n and n is 0, 1, 2, 3, 4, 5, or 6 (for example, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 2 to 3, 2 to 4, 2 to 5, or 2 to 6). In a preferred embodiment, n is 2, 3, or 4.

[0126] In certain embodiments, the cationic lipid of formula I has the following structure: TIFF2024161074000004.tif26128, or a salt thereof; In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , X, and n are as previously described.

[0127] In some embodiments, the cationic lipid of formula I forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of formula I is its oxalate (e.g., hemioxalate) salt, which is preferably a crystalline salt.

[0128] In particularly preferred embodiments, the cationic lipid of formula I has one of the following structures: TIFF2024161074000005.tif174131TIFF2024161074000006.tif238128TIFF20241610740 00007.tif220117TIFF2024161074000008.tif251121TIFF2024161074000009.tif46128.

[0129] The compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in the examples. In some embodiments, the synthesis of the cationic lipids of the present invention may require the use of protecting groups. Protecting group methodology is well known to those skilled in the art (see, for example, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, Green,TW et. al., Wiley-Interscience, New York City, 1999). Briefly, a protecting group in the context of the present invention is any group that reduces or eliminates the undesired reactivity of a functional group. A protecting group is added to a functional group to mask its reactivity during a reaction, and can then be removed to expose the original functional group. In some cases, an "alcohol protecting group" is used. An "alcohol protecting group" is any group that reduces or eliminates the undesired reactivity of an alcohol functional group. Protecting groups can be added and removed using techniques well known in the art.

[0130] In some embodiments, the cationic lipid of the present invention has at least one protonatable or deprotonatable group, so that the lipid is positively charged at or below physiological pH (e.g. pH 7.4) and neutral at a second pH, preferably at or above physiological pH.It will be understood by those skilled in the art that the addition or removal of protons as a function of pH is an equilibrium process, and reference to charged or neutral lipids refers to the nature of the most common species and does not require all lipids to exist in charged or neutral form.Lipids with two or more protonatable or deprotonatable groups or zwiterionic lipids are not excluded from use in the present invention.

[0131] In certain other embodiments, the protonatable lipids according to the present invention have a pK in the range of about 4 to about 11. a Most preferred are those having a pK of about 4 to about 7. abecause these lipids are cationic at the lower pH formulation stage, whereas at physiological pH of approximately pH 7.4 the particle surface is largely (if not completely) neutralized. a One advantage of is that at least a portion of the nucleic acid bound to the outer surface of the particle loses its electrostatic interactions at physiological pH and can be removed by simple dialysis, thus greatly reducing the susceptibility of the particle to clearance.

[0132] IV. Active Ingredients Active ingredients (e.g., therapeutic agents) include any molecule or compound capable of exerting a desired effect on a cell, tissue, tumor, organ, or subject. Such effects can be, for example, biological, physiological, and / or cosmetic. Active ingredients can be any type of molecule or compound, including, but not limited to, nucleic acids, peptides, polypeptides, small molecules, and mixtures thereof. Non-limiting examples of nucleic acids include interfering RNA molecules (e.g., dsRNA such as siRNA, Dicer substrate dsRNA, shRNA, aiRNA, and / or miRNA), antisense oligonucleotides, plasmids, ribozymes, immunostimulatory oligonucleotides, and mixtures thereof. Examples of peptides or polypeptides include, but are not limited to, antibodies (e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments; humanized antibodies, recombinant antibodies, recombinant human antibodies, and / or Primatized™ antibodies), cytokines, growth factors, apoptotic factors, differentiation inducers, cell surface receptors and their ligands, hormones, and mixtures thereof. Examples of small molecules include, but are not limited to, small organic molecules or small molecule compounds, such as any conventional agent or drug known to one of skill in the art.

[0133] In some embodiments, the active ingredient is a therapeutic agent, or a salt or derivative thereof. The therapeutic agent derivative may be therapeutically active itself or may be a prodrug that becomes active upon further modification. Thus, in one embodiment, the therapeutic agent derivative retains some or all of the therapeutic activity compared to the unmodified agent, while in another embodiment, the therapeutic agent derivative is a prodrug that lacks therapeutic activity but becomes active upon further modification.

[0134] In a preferred embodiment, the lipid particles described herein are bound to nucleic acid to produce nucleic acid-lipid particles (e.g., SNALP).Non-limiting exemplary embodiments of selecting, synthesizing and modifying nucleic acids such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, miRNA, antisense oligonucleotides, ribozymes and immunostimulatory oligonucleotides are described, for example, in US Patent Publication No. 20070135372; US Patent Publication No. 20110076335; and International Publication No. 2010 / 105372, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0135] In some embodiments, the nucleic acid (e.g., interfering RNA) component of the nucleic acid-lipid particle (e.g., SNALP) comprises at least one modified nucleotide (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more modified nucleotides). In some cases, the nucleic acid (e.g., interfering RNA, such as siRNA) comprises modified nucleotides, including, but not limited to, 2'-O-methyl (2'OMe) nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy nucleotides, 2'-O-(2-methoxyethyl) (MOE) nucleotides, locked nucleic acid (LNA) nucleotides, 5-C-methyl nucleotides, 4'-thio nucleotides, 2'-amino nucleotides, 2'-C-allyl nucleotides, and mixtures thereof. In certain embodiments, modified interfering RNA (e.g., modified siRNA) generally has less immunostimulatory activity than the corresponding unmodified interfering RNA (e.g., unmodified siRNA) sequence and retains RNAi activity against the target gene of interest. In some embodiments, the modified interfering RNA (e.g., modified siRNA) has at least one 2'OMe purine or pyrimidine nucleotide, such as 2'OMe-guanosine, 2'OMe-uridine, 2'OMe-adenosine, and / or 2'OMe-cytosine nucleotide. The modified nucleotide can be present in one strand (i.e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA). In some preferred embodiments, one or more of the uridine and / or guanosine nucleotides are modified (e.g., 2'OMe-modified) in one strand (i.e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA). In these embodiments, the modified interfering RNA (e.g., modified siRNA) can further include one or more modified (e.g., 2'OMe-modified) adenosine nucleotides and / or modified (e.g., 2'OMe-modified) cytosine nucleotides.In other preferred embodiments, only uridine and / or guanosine nucleotides are modified (e.g., 2'OMe-modified) in one strand (i.e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA). The interfering RNA (e.g., siRNA) sequence may have an overhang (e.g., 3' or 5' overhang as described in Elbashir et al., Genes Dev., 15:188 (2001) or Nykaenen et al., Cell, 107:309 (2001)) or may lack an overhang (i.e., have a blunt end). The interfering RNA (e.g., siRNA) sequence may contain one or more modified nucleotides in the double-stranded (duplex) region and / or in one or both of the overhangs (e.g., 3' overhangs), if present.

[0136] The nucleic acid (e.g., interfering RNA) component of the nucleic acid-lipid particle (e.g., SNALP) can be used to downregulate or silence the translation (i.e., expression) of a gene of interest.Non-limiting examples of genes of interest include genes related to metabolic diseases and disorders (e.g., liver diseases or disorders), genes related to cell proliferation, tumorigenesis, and / or cell transformation (e.g., cell proliferation disorders such as cancer), angiogenesis genes, receptor ligand genes, immune regulator genes (e.g., genes related to inflammatory and autoimmune responses), genes related to viral infection and survival, and genes related to neurodegenerative disorders.For example, see US Patent Publication No. 20110076335 for a description of exemplary target genes (including their Genbank accession numbers) that can be downregulated or silenced by the nucleic acid (e.g., interfering RNA) of the nucleic acid-lipid particle (e.g., SNALP).

[0137] Non-limiting examples of gene sequences related to tumorigenesis or cell transformation include polo-like kinase 1 (PLK-1), cyclin-dependent kinase 4 (CDK4), COP1, ring-box 1 (RBX1), WEE1, Eg5 (KSP, KIF11), forkhead box M1 (FOXM1), RAM2 (R1, CDCA7L), XIAP, CSN5 (JAB1), and HDAC2. Non-limiting examples of gene sequences related to metabolic diseases and disorders include apolipoprotein B (APOB), apolipoprotein CIII (APOC3), apolipoprotein E (APOE), proprotein convertase subtilisin / kexin type 9 (PCSK9), diacylglycerol O-acyltransferase type 1 (DGAT1), and diacylglycerol O-acyltransferase type 2 (DGAT2). Non-limiting examples of gene sequences associated with viral infection and survival include nucleic acid sequences from host factors such as tissue factor (TF) or filoviruses such as Ebola virus and Marburg virus (e.g., VP30, VP35, nucleoprotein (NP), polymerase protein (L-pol), VP40, glycoprotein (GP), and VP24); arenaviruses such as Lassa virus (e.g., NP, GP, L, and / or Z genes), Junin virus, Machupo virus, Guanarito virus, and Sabia virus; hepatitis viruses such as hepatitis A, B, C, D, and E virus; influenza viruses such as influenza A, B, and C virus; human immunodeficiency virus (HIV); Herpes virus; and human papilloma virus (HPV).

[0138] In other embodiments, the active ingredient bound to the lipid particles of the present invention may comprise one or more therapeutic proteins, polypeptides, or small organic molecules or small molecule compounds.Non-limiting examples of such therapeutically effective agents or drugs include oncology drugs (e.g., chemotherapeutic drugs, hormonal therapy drugs, immunotherapy drugs, radiotherapy drugs, etc.), lipid-lowering drugs, antiviral drugs, anti-inflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, contraceptives, antipyretics, vasodilators, angiogenesis inhibitors, vascular agents, signal transduction inhibitors, cardiovascular drugs such as antiarrhythmic drugs, hormones, vasoconstrictors, and steroids.These active ingredients may be administered alone in the lipid particles of the present invention or in combination (e.g., co-administration) with the lipid particles of the present invention that contain nucleic acids such as interfering RNA.Non-limiting examples of these types of active ingredients are described, for example, in US Patent Publication No. 20110076335, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0139] V. Lipid particles In one aspect, the present invention provides lipid particles comprising one or more cationic (amino) lipids or salts thereof described herein.In some embodiments, the lipid particles of the present invention further comprise one or more non-cationic lipids.In other embodiments, the lipid particles further comprise one or more binding lipids that can reduce or inhibit particle aggregation.In further embodiments, the lipid particles further comprise one or more active ingredients or therapeutic agents, such as therapeutic nucleic acids (e.g., interfering RNA such as siRNA).

[0140] Lipid particles include, but are not limited to, lipid vesicles such as liposomes. As used herein, lipid vesicles include structures having a lipid-containing membrane enclosing an aqueous interior. In certain embodiments, lipid vesicles comprising one or more cationic lipids as described herein are used to encapsulate nucleic acid within the lipid vesicle. In other embodiments, lipid vesicles comprising one or more cationic lipids as described herein are complexed with nucleic acid to form lipoplexes.

[0141] The lipid particles of the present invention typically include an active or therapeutic agent, a cationic lipid, a non-cationic lipid, and a binding lipid that inhibits particle aggregation. In some embodiments, the active or therapeutic agent is fully encapsulated within the lipid portion of the lipid particle such that the active or therapeutic agent in the lipid particle is resistant to enzymatic degradation, for example by nucleases or proteases, in aqueous solution. In other embodiments, the lipid particles described herein are substantially non-toxic to mammals, such as humans. The lipid particles of the present invention typically have an average diameter of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, or about 70 to about 90 nm. The lipid particles of the present invention also typically have a lipid:therapeutic agent (e.g., lipid:nucleic acid) ratio (mass / mass ratio) of about 1:1 to about 100:1, about 1:1 to about 50:1, about 2:1 to about 25:1, about 3:1 to about 20:1, about 5:1 to about 15:1, or about 5:1 to about 10:1.

[0142] In a preferred embodiment, the lipid particles of the present invention are serum-stable nucleic acid-lipid particles (SNALPs) that contain an interfering RNA (e.g., dsRNA such as siRNA, dicer substrate dsRNA, shRNA, aiRNA, and / or miRNA), a cationic lipid (e.g., one or more cationic lipids of formula I as set forth herein or salts thereof), a non-cationic lipid (e.g., a mixture of one or more phospholipids and cholesterol), and a conjugated lipid that inhibits particle aggregation (e.g., one or more PEG-lipid conjugates). The SNALPs can contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more unmodified and / or modified interfering RNA molecules (e.g., siRNAs). Nucleic acid-lipid particles and methods for their preparation are described, for example, in U.S. Pat. Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501; 6,110,745; and 6,320,017; and WO 96 / 40964, the disclosures of each of which are incorporated herein by reference in their entirety for all purposes.

[0143] In the nucleic acid-lipid particle of the present invention, nucleic acid is completely encapsulated in the lipid portion of the particle, which can protect nucleic acid from nuclease degradation.In a preferred embodiment, SNALP containing nucleic acid such as interfering RNA is completely encapsulated in the lipid portion of the particle, which can protect nucleic acid from nuclease degradation.In some cases, the nucleic acid in SNALP is not substantially degraded after exposing the particle to nuclease at 37°C for at least about 20, 30, 45, or 60 minutes.In some other cases, the nucleic acid in SNALP is not substantially degraded after incubating the particle in serum at 37°C for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours.In other embodiments, nucleic acid is complexed with lipid portion of the particle. One advantage of the present formulations is that the nucleic acid-lipid particle compositions are substantially non-toxic to mammals, including humans.

[0144] The term "fully encapsulated" indicates that the nucleic acid in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or nuclease assays, which can significantly degrade free DNA or RNA.In a fully encapsulated system, preferably less than about 25% of the nucleic acid in the particle is degraded, more preferably less than about 10%, and most preferably less than about 5% of the nucleic acid in the particle is degraded in a process that can usually degrade 100% of free nucleic acid."Fully encapsulated" also indicates that the nucleic acid-lipid particle is serum stable, i.e., it is not rapidly degraded into its constituents immediately after in vivo administration.

[0145] In the context of nucleic acids, complete encapsulation can be determined by performing a membrane-impermeable fluorescent dye exclusion assay using a dye that emits an amplified fluorescence when bound to nucleic acid. Specific dyes such as OliGreen® and RiboGreen® (Invitrogen Corp.; Carlsbad, CA) are available for quantification of plasmid DNA, single-stranded deoxyribonucleotides, and / or single- or double-stranded ribonucleotides. Encapsulation is determined by adding the dye to the liposome formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed when a small amount of non-ionic detergent is added. Detergent-mediated disruption of the liposome bilayer releases the encapsulated nucleic acid, thereby allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation can be calculated as E=(I-I) / I, where I and I represent the fluorescence intensity before and after the addition of surfactant (see Wheeler et al., Gene Ther., 6:271-281 (1999)).

[0146] In another aspect, the present invention provides nucleic acid-lipid particle (eg, SNALP) compositions comprising a plurality of nucleic acid-lipid particles.

[0147] In some cases, the SNALP composition comprises about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 30% to about 95%, about 40% to about 95%, about 50% to about 95%, about 60% to about 95%, about 70% to about 95%, about 80% to about 95%, about 85% to about 95%, about 90% to about 95%, about 30% to about 90%, about 40% to about 90%, The nucleic acid is completely encapsulated within the lipid portion of the particle such that about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any percentage or range therein) of the nucleic acid is encapsulated within.

[0148] In other cases, the SNALP composition comprises from about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 30% to about 95%, about 40% to about 95%, about 50% to about 95%, about 60% to about 95%, about 70% to about 95%, about 80% to about 95%, about 85% to about 95%, about 90% to about 95%, about 30% to about 90%, about 40% to about 90%, The nucleic acid is completely encapsulated within the lipid portion of the particle such that about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any percentage or range therein) is encapsulated in the particle.

[0149] Depending on the intended use of the lipid particles of the present invention, the ratio of the components can be varied, and the delivery efficiency of a particular formulation can be measured, for example, using an endosomal release parameter (ERP) assay.

[0150] In certain embodiments, the present invention provides a lipid particle (e.g., SNALP) composition comprising a plurality of lipid particles and an antioxidant as described herein.In some cases, the antioxidant in the lipid particle composition reduces, inhibits, and / or inhibits the degradation of cationic lipids (e.g., polyunsaturated cationic lipids) present in the lipid particle.When the active ingredient is a therapeutic nucleic acid such as an interfering RNA (e.g., siRNA), the antioxidant in the lipid particle composition reduces, inhibits, and / or inhibits the degradation of nucleic acid payload, for example, by reducing, inhibiting, and / or inhibiting the oxidation of cationic lipids, by reducing, inhibiting, and / or inhibiting the degradation of nucleic acid payload, by reducing, inhibiting, and / or inhibiting the desulfurization of phosphorothioate (PS) modified nucleic acid payload, and / or by stabilizing both lipid and nucleic acid components.

[0151] Examples of antioxidants include, but are not limited to, metal chelators (e.g., ethylenediaminetetraacetic acid (EDTA), citrate salts, etc.), primary antioxidants (e.g., vitamin E isomers such as α-tocopherol or its salts, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), tert-butylhydroquinone (TBHQ), etc.), secondary antioxidants (e.g., ascorbic acid, ascorbyl palmitate, cysteine, glutathione, α-lipoic acid, etc.), salts thereof, and mixtures thereof. If necessary, the antioxidant is present in an amount sufficient to inhibit, inhibit, and / or reduce the degradation of the cationic lipids and / or active ingredients typically present in the lipid particles. In certain embodiments, the antioxidant comprises EDTA or a salt thereof (e.g., about 20 mM to about 100 mM), alone or in combination with a primary antioxidant such as α-tocopherol or a salt thereof (e.g., about 0.02 mol % to about 0.5 mol %) and / or a secondary antioxidant such as ascorbyl palmitate or a salt thereof (e.g., about 0.02 mol % to about 5.0 mol %). Antioxidants such as EDTA can be included at any step or steps in the lipid particle formation process described in Section VI (e.g., before, during, and / or after formation of the lipid particles).

[0152] Further aspects relating to methods for inhibiting degradation of cationic lipids and / or active ingredients (e.g., therapeutic nucleic acids) present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods for making these lipid particles, and methods for delivering and / or administering these lipid particles are described in PCT Application No. PCT / CA2010 / 001919, filed December 1, 2010, the disclosure of which is incorporated by reference herein in its entirety for all purposes.

[0153] In one aspect, the lipid particles of the present invention can include a targeting lipid. In some embodiments, the targeting lipid includes a GalNAc moiety (i.e., an N-galactosamine moiety). As a non-limiting example, the targeting lipid that includes a GalNAc moiety can include the lipids described in U.S. Patent Application No. 12 / 328,669, filed December 4, 2008, the disclosure of which is incorporated herein by reference in its entirety for all purposes. The targeting lipid can also include any other lipid (e.g., a targeting lipid) known in the art, such as those described in U.S. Patent Application No. 12 / 328,669 or International Publication No. WO 2008 / 042973, the contents of each of which are incorporated herein by reference in their entirety for all purposes. In some embodiments, the targeting lipid includes multiple GalNAc moieties, such as two or three GalNAc moieties. In some embodiments, the targeting lipid contains multiple N-acetylgalactosamine (GalNAc) moieties, for example, 2 or 3. In some embodiments, the lipid in the targeting lipid is 1,2-di-O-hexadecyl-sn-glyceride (i.e., DSG). In some embodiments, the targeting lipid comprises a PEG moiety (e.g., a PEG moiety having a molecular weight of at least about 500 Da, such as about 1000 Da, 1500 Da, 2000 Da or more), for example, the targeting moiety is bound to the lipid via the PEG moiety. Examples of GalNAc targeting lipid include, but are not limited to, (GalNAc)3-PEG-DSG, (GalNAc)3-PEG-LCO, and mixtures thereof.

[0154] In some embodiments, targeting lipid comprises folic acid moiety.For example, targeting lipid comprising folic acid moiety can comprise the lipid described in US patent application Ser. No. 12 / 328,669, the disclosure of which is incorporated herein by reference in its entirety for all purposes.Examples of folic acid targeting lipid include, but are not limited to, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folic acid (polyethylene glycol)-2000] (ammonium salt) (folic acid-PEG-DSPE), folic acid-PEG2000-DSG, folic acid-PEG3400-DSG, and mixtures thereof.

[0155] In another aspect, the lipid particles of the present invention can further comprise one or more apolipoproteins.The term "apolipoprotein" or "lipoprotein" as used herein refers to the apolipoproteins known to those skilled in the art and their variants and fragments, and the apolipoprotein agonists, analogs or fragments thereof, for example, as described in International Publication No. WO 2010 / 0088537, the disclosure of which is incorporated herein by reference in its entirety for all purposes.Suitable apolipoproteins include, but are not limited to, ApoA-I, ApoA-II, ApoA-IV, ApoA-V, and ApoE (e.g., ApoE2, ApoE3, etc.), and active polymorphs, isoforms, variants and mutants, and fragments or truncations thereof. Isolated ApoE and / or its active fragments and polypeptide analogs, including recombinantly produced forms thereof, are described in U.S. Patent Nos. 5,672,685; 5,525,472; 5,473,039; 5,182,364; 5,177,189; 5,168,045; and 5,116,739, the disclosures of which are incorporated by reference in their entireties herein for all purposes.

[0156] A. Cationic lipids Any of the novel cationic lipids of Formula I provided herein, or salts thereof, can be used in the lipid particles of the present invention (e.g., SNALP), either alone or in combination with one or more other cationic or non-cationic lipid species.

[0157] Other cationic lipids or salts thereof that may also be included in the lipid particles of the present invention include, but are not limited to, one or more of the cationic lipids of formulas I-XXII or salts thereof described in U.S. Patent Application No. 13 / 077,856, filed March 31, 2011, one or more of the cationic lipids of formulas I-XIX or salts thereof described in PCT Application No. PCT / CA2010 / 001919, filed December 1, 2010, and / or the cationic lipids of formulas I-XIX or salts thereof described in PCT Application No. PCT / CA2010 / 001919, filed May 12, 2011, entitled "Novel Cyclic Cationic Lipids and Methods of Use Thereof," Attorney Docket No. 86399-010110PC (805953) and / or Reference No. N. 114015 The present invention also includes one or more of the cationic lipids, or salts thereof, of formulas I-III, as described in PCT Application No. PCT / GB2011 / ______ having PJC / JRN, the disclosures of which are incorporated by reference herein in their entireties for all purposes.Further non-limiting examples of suitable cationic lipids include 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA; "XTC2" or "C2K"); -Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-Dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C3-DMA; "C3K"), 2,2-Dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane (DLin-K-C4-DMA; "C4K"), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA; "C4K"), DLin-K6-DMA, 2,2-dilinoleyl-4-N-methylpepiazino-[1,3]-dioxolane (DLin-K-MPZ), 2,2-dioleoyl-4-dimethylaminomethyl-[1,3]-dioxolane (DO-K-DMA), 2,2-distearoyl-4-dimethylaminomethyl-[1,3]-dioxolane (DO-K-DMA), Nomethyl-[1,3]-dioxolane (DS-K-DMA), 2,2-Dilinoleyl-4-N-morpholino-[1,3]-dioxolane (DLin-K-MA), 2,2-Dilinoleyl-4-trimethylamino-[1,3]-dioxolane chloride (DLin-K-TMA.Cl), 2,2-Dilinoleyl-4,5-bis(dimethylaminomethyl)-[1,3]-dioxolane (DLin-K. 2-DMA), 2,2-Dilinoleyl-4-methylpiperzine-[1,3]-dioxolane (D-Lin-KN-methylpiperazine), DLen-C2K-DMA, γ-DLen-C2K-DMA, DPan-C2K-DMA, DPan-C3K-DMA, DLen-C2K-DMA, γ-DLen-C2K-DMA, DPan-C2K-DMA, TLinDMA, C2-TLinDMA, C3-TLinDMA, 1,2-Di-γ-linoleyloxy-N,N-dimethylaminopropane (γ-DLenDMA), 1,2-Dilinoleyloxy-(N,N-dimethyl)-butyl-4-amine (C2-DLinDMA), 1,2-Dilinoleoyloxy-(N,N-dimethyl)-butyl-4-amine (C 2-DLinDAP), dilinoleyl methyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-M-C3-DMA or "MC3"; also known as dilinoleyl methyl 4-(dimethylamino)butanoate), CP-LenMC3, CP-γ-LenMC3, CP-MC3, CP-DLen-C2K-DMA, CP-γDLen-C2K-DMA, CP-C2K-DMA, CP-DODMA, CP-DPetroDMA, CP-DLinDMA, CP-DLenDMA, CP-γDLenDMA, analogs thereof, salts thereof, and mixtures thereof.

[0158] Still further examples of cationic lipids include, but are not limited to, 1,2-dioeylcarbamoyloxy-3-dimethylaminopropane (DO-C-DAP), 1,2-dimyristoleoyl-3-dimethylaminopropane (DMDAP), 1,2-dioleoyl-3-trimethylaminopropane chloride (DOTAP.Cl), 1,2-dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleyoxy-3-(dimethylamino)acetoxypropane, DLin-DAC, 1,2-dilinoleyloxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLin-DAP), 1,2-dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanediol (DOAP), 1,2-dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 3-dimethylamino-2-(cholest-5-ene-3-β-oxybutane-4-oxy)-1-(cis,cis-9,12-octadecamethylphenyl) 2-[5'-(cholest-5-en-3-β-oxy)-3'-oxapentoxy]-3-dimethyl(dimethy)-1-(cis,cis-9',1-2'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 1,2-N,N'-dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP) , N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), dioctadecylamidoglycylspermine (DOGS), analogs thereof, salts thereof and mixtures thereof.

[0159] In some embodiments, the additional cationic lipid forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the additional cationic lipid is an oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.

[0160] The synthesis of cationic lipids such as DLinDMA and DLenDMA, as well as additional cationic lipids, is described in U.S. Patent Application Publication No. 20060083780, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0161] DLin-K-C2-DMA, DLin-K-C3-DMA, DLin-K-C4-DMA, DLin-K6-DMA, DLin-K-MPZ, DO-K-DMA, DS-K-DMA, DLin-K-MA, DLin-K-TMA.Cl, DLin-K 2 The synthesis of cationic lipids such as D-Lin-KN-methylpiperazine, DLin-M-C2-DMA, DO-C-DAP, DMDAP, and DOTAP.Cl, as well as additional cationic lipids, is described in WO 2010 / 042877, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0162] The synthesis of cationic lipids such as DLin-K-DMA, DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in WO 09 / 086558, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0163] The synthesis of cationic lipids such as γ-DLenDMA, DLen-C2K-DMA, γ-DLen-C2K-DMA, DPan-C2K-DMA, DPan-C3K-DMA, DLen-C2K-DMA, γ-DLen-C2K-DMA, DPan-C2K-DMA, TLinDMA, C2-TLinDMA, C3-TLinDMA, C2-DLinDMA, and C2-DLinDAP, as well as further cationic lipids, is described in WO 2011 / 000106, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0164] The synthesis of cationic lipids such as CP-LenMC3, CP-γ-LenMC3, CP-MC3, CP-DLen-C2K-DMA, CP-γDLen-C2K-DMA, CP-C2K-DMA, CP-DODMA, CP-DPetroDMA, CP-DLinDMA, CP-DLenDMA, and CP-γDLenDMA is described in Attorney Docket No. 86399-010110PC (805953), entitled "Novel Cyclic Cationic Lipids and Methods of Use Thereof," filed May 12, 2011, and / or PCT Application No. PCT / GB2011 / ______ having Reference No. N.114015 PJC / JRN, the disclosures of which are incorporated by reference herein in their entirety for all purposes.

[0165] The synthesis of cationic lipids such as CLinDMA, and additional cationic lipids, is described in US Patent Publication No. 20060240554, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0166] The synthesis of some other cationic lipids and related analogues is described in U.S. Patent Nos. 5,208,036; 5,264,618; 5,279,833; 5,283,185; 5,753,613; and 5,785,992; and International Publication No. WO 96 / 10390, the disclosures of which are each incorporated herein by reference in their entirety for all purposes.In addition, some commercially available preparations of cationic lipids can be used, such as, for example, LIPOFECTIN (comprising DOTMA and DOPE, available from GIBCO / BRL); LIPOFECTAMINE (comprising DOSPA and DOPE, available from GIBCO / BRL); and TRANSFECTAM (comprising DOGS, available from Promega Corp.).

[0167] The synthesis of additional cationic lipids suitable for use in the lipid particles of the present invention are described in WO 2010 / 054401, WO 2010 / 054405, WO 2010 / 054406, WO 2010 / 054384, and WO 2010 / 144740; U.S. Patent Application Publication No. 20090023673; and U.S. Provisional Patent Application No. 61 / 287,995, filed December 18, 2009, entitled "Methods and Compositions for Delivery of Nucleic Acids," the disclosures of which are incorporated by reference in their entireties for all purposes.

[0168] In some embodiments, the cationic lipid comprises about 45 mol% to about 90 mol%, about 45 mol% to about 85 mol%, about 45 mol% to about 80 mol%, about 45 mol% to about 75 mol%, about 45 mol% to about 70 mol%, about 45 mol% to about 65 mol%, about 45 mol% to about 60 mol%, about 45 mol% to about 55 mol%, about 50 mol% to about 90 mol%, about 50 mol% to about 85 mol%, about 50 mol% to about 80 mol%, about 50 mol% to about 75 mol%, about 50 mol% to about 70 mol%, about 50 mol% to about 65 mol%, about 50 mol% to about 60 mol%, about 55 mol% to about 65 mol%, or about 55 mol% to about 70 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0169] In certain preferred embodiments, the cationic lipid comprises about 50 mol% to about 58 mol%, about 51 mol% to about 59 mol%, about 51 mol% to about 58 mol%, about 51 mol% to about 57 mol%, about 52 mol% to about 58 mol%, about 52 mol% to about 57 mol%, about 52 mol% to about 56 mol%, or about 53 mol% to about 55 mol% (or any percentage or range therein) of the total lipid present in the particle. In certain embodiments, the cationic lipid comprises about 50 mol%, 51 mol%, 52 mol%, 53 mol%, 54 mol%, 55 mol%, 56 mol%, 57 mol%, 58 mol%, 59 mol%, 60 mol%, 61 mol%, 62 mol%, 63 mol%, 64 mol%, or 65 mol% (or any percentage or range therein) of the total lipid present in the particle. In other embodiments, the cationic lipid comprises (at least) about 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0170] In further embodiments, the cationic lipid comprises from about 2 mol% to about 60 mol%, from about 5 mol% to about 50 mol%, from about 10 mol% to about 50 mol%, from about 20 mol% to about 50 mol%, from about 20 mol% to about 40 mol%, from about 30 mol% to about 40 mol%, or about 40 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0171] Further percentages and ranges of cationic lipids suitable for use in the lipid particles of the present invention are described in WO 09 / 127060, U.S. Patent Application Publication No. 20110071208, and U.S. Patent Application Publication No. 20110076335, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0172] It should be understood that the percentage of cationic lipid present in lipid particles of the present invention is a target amount, and the actual amount of cationic lipid present in the formulation may vary, for example, by ±5mol%.For example, in a 1:57 lipid particle (e.g. SNALP) formulation, the target amount of cationic lipid is 57.1mol%, but the actual amount of cationic lipid can be ±5mol%, ±4mol%, ±3mol%, ±2mol%, ±1mol%, ±0.75mol%, ±0.5mol%, ±0.25mol%, or ±0.1mol% of the target amount, and the remainder of the formulation is composed of other lipid components (which add up to 100mol% of the total lipid present in the particle). Similarly, in a 7:54 lipid particle (e.g., SNALP) formulation, the target amount of cationic lipid is 54.06 mol%, but the actual amount of cationic lipid can be ±5 mol%, ±4 mol%, ±3 mol%, ±2 mol%, ±1 mol%, ±0.75 mol%, ±0.5 mol%, ±0.25 mol%, or ±0.1 mol% of the target amount, with the remainder of the formulation made up of other lipid components (which add up to 100 mol% of the total lipid present in the particle).

[0173] B. Noncationic Lipids The non-cationic lipids used in the lipid particles of the present invention (eg, SNALP) can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of forming a stable complex.

[0174] Non-limiting examples of non-cationic lipids include lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (DPPG), dioleoyl ... Phospholipids include phospholipids such as phosphatidylethanolamine (POPE), palmitoyloleoyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, dielaidoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. Other phospholipids, diacylphosphatidylcholine and diacylphosphatidylethanolamine, can also be used. The acyl group of these lipids is preferably C 10 -C 24Acyl groups derived from fatty acids having carbon chains, for example, lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.

[0175] Additional examples of non-cationic lipids include sterols such as cholesterol and its derivatives.Non-limiting examples of cholesterol derivatives include polar analogs such as 5α-cholestanol, 5β-coprostanol, cholesteryl-(2'-hydroxy)-ethyl ether, cholesteryl-(4'-hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogs such as 5α-cholestan, cholestenone, 5α-cholestanone, 5β-cholestanone, and cholesteryl decanoate; and mixtures thereof.In a preferred embodiment, the cholesterol derivative is a polar analog such as cholesteryl-(4'-hydroxy)-butyl ether.The synthesis of cholesteryl-(2'-hydroxy)-ethyl ether is described in WO 09 / 127060, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0176] In some embodiments, the non-cationic lipid present in the lipid particle (e.g., SNALP) comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the non-cationic lipid present in the lipid particle (e.g., SNALP), e.g., in a cholesterol-free lipid particle formulation, comprises or consists of one or more phospholipids. In yet other embodiments, the non-cationic lipid present in the lipid particle (e.g., SNALP), e.g., in a phospholipid-free lipid particle formulation, comprises or consists of cholesterol or a derivative thereof.

[0177] Other examples of non-cationic lipids suitable for use in the present invention include phosphorus-free lipids such as, for example, stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerol lysine oleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethylammonium bromide, ceramides, sphingomyelin, and the like.

[0178] In some embodiments, the non-cationic lipid comprises about 10 mol% to about 60 mol%, about 20 mol% to about 55 mol%, about 20 mol% to about 45 mol%, about 20 mol% to about 40 mol%, about 25 mol% to about 50 mol%, about 25 mol% to about 45 mol%, about 30 mol% to about 50 mol%, about 30 mol% to about 45 mol%, about 30 mol% to about 40 mol%, about 35 mol% to about 45 mol%, about 37 mol% to about 42 mol%, or about 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, or 45 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0179] In embodiments in which the lipid particle contains a mixture of phospholipids and cholesterol or a cholesterol derivative, the mixture may constitute up to about 40 mol%, 45 mol%, 50 mol%, 55 mol%, or 60 mol% of the total lipid present in the particle.

[0180] In some embodiments, the phospholipid component in the mixture may comprise about 2 mol% to about 20 mol%, about 2 mol% to about 15 mol%, about 2 mol% to about 12 mol%, about 4 mol% to about 15 mol%, or about 4 mol% to about 10 mol% (or any percentage or range therein) of the total lipid present in the particle. In certain preferred embodiments, the phospholipid component in the mixture comprises about 5 mol% to about 10 mol%, about 5 mol% to about 9 mol%, about 5 mol% to about 8 mol%, about 6 mol% to about 9 mol%, about 6 mol% to about 8 mol%, or about 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:57 lipid particle formulation comprising a mixture of phospholipids and cholesterol may comprise about 7 mol% (or any percentage thereof) of a phospholipid such as DPPC or DSPC of the total lipid present in the particle, mixed with, for example, about 34 mol% (or any percentage thereof) of a cholesterol or cholesterol derivative. As another non-limiting example, a 7:54 lipid particle formulation comprising a mixture of phospholipids and cholesterol may comprise about 7 mol% (or any percentage thereof) of a phospholipid such as DPPC or DSPC, mixed with, for example, about 32 mol% (or any percentage thereof) of a cholesterol or cholesterol derivative of the total lipid present in the particle.

[0181] In other embodiments, the cholesterol component in the mixture may comprise about 25 mol% to about 45 mol%, about 25 mol% to about 40 mol%, about 30 mol% to about 45 mol%, about 30 mol% to about 40 mol%, about 27 mol% to about 37 mol%, about 25 mol% to about 30 mol%, or about 35 mol% to about 40 mol% (or any percentage or range therein) of the total lipid present in the particle. In certain preferred embodiments, the cholesterol component in the mixture comprises about 25 mol% to about 35 mol%, about 27 mol% to about 35 mol%, about 29 mol% to about 35 mol%, about 30 mol% to about 35 mol%, about 30 mol% to about 34 mol%, about 31 mol% to about 33 mol%, or about 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, or 35 mol% (or any percentage or range therein) of the total lipid present in the particle. In other embodiments, the cholesterol component in the mixture comprises about 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 mol% (or any percentage or range therein) of the total lipid present in the particle.Typically, a 1:57 lipid particle formulation comprising a mixture of phospholipids and cholesterol may comprise about 34 mol% (or any percentage) of cholesterol or cholesterol derivative of the total lipid present in the particle, mixed with about 7 mol% (or any percentage) of phospholipid such as DPPC or DSPC.Typically, a 7:54 lipid particle formulation comprising a mixture of phospholipids and cholesterol may comprise about 32 mol% (or any percentage) of cholesterol or cholesterol derivative of the total lipid present in the particle, mixed with about 7 mol% (or any percentage) of phospholipid such as DPPC or DSPC.

[0182] In embodiments in which the lipid particle does not contain phospholipids, cholesterol or a derivative thereof may constitute up to about 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, 55 mol%, or 60 mol% of the total lipid present in the particle.

[0183] In some embodiments, cholesterol or a derivative thereof in the phospholipid-free lipid particle formulation may constitute about 25 mol% to about 45 mol%, about 25 mol% to about 40 mol%, about 30 mol% to about 45 mol%, about 30 mol% to about 40 mol%, about 31 mol% to about 39 mol%, about 32 mol% to about 38 mol%, about 33 mol% to about 37 mol%, about 35 mol% to about 45 mol%, about 30 mol% to about 35 mol%, about 35 mol% to about 40 mol%, or about 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, or 45 mol% (or any percentage or range therein) of the total lipid present in the particle. As a non-limiting example, a 1:62 lipid particle formulation may contain about 37 mol% (or any percentage thereof) cholesterol of the total lipid present in the particle. As another non-limiting example, a 7:58 lipid particle formulation may contain about 35 mol% (or any percentage thereof) cholesterol of the total lipid present in the particle.

[0184] In other embodiments, the non-cationic lipid comprises about 5 mol% to about 90 mol%, about 10 mol% to about 85 mol%, about 20 mol% to about 80 mol%, about 10 mol% (e.g., phospholipids only), or about 60 mol% (e.g., phospholipids and cholesterol or derivatives thereof) (or any percentage or range therein) of the total lipid present in the particle.

[0185] Further percentages and ranges of non-cationic lipids suitable for use in the lipid particles of the present invention are described in WO 09 / 127060, U.S. Patent Application Publication No. 20110071208, and U.S. Patent Application Publication No. 20110076335, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0186] It should be understood that the percentage of non-cationic lipid present in lipid particles of the present invention is a target amount, and the actual amount of non-cationic lipid present in the formulation may vary, for example, by ±5mol%.For example, in a 1:57 lipid particle (e.g. SNALP) formulation, the target amount of phospholipid is 7.1mol% and the target amount of cholesterol is 34.3mol%, but the actual amount of phospholipid can be ±2mol%, ±1.5mol%, ±1mol%, ±0.75mol%, ±0.5mol%, ±0.25mol%, or ±0.1mol% of the target amount, and the actual amount of cholesterol can be ±3mol%, ±2mol%, ±1mol%, ±0.75mol%, ±0.5mol%, ±0.25mol%, or ±0.1mol% of the target amount, and the rest of the formulation is composed of other lipid components (which add up to 100mol% of the total lipid present in the particle). Similarly, in a 7:54 lipid particle (e.g., SNALP) formulation, the target amount of phospholipid is 6.75 mol% and the target amount of cholesterol is 32.43 mol%, but the actual amount of phospholipid may be ±2 mol%, ±1.5 mol%, ±1 mol%, ±0.75 mol%, ±0.5 mol%, ±0.25 mol%, or ±0.1 mol% of the target amount, and the actual amount of cholesterol may be ±3 mol%, ±2 mol%, ±1 mol%, ±0.75 mol%, ±0.5 mol%, ±0.25 mol%, or ±0.1 mol% of the target amount, with the remainder of the formulation made up of other lipid components (which add up to 100 mol% of the total lipid present in the particle).

[0187] C. Lipid Conjugates In addition to cationic and non-cationic lipids, lipid particles (e.g., SNALP) of the present invention can further comprise lipid conjugates. Bound lipids are useful in inhibiting particle aggregation. Suitable bound lipids include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic polymer-lipid conjugates (CPLs), and mixtures thereof. In some embodiments, lipid particles comprise PEG-lipid conjugates or ATTA-lipid conjugates together with CPLs. The term "ATTA" or "polyamide" includes, but is not limited to, compounds described in U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0188] In a preferred embodiment, lipid conjugate is PEG-lipid.Examples of PEG-lipid include, but are not limited to, PEG coupled to dialkyloxypropyl (PEG-DAA), for example as described in WO 05 / 026372, PEG coupled to diacylglycerol (PEG-DAG), for example as described in US Patent Application Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG coupled to ceramide, for example as described in US Patent No. 5,885,613, PEG coupled to cholesterol or its derivatives, and mixtures thereof.The disclosures of these patent documents are incorporated herein by reference in their entirety for all purposes.

[0189] Additional PEG-lipids suitable for use in the present invention include, but are not limited to, mPEG2000-1,2-di-O-alkyl-sn3-carbomoyl glycerides (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in International Publication WO 09 / 086558, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Still additional suitable PEG-lipid conjugates include, but are not limited to, 1-[8'-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3',6'-dioxaoctanyl]carbamoyl-ω-methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0190] PEG is a linear water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEG is classified according to its molecular weight; for example, PEG2000 has an average molecular weight of about 2,000 Daltons, and PEG5000 has an average molecular weight of about 5,000 Daltons. PEG is commercially available from Sigma Chemical Co. and other companies, including, but not limited to, monomethoxypolyethyleneglycol (MePEG-OH), monomethoxypolyethyleneglycol-succinate (MePEG-S), monomethoxypolyethyleneglycol-succinimidylsuccinate (MePEG-S-NHS), monomethoxypolyethyleneglycol-amine (MePEG-NH2), monomethoxypolyethyleneglycol-tresylate (MePEG-TRES), monomethoxypolyethyleneglycol-imidazolyl-carbonyl (MePEG-IM), and such compounds that contain terminal hydroxyl groups instead of terminal methoxy groups (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH2, etc.). Other PEGs, such as the PEGs described in U.S. Patent Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20KDa) amine), are also useful for preparing the PEG-lipid conjugates of the present invention.The disclosures of these patents are incorporated herein by reference in their entirety for all purposes.In addition, monomethoxypolyethyleneglycol-acetic acid (MePEG-CH2COOH) is particularly useful for preparing PEG-lipid conjugates, including, for example, PEG-DAA conjugates.

[0191] The PEG component of the PEG-lipid conjugates described herein can comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In some cases, the PEG component has an average molecular weight of about 750 daltons to about 5,000 daltons (e.g., about 1,000 daltons to about 5,000 daltons, about 1,500 daltons to about 3,000 daltons, about 750 daltons to about 3,000 daltons, about 750 daltons to about 2,000 daltons, etc.). In other cases, the PEG component has an average molecular weight of about 550 daltons to about 1000 daltons, about 250 daltons to about 1000 daltons, about 400 daltons to about 1000 daltons, about 600 daltons to about 900 daltons, about 700 daltons to about 800 daltons, or about 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 daltons. In preferred embodiments, the PEG component has an average molecular weight of about 2,000 daltons or about 750 daltons.

[0192] In some cases, PEG can be substituted with alkyl, alkoxy, acyl or aryl groups. PEG can be directly bound to lipid or can be linked to lipid via a linker moiety. Any linker moiety suitable for coupling PEG to lipid can be used, including, for example, ester-free linker moieties and ester-containing linker moieties. In a preferred embodiment, the linker moiety is an ester-free linker moiety. As used herein, the term "ester-free linker moiety" refers to a linker moiety that does not contain a carboxylic acid ester bond (-OC(O)-). Suitable non-ester containing linker moieties include, but are not limited to, amide (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), disulfide (-SS-), ether (-O-), succinyl (-(O)CCH2CH2C(O)-), succinamidyl (-NHC(O)CH2CH2C(O)NH-), ether, disulfide, and combinations thereof, such as linkers containing both carbamate and amide linker moieties. In a preferred embodiment, a carbamate linker is used to couple the PEG to the lipid.

[0193] In other embodiments, an ester-containing linker moiety is used to couple the PEG to the lipid. Suitable ester-containing linker moieties include, for example, carbonate (-OC(O)O-), succinoyl, phosphate ester (-O-(O)POH-O-), sulfonate ester, and combinations thereof.

[0194] Phosphatidylethanolamines having a variety of acyl chain groups of various chain lengths and degrees of saturation can be attached to PEG to form lipid conjugates. Such phosphatidylethanolamines are commercially available or can be isolated or synthesized using conventional techniques known to those skilled in the art. 10 ~C 20Phosphatidylethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of 0 to 100 are preferred. Phosphatidylethanolamines with mono- or di-unsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).

[0195] The term "diacylglycerol" or "DAG" contains two fatty acyl chains, R 1 and R 2 and having 2-30 carbons, both of which are independently attached to the 1- and 2-positions of glycerol by ester bonds. The acyl groups may be saturated or have various degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C 12 ), myristoyl (C 14 ), palmitoyl (C 16 ), stearoyl (C 18 ), and Icosoil (C 20 In a preferred embodiment, R 1 and R 2 are identical, i.e. R 1 and R 2 are both myristoyl (i.e. dimyristoyl), and R 1 and R 2 are stearoyl (i.e., distearoyl), etc. Diacylglycerols have the general formula I have TIFF2024161074000010.tif49128.

[0196] The term "dialkyloxypropyl" or "DAA" includes two alkyl chains R, each of which independently has 2 to 30 carbons. 1 and R 2The alkyl groups can be saturated or have varying degrees of unsaturation. Dialkyloxypropyls include compounds having the general formula I have TIFF2024161074000011.tif35128.

[0197] In a preferred embodiment, the PEG-lipid has the formula TIFF2024161074000012.tif26128 is a PEG-DAA conjugate having: In the formula, R 1 and R 2 are independently selected and are long chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is polyethylene glycol; and L is an ester-free or ester-containing linker moiety as described above. The long chain alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (C 10 ), Lauryl (C 12 ), myristyl (C 14 ), Palmityl (C 16 ), Stearyl (C 18 ), and Eicosil (C 20 In a preferred embodiment, R 1 and R 2 are the same, i.e. R 1 and R 2 are both myristyl (i.e. dimyristyl), and R 1 and R 2 are both stearyl (i.e. distearyl), etc.

[0198] In the above formula IV, PEG has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In some cases, PEG has an average molecular weight of about 750 daltons to about 5,000 daltons (e.g., about 1,000 daltons to about 5,000 daltons, about 1,500 daltons to about 3,000 daltons, about 750 daltons to about 3,000 daltons, about 750 daltons to about 2,000 daltons, etc.). In other cases, the PEG moiety has an average molecular weight of about 550 daltons to about 1000 daltons, about 250 daltons to about 1000 daltons, about 400 daltons to about 1000 daltons, about 600 daltons to about 900 daltons, about 700 daltons to about 800 daltons, or about 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 daltons. In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons. The PEG may be substituted with alkyl, alkoxy, acyl, or aryl groups. In some embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.

[0199] In a preferred embodiment, "L" is an ester-free linker moiety. Suitable ester-free linkers include, but are not limited to, amide linker moieties, amino linker moieties, carbonyl linker moieties, carbamate linker moieties, urea linker moieties, ether linker moieties, disulfide linker moieties, succinamidyl linker moieties, and combinations thereof. In a preferred embodiment, the ester-free linker moiety is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate). In another preferred embodiment, the ester-free linker moiety is an amide linker moiety (i.e., a PEG-A-DAA conjugate). In yet another preferred embodiment, the ester-free linker moiety is a succinamidyl linker moiety (i.e., a PEG-S-DAA conjugate).

[0200] In certain embodiments, the PEG-lipid conjugate comprises Selected from TIFF2024161074000013.tif43147.

[0201] PEG-DAA conjugates are synthesized using standard techniques and reagents known to those skilled in the art. It will be recognized that PEG-DAA conjugates contain various amide, amine, ether, sulfur, carbamate, and urea bonds. Those skilled in the art will be aware that the methods and reagents for forming these bonds are well known and readily available. See, for example, March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989). It will also be recognized that any functional groups present may require protection and deprotection at different points in the synthesis of PEG-DAA conjugates. Those skilled in the art will be aware that such techniques are well known. See, for example, Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991).

[0202] Preferably, the PEG-DAA conjugate is PEG-didecyloxypropyl (C 10 ) conjugate, PEG-dilauryloxypropyl (C 12 ) conjugate, PEG-dimyristyloxypropyl (C 14 ) conjugate, PEG-dipalmityloxypropyl (C 16 ) conjugate, or PEG-distearyloxypropyl (C 18) conjugates. In these embodiments, the PEG preferably has an average molecular weight of about 750 or about 2,000 daltons. In one particularly preferred embodiment, the PEG-lipid conjugate comprises PEG2000-C-DMA, where "2000" represents the average molecular weight of PEG, "C" represents the carbamate linker moiety, and "DMA" represents dimyristyloxypropyl. In another particularly preferred embodiment, the PEG-lipid conjugate comprises PEG750-C-DMA, where "750" represents the average molecular weight of PEG, "C" represents the carbamate linker moiety, and "DMA" represents dimyristyloxypropyl. In certain embodiments, the terminal hydroxyl group of PEG is replaced with a methyl group. Those skilled in the art will readily recognize that other dialkyloxypropyls can be used in the PEG-DAA conjugates of the present invention.

[0203] In addition to the above, it will be readily apparent to one skilled in the art that other hydrophilic polymers can be used in place of PEG. Examples of suitable polymers that can be used in place of PEG include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.

[0204] In addition to the above components, the lipid particles (e.g., SNALP) of the present invention can further include cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et al., Bioconj. Chem., 11:433-437 (2000); U.S. Pat. No. 6,852,334; WO 00 / 62813, the disclosures of which are incorporated by reference in their entireties for all purposes).

[0205] In some embodiments, the lipid conjugate (e.g., PEG-lipid) is about 0.1 mol% to about 2 mol%, about 0.5 mol% to about 2 mol%, about 1 mol% to about 2 mol%, about 0.6 mol% to about 1.9 mol%, about 0.7 mol% to about 1.8 mol%, about 0.8 mol% to about 1.7 mol%, about 0.9 mol% to about 1.6 mol%, about 0.9 mol% to about 1.8 ... It constitutes about 1 mol% to about 1.8 mol%, about 1 mol% to about 1.7 mol%, about 1.2 mol% to about 1.8 mol%, about 1.2 mol% to about 1.7 mol%, about 1.3 mol% to about 1.6 mol%, about 1.4 mol% to about 1.5 mol%, or about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 mol% (or any percentage or range therein).

[0206] In other embodiments, the lipid conjugate (e.g., PEG-lipid) constitutes about 0 mol% to about 20 mol%, about 0.5 mol% to about 20 mol%, about 2 mol% to about 20 mol%, about 1.5 mol% to about 18 mol%, about 2 mol% to about 15 mol%, about 4 mol% to about 15 mol%, about 2 mol% to about 12 mol%, about 5 mol% to about 12 mol%, or about 2 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0207] In further embodiments, the lipid conjugate (e.g., PEG-lipid) constitutes about 4 mol% to about 10 mol%, about 5 mol% to about 10 mol%, about 5 mol% to about 9 mol%, about 5 mol% to about 8 mol%, about 6 mol% to about 9 mol%, about 6 mol% to about 8 mol%, or about 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range therein) of the total lipid present in the particle.

[0208] Further examples, percentages, and / or ranges of lipid conjugates suitable for use in the lipid particles of the present invention are described in WO 09 / 127060, U.S. Patent Application Publication No. 20110071208, U.S. Patent Application Publication No. 20110076335, U.S. Patent Application No. 13 / 006,277 filed January 13, 2011, and WO 2010 / 006282, the disclosures of which are incorporated by reference in their entireties herein for all purposes.

[0209] It should be understood that the percentage of lipid conjugate (e.g. PEG-lipid) present in lipid particles of the present invention is a target amount, and the actual amount of lipid conjugate present in the formulation may vary, for example, by ±2mol%.For example, in a 1:57 lipid particle (e.g. SNALP) formulation, the target amount of lipid conjugate is 1.4mol%, but the actual amount of lipid conjugate may be ±0.5mol%, ±0.4mol%, ±0.3mol%, ±0.2mol%, ±0.1mol%, or ±0.05mol% of the target amount, with the remainder of the formulation being composed of other lipid components (which add up to 100mol% of the total lipid present in the particle). Similarly, in a 7:54 lipid particle (e.g., SNALP) formulation, the target amount of lipid conjugate is 6.76 mol%, but the actual amount of lipid conjugate can be ±2 mol%, ±1.5 mol%, ±1 mol%, ±0.75 mol%, ±0.5 mol%, ±0.25 mol%, or ±0.1 mol% of that target amount, with the remainder of the formulation made up of other lipid components (which add up to 100 mol% of the total lipid present in the particle).

[0210] One of skill in the art will recognize that the concentration of lipid conjugate can be varied depending on the lipid conjugate used and on the rate at which the lipid particles become fusogenic.

[0211] By controlling the composition and concentration of lipid conjugate, the exchange rate of lipid conjugate from lipid particle, and in turn the rate at which lipid particle becomes fusogenic, can be controlled.For example, when PEG-DAA conjugate is used as lipid conjugate, the rate at which lipid particle becomes fusogenic can be varied, for example, by varying the concentration of lipid conjugate, by varying the molecular weight of PEG, or by varying the chain length and saturation of alkyl group on PEG-DAA conjugate.In addition, other variables, including, for example, pH, temperature, ionic strength, etc., can be used to vary and / or control the rate at which lipid particle becomes fusogenic.Other methods that can be used to control the rate at which lipid particle becomes fusogenic will be clear to those skilled in the art upon reading this disclosure.In addition, the particle size of lipid particle (e.g., SNALP) can be controlled by controlling the composition and concentration of lipid conjugate.

[0212] VI. Preparation of lipid particles The lipid particles of the present invention (in which an active ingredient such as a nucleic acid (e.g., an interfering RNA such as siRNA) is entrapped in the lipid portion of the particle and protected from degradation), e.g., SNALP, can be formed by any method known in the art, including, but not limited to, continuous mixing, direct dilution, and in-line dilution processes. In some embodiments, one or more antioxidants, such as a metal chelator (e.g., EDTA), a primary antioxidant, and / or a secondary antioxidant, can be included at any step or steps in the process described in PCT Application No. PCT / CA2010 / 001919 (the disclosure of which is incorporated by reference in its entirety for all purposes) (e.g., before, during, and / or after the formation of the lipid particles).

[0213] In certain embodiments, the cationic lipids may include at least one, two, three, four, five, or more cationic lipids, such as those shown in Formula I, or salts thereof, alone or in combination with other cationic lipid species. In other embodiments, the non-cationic lipid is one, two, or more lipids, such as egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, 14:0 PE (1,2-dimyristoyl-phosphatidylethanolamine (DMPE)), 16:0 PE (1,2-dipalmitoyl-phosphatidylethanolamine (DPPE)), 18:0 PE (1,2-distearoyl-phosphatidylethanolamine (DSPE)), 18:1 PE (1,2-dioleoyl-phosphatidylethanolamine (DOPE)), 18:1 The phosphatidylethanolamine may include trans PE (1,2-dielideyl-phosphatidylethanolamine (DEPE)), 18:0 to 18:1 PE (1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE)), 16:0 to 18:1 PE (1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE)), polyethylene glycol-based polymers (e.g., PEG2000, PEG5000, PEG-modified diacylglycerol, or PEG-modified dialkyloxypropyl), cholesterol, derivatives thereof, or combinations thereof.

[0214] In one embodiment, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced by a process that includes, for example, providing an aqueous solution containing a nucleic acid (e.g., an interfering RNA) in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the organic lipid solution with the aqueous solution such that the organic lipid solution is mixed with the aqueous solution to substantially instantly produce lipid vesicles (e.g., liposomes) encapsulating the nucleic acid therein. This process and an apparatus for carrying out this process are described in detail in U.S. Patent Application Publication No. 20040142025, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0215] By continuously introducing lipid and buffer solution into a mixing environment, such as in a mixing chamber, the lipid solution is continuously diluted by the buffer solution, which generates lipid vesicles substantially instantly upon mixing.As used herein, the phrase "continuously dilute lipid solution with buffer solution" (and variations) generally means that the lipid solution is diluted sufficiently quickly and with sufficient force to achieve vesicle production in the hydration process.By mixing an aqueous solution containing nucleic acid with an organic lipid solution, the organic lipid solution undergoes continuous stepwise dilution in the presence of a buffer solution (i.e., an aqueous solution) to generate nucleic acid-lipid particles.

[0216] Nucleic acid-lipid particles formed using the continuous mixing method typically have a size of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 to about 90 nm, about 80 nm to about 90 nm, about 70 nm to about 80 nm, less than about 120 nm, less than 110 nm, less than 100 nm, The particles so formed have a size of less than 90 nm, or less than 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction or range therein). The particles so formed do not aggregate and are sized, if desired, to achieve a uniform particle size.

[0217] In another embodiment, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via a direct dilution process, which includes forming a lipid vesicle (e.g., liposome) solution and immediately introducing the lipid vesicle solution directly into a collection vessel containing a controlled amount of dilution buffer. In a preferred aspect, the collection vessel includes one or more elements designed to agitate the contents of the collection vessel to facilitate dilution. In one aspect, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of lipid vesicle solution introduced therein. As a non-limiting example, a 45% ethanol solution of lipid vesicles can advantageously result in smaller particles when introduced into a collection vessel containing an equal volume of dilution buffer.

[0218] In yet another embodiment, the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via an in-line dilution process in which a third reservoir containing a dilution buffer is in fluid communication with the second mixing region. In this embodiment, the lipid vesicle (e.g., liposome) solution formed in the first mixing region is immediately mixed directly with the dilution buffer in the second mixing region. In a preferred aspect, the second mixing region includes a T-linker arranged such that the lipid vesicle solution and the dilution buffer streams meet as 180° opposing streams, although connectors providing shallower angles, e.g., from about 27° to about 180° (e.g., about 90°), can also be used. A pump mechanism delivers a controllable buffer flow to the second mixing region. In one aspect, the flow rate of the dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of the lipid vesicle solution introduced thereto from the first mixing region. This embodiment advantageously allows for further control of the flow of the dilution buffer that is mixing with the lipid vesicle solution in the second mixing region, and therefore the concentration of the lipid vesicle solution in the buffer throughout the second mixing process. Such control of the dilution buffer flow rate advantageously allows for the formation of smaller particle sizes at lower concentrations.

[0219] These processes and equipment for carrying out these direct and in-line dilution processes are described in detail in U.S. Patent Application Publication No. 20070042031, the disclosure of which is incorporated by reference herein in its entirety for all purposes.

[0220] Nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes typically have a diameter of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 to about 90 nm, about 80 nm to about 90 nm, about 70 nm to about 80 nm, less than about 120 nm, less than 110 nm, The particles thus formed have a size of less than 100 nm, less than 90 nm, or less than 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction or range therein). The particles thus formed do not aggregate and may be sized to achieve a uniform particle size.

[0221] If necessary, the lipid particles (e.g., SNALP) of the present invention can be sized by any method available for sizing liposomes. Sizing can be carried out to achieve a desired size range and relatively narrow particle size distribution.

[0222] Several techniques can be used to size the particles to the desired size. One granulation method used for liposomes and equally applicable to the particles of the present invention is described in U.S. Pat. No. 4,737,323, the disclosure of which is incorporated herein by reference in its entirety for all purposes. The particle suspension is sonicated by bath or probe sonication to gradually reduce the particle size to less than about 50 nm. Homogenization is another method that relies on shear energy to fragment larger particles into smaller particles. In a typical homogenization procedure, the particles are recirculated through a standard emulsion homogenizer until a selected particle size is observed, typically between about 60 and about 80 nm. In both methods, the particle size distribution can be monitored by conventional laser light particle size discrimination or QELS.

[0223] Extrusion of particles through fine-pored polycarbonate or asymmetric ceramic membranes is also an effective method for reducing particle size to a relatively well-defined size distribution. Typically, the suspension is circulated through the membrane one or more times until the desired particle size distribution is achieved. The particles can be extruded through successively smaller pore membranes to gradually reduce the size.

[0224] In some embodiments, the nucleic acids present in the particles are pre-concentrated, for example, as described in U.S. patent application Ser. No. 09 / 744,103, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0225] In another embodiment, the method further comprises adding a non-lipid polycation useful for lipofection of cells using the composition of the present invention. Examples of suitable non-lipid polycations include hexadimethrine bromide (sold under the trade name POLYBRENE® by Aldrich Chemical Co., Milwaukee, Wisconsin, USA) or other hexadimethrine salts. Other suitable polycations include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. These salts are preferably added after the particles are formed.

[0226] In some embodiments, the nucleic acid / lipid ratio (mass / mass ratio) in the formed nucleic acid-lipid particles (e.g., SNALP) can range from about 0.01 to about 0.2, about 0.05 to about 0.2, about 0.02 to about 0.1, about 0.03 to about 0.1, or about 0.01 to about 0.08. The ratio of starting materials (input amounts) also falls within this range. In other embodiments, the particle preparation uses about 400 μg of nucleic acid per 10 mg of total lipid, or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08, more preferably about 0.04, corresponding to 1.25 mg of total lipid per 50 μg of nucleic acid. In other preferred embodiments, the particles have a nucleic acid:lipid mass ratio of about 0.08.

[0227] In other embodiments, the lipid to nucleic acid ratio (mass / mass ratio) in the formed nucleic acid-lipid particles (e.g., SNALP) is from about 1 (1:1) to about 100 (100:1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), or from about 4 (4:1) to about 50 (50:1). (50:1), about 4 (4:1) to about 50 (50:1), about 5 (5:1) to about 50 (50:1), about 1 (1:1) to about 25 (25:1), about 2 (2:1) to about 25 (25:1), about 3 (3:1) to about 25 (25:1), about 4 (4:1) to about 25 (25:1), about 5 (5:1) to about 25 (25:1), about The ratio is in the range of 5 (5:1) to about 20 (20:1), about 5 (5:1) to about 15 (15:1), about 5 (5:1) to about 10 (10:1), or about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), 15 (15:1), 16 (16:1), 17 (17:1), 18 (18:1), 19 (19:1), 20 (20:1), 21 (21:1), 22 (22:1), 23 (23:1), 24 (24:1), or 25 (25:1), or any ratio or range therein. The ratios of starting materials (feed amounts) also fall within this range.

[0228] As mentioned above, the conjugated lipid may further include a CPL. Various general methods for producing SNALP-CPL (CPL-containing SNALP) are described herein. Two general techniques include the "post-insertion" technique, i.e., inserting CPL into, for example, a preformed SNALP, and the "standard" technique, in which CPL is included in the lipid mixture, for example, during the SNALP formation stage. The post-insertion technique produces SNALPs with CPL mainly on the outer surface of the SNALP bilayer membrane, while the standard technique provides SNALPs with CPL on both the inner and outer surfaces. This method is particularly useful for vesicles made from phospholipids (which may contain cholesterol) and vesicles containing PEG-lipids (such as PEG-DAA and PEG-DAG). Methods for producing SNALP-CPLs are taught, for example, in U.S. Pat. Nos. 5,705,385; 6,586,410; 5,981,501; 6,534,484; and 6,852,334; U.S. Patent Application Publication No. 20020072121; and WO 00 / 62813, the disclosures of which are incorporated by reference herein in their entireties for all purposes.

[0229] VII. Kits The present invention also provides lipid particles (e.g., SNALP) in kit form. In some embodiments, the kit includes a container that is compartmentalized to hold various components of the lipid particle (e.g., an active ingredient or therapeutic agent, such as a nucleic acid, and individual lipid components of the particle). Preferably, the kit includes a container (e.g., a vial or an ampoule) that holds the lipid particles (e.g., SNALP) of the present invention, where the particles are manufactured by one of the processes set forth herein. In some embodiments, the kit may further include one or more antioxidants, such as a metal chelator (e.g., EDTA), a primary antioxidant, and / or a secondary antioxidant. In other embodiments, the kit may further include an endosomal membrane destabilizing agent (e.g., calcium ions). Typically, the kit includes the particle composition of the present invention, either as a suspension in a pharma- ceutically acceptable carrier or in dehydrated form, along with instructions for its rehydration (if lyophilized) and administration.

[0230] The lipid particles of the present invention can be customized to preferentially target specific tissues, organs or tumors of interest.In some cases, preferential targeting of lipid particles such as SNALP can be achieved by controlling the composition of the particle itself.In some cases, 1:57 lipid particle (e.g. SNALP) formulation can be used to preferentially target liver (e.g. normal liver tissue).In other cases, 7:54 lipid particle (e.g. SNALP) formulation can be used to preferentially target solid tumors such as liver tumors and tumors outside the liver.In a preferred embodiment, the kit of the present invention comprises these liver-targeting and / or tumor-targeting lipid particles, where the particles are present in a container as a suspension or in a dehydrated form.

[0231] In some cases, it may be desirable to attach targeting moieties to the surface of the lipid particles to further enhance targeting of the particles. Methods for attaching targeting moieties (e.g., antibodies, proteins, etc.) to lipids (such as those used in the particles of the present invention) are known to those of skill in the art.

[0232] VIII. Administration of Lipid Particles Once formed, the lipid particles (e.g., SNALP) of the present invention are useful for the introduction of active ingredients or therapeutic agents (e.g., nucleic acids such as interfering RNA) into cells. Thus, the present invention also provides a method for introducing active ingredients or therapeutic agents, such as nucleic acids (e.g., interfering RNA), into cells. In some cases, the cells are liver cells, such as hepatocytes present in liver tissue. In other cases, the cells are tumor cells, such as tumor cells present in solid tumors. This method is carried out in vitro or in vivo by first forming the above-mentioned particles, and then contacting the cells with the particles for a sufficient time for delivery of the active ingredients or therapeutic agents to the cells to occur.

[0233] The lipid particles (e.g., SNALP) of the present invention can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with the cell membrane, or fuse with the cells. Delivery or incorporation of the active or therapeutic (e.g., nucleic acid) components of the particles can be achieved by any one of these routes. In particular, when fusion occurs, the membrane of the particle is incorporated into the cell membrane and the contents of the particle are miscible with the intracellular fluid.

[0234] The lipid particles (e.g., SNALP) of the present invention can be administered alone or in admixture with a pharma- ceutically acceptable carrier (e.g., saline or phosphate buffer) selected according to the route of administration and standard pharmaceutical practice. Generally, physiological buffered saline (e.g., 135-150 mM NaCl) will be used as the pharma- ceutically acceptable carrier. Other suitable carriers include, for example, water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins such as albumin, lipoproteins, globulins, and the like, for enhanced stability. Further suitable carriers are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company Philadelphia, PA, 17th ed. (1985). As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The phrase "pharmacologically acceptable" refers to molecular entities and compositions that do not produce allergic or similar adverse reactions when administered to humans.

[0235] The pharma- ceutically acceptable carrier is generally added after the formation of the lipid particles. Thus, after the lipid particles (e.g., SNALP) are formed, the particles can be diluted in a pharma- ceutically acceptable carrier, such as physiological buffered saline.

[0236] The concentration of particles in a pharmaceutical formulation may vary widely, i.e., from less than about 0.05% by weight, usually about or at least about 2-5% by weight, and as much as about 10-90% by weight, and will be selected primarily by fluid volume, viscosity, etc., in accordance with the particular mode of administration selected. For example, the concentration can be increased to reduce the fluid load associated with the treatment. This may be particularly desirable for patients with congestive heart failure or severe hypertension associated with atherosclerosis. Alternatively, particles composed of irritating lipids can be diluted to low concentrations to reduce inflammation at the site of administration.

[0237] The pharmaceutical composition of the present invention can be sterilized by conventional well-known sterilization techniques. The aqueous solution can be packaged for use, or filtered and lyophilized under aseptic conditions, and the lyophilized preparation can be mixed with a sterile aqueous solution before administration. The composition can contain pharma- ceutically acceptable auxiliary substances, such as pH-adjusting buffers, osmolality adjusting agents, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride, as required for appropriate physiological conditions. Additionally, the particle suspension can contain lipid protective agents that protect lipids from free radical damage and lipid peroxidation damage during storage. Lipophilic free radical quenchers such as α-tocopherol and water-soluble iron-specific chelators such as ferrioxamine are suitable.

[0238] In some embodiments, the lipid particles (e.g., SNALP) of the present invention are particularly useful in methods for therapeutic delivery of one or more nucleic acids, including interfering RNA sequences (e.g., siRNA). In particular, it is an object of the present invention to provide in vitro and in vivo methods for treating disease or disorder in a mammal (e.g., rodent, such as mouse, or primate, such as human, chimpanzee, or monkey) by downregulating or silencing the transcription and / or translation of one or more target nucleic acid sequences or genes of interest. As a non-limiting example, the method of the present invention is useful for in vivo delivery of interfering RNA (e.g., siRNA) to the liver and / or tumor of a mammalian subject. In some embodiments, the disease or disorder is associated with the expression and / or overexpression of a gene, and the expression or overexpression of the gene is reduced by the interfering RNA (e.g., siRNA). In some other embodiments, a therapeutically effective amount of lipid particles can be administered to a mammal. In some cases, the interfering RNA (e.g., siRNA) is formulated into SNALP, and the particles are administered to a patient in need of such treatment. In other cases, cells are removed from the patient, interfering RNA is delivered in vitro (eg, using SNALP as described herein), and the cells are re-infused into the patient.

[0239] A. In Vivo Administration Systemic delivery for in vivo therapy, e.g., delivery of therapeutic nucleic acids to distant target cells via a body system such as the circulation, is accomplished using nucleic acid-lipid particles such as those described in WO 05 / 007196, WO 05 / 121348, WO 05 / 120152, and WO 04 / 002453, the disclosures of which are incorporated by reference in their entirety for all purposes. The present invention also provides fully encapsulated lipid particles that protect nucleic acids from nuclease degradation in serum, are non-immunogenic, small in size, and suitable for repeated dosing.

[0240] For in vivo administration, administration can be by any method known in the art, such as injection, oral administration, inhalation (e.g., intranasal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished by single or divided doses. Pharmaceutical compositions can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, pharmaceutical compositions are administered intravenously or intraperitoneally by bolus injection (see, e.g., U.S. Patent No. 5,286,634). Intracellular nucleic acid delivery is also described in Straubringer et al., Methods Enzymol., 101:512 (1983); Mannino et al., Biotechniques, 6:682 (1988); Nicolau et al., Crit. Rev. Ther. Drug Carrier Syst., 6:239 (1989); and Behr, Acc. Chem. Res., 26:274 (1993). Still other methods of administering lipid-based therapeutic agents are described in, for example, U.S. Patent Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578. The lipid particles can be administered by direct injection at the disease site or by injection at a site distal to the disease site (see, e.g., Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York. pp.70-71(1994)). The disclosures of the above references are incorporated herein by reference in their entirety for all purposes.

[0241] In an embodiment in which the lipid particles (e.g., SNALP) of the present invention are administered intravenously, at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma at about 8, 12, 24, 36, or 48 hours after injection. In other embodiments, more than about 20%, 30%, 40%, and as much as about 60%, 70%, or 80% of the total injected dose of the lipid particles is present in plasma at about 8, 12, 24, 36, or 48 hours after injection. In some cases, more than about 10% of the particles are present in the plasma of the mammal at about 1 hour after administration. In some other cases, the presence of the lipid particles is detectable at least about 1 hour after administration of the particles. In some embodiments, the presence of the therapeutic agent, such as nucleic acid, is detectable in lung, liver, tumor cells, or in cells at inflammation sites at about 8, 12, 24, 36, 48, 60, 72, or 96 hours after administration. In other embodiments, the downregulation of the expression of target sequence by interfering RNA (e.g., siRNA) is detectable about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.In yet other embodiments, the downregulation of the expression of target sequence by interfering RNA (e.g., siRNA) occurs preferentially in liver cells (e.g., hepatocytes), in tumor cells, or in cells at inflammation sites.In further embodiments, the presence or effect of interfering RNA (e.g., siRNA) in cells proximal or distal to the administration site or in lung, liver, or tumor cells is detectable about 12, 24, 48, 72 or 96 hours after administration, or about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26 or 28 days after administration.In additional embodiments, the lipid particles (e.g., SNALP) of the present invention are administered parenterally or intraperitoneally.

[0242] The compositions of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., the formulations can be "nebulized") for administration via inhalation (e.g., intranasally or intratracheally) (see Brigham et al., Am. J Sci., 298:278 (1989)). The aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

[0243] In some embodiments, pharmaceutical compositions can be delivered by intranasal spray, inhalation, and / or other aerosol delivery vehicles. Methods for delivering nucleic acid compositions directly to the lungs by nasal aerosol spray are described, for example, in U.S. Patent Nos. 5,756,353 and 5,804,212. Similarly, drug delivery using intranasal microparticle resins and lysophosphatidyl-glycerol compounds (U.S. Patent No. 5,725,871) is also well known in the pharmaceutical art. Similarly, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is ​​described in U.S. Patent No. 5,780,045. The disclosures of the above patents are incorporated herein by reference in their entirety for all purposes.

[0244] Formulations suitable for parenteral administration, such as by intraarticular (into a joint), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous isotonic sterile injections which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may contain suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of the invention, compositions are preferably administered orally, topically, intraperitoneally, intravesically, or intrathecally, for example, by intravenous infusion.

[0245] Generally, lipid particle formulations are formulated with a suitable pharmaceutical carrier when administered intravenously. Many pharma- ceutically acceptable carriers can be used in the compositions and methods of the present invention. Formulations suitable for use in the present invention can be found, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). A variety of aqueous carriers can be used, such as water, buffered water, 0.4% saline, 0.3% glycine, and the like, which may contain glycoproteins such as albumin, lipoproteins, globulins, etc., to enhance stability. Physiologically buffered saline (135-150 mM NaCl) is commonly used as a pharma- ceutically acceptable carrier, although other suitable carriers may suffice. These compositions can be sterilized by conventional liposome sterilization techniques, such as filtration. These compositions may contain pharma- ceutically acceptable auxiliary substances, such as pH adjusting buffers, osmotic adjusting agents, wetting agents, etc., as required to approximate physiological conditions, e.g., sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. These compositions may be sterilized using the techniques described above, or alternatively, may be prepared under sterile conditions. The resulting aqueous solutions may be packaged for use, or filtered and lyophilized under aseptic conditions, and the lyophilized preparation may be mixed with a sterile aqueous solution prior to administration.

[0246] In some applications, lipid particles disclosed herein can be delivered by oral administration to an individual.Particles can be mixed with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwashes, suspensions, oral sprays, syrups, wafers, etc. (see, for example, U.S. Patent Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are incorporated herein by reference in their entirety for all purposes).These oral dosage forms can also contain: binders, gelatin; excipients, lubricants, and / or flavorings.When the unit dosage form is a capsule, it can contain a liquid carrier in addition to the above-mentioned materials.Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharma- ceutical pure and substantially non-toxic in the amounts employed.

[0247] Typically, these oral formulations may contain at least about 0.1% or more lipid particles, but the percentage of particles may of course vary and may conveniently be between about 1% or 2% and about 60% or 70% or more of the total weight or volume of the formulation.Of course, the amount of particles in each therapeutically useful composition can be prepared in any given unit dose of compound in such a manner that an appropriate dosage is obtained.Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life and other pharmacological considerations are taken into account by those skilled in the art who prepare such pharmaceutical formulations, and thus, various dosages and treatment regimes may be desirable.

[0248] Formulations suitable for oral administration may consist of: (a) an effective amount of a packaged therapeutic agent, such as a nucleic acid (e.g., an interfering RNA), suspended in a liquid, e.g., water, saline, or diluent such as PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a therapeutic agent, such as a nucleic acid (e.g., an interfering RNA), as a liquid, solid, granules, or gelatin; (c) a suspension in a suitable liquid; and (d) a suitable emulsion. Tablet dosage forms may contain one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphate, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffers, wetting agents, preservatives, flavorings, dyes, disintegrants, and pharma- ceutically compatible carriers. Lozenge dosage forms may contain a therapeutic agent such as a nucleic acid (e.g., interfering RNA) in a flavoring agent, e.g., sucrose; similarly, pastilles contain a therapeutic agent in an inert base such as gelatin and glycerin, or sucrose and gum arabic; emulsions, gels, and the like may contain, in addition to the therapeutic agent, carriers known in the art.

[0249] In another example of their use, the lipid particles can be incorporated into a wide variety of topical dosage forms. For example, suspensions containing nucleic acid-lipid particles, such as SNALP, can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.

[0250] When preparing pharmaceutical formulations of the lipid particles of the present invention, it is preferable to use bulk particles that have been purified to reduce or remove empty particles or particles that have therapeutic agents, such as nucleic acids, bound to their outer surface.

[0251] The methods of the invention can be practiced in a variety of hosts. Preferred hosts include mammalian species such as primates (e.g., humans and chimpanzees, as well as other non-human primates), dogs, cats, horses, cows, sheep, goats, rodents (e.g., rats and mice), rabbits, and pigs.

[0252] The amount of particles administered will depend on the ratio of therapeutic agent (e.g., nucleic acid) to lipid, the particular therapeutic agent (e.g., nucleic acid) being used, the disease or disorder being treated, the age, weight, and condition of the patient, and the judgment of the practitioner, but will generally be between about 0.01 and about 50 mg / kg body weight, preferably between about 0.1 and about 5 mg / kg body weight, or about 10 mg / kg of particles per administration (e.g., injection). 8 ~10 10 There can be one.

[0253] B. In Vitro Administration For in vitro applications, delivery of therapeutic agents such as nucleic acids (e.g., interfering RNA) can be to any cell in culture, whether of plant or animal origin, vertebrate or invertebrate, of any tissue or type. In a preferred embodiment, the cell is an animal cell, more preferably a mammalian cell, and most preferably a human cell (e.g., a tumor cell or a hepatocyte).

[0254] When performed in vitro, contact between cells and lipid particles is performed in a biologically compatible medium. The concentration of particles varies widely depending on the particular application, but is generally between about 1 μmol and about 10 mmol. Treatment of cells with lipid particles is generally performed at physiological temperature (about 37° C.) for a period of about 1 to 48 hours, preferably about 2 to 4 hours.

[0255] In one group of preferred embodiments, the lipid particle suspension comprises about 10 3 ~about 10 5 / ml, more preferably about 2 × 10 4 The suspension is added to 60-80% confluent plated cells having a cell density of about 10 ...

[0256] To the extent that it may be required, cell tissue culture is well known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley-Liss, New York (1994), Kuchler et al., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and references cited therein provide general guidance to cell culture. The cell line that is cultured is often in the form of a monolayer of cells, although cell suspensions are also used.

[0257] Endosomal release parameter (ERP) assay can be used to optimize the delivery efficiency of SNALP or other lipid particles of the present invention. ERP assay is described in detail in US Patent Publication No. 20030077829, the disclosure of which is incorporated herein by reference in its entirety for all purposes. More specifically, the purpose of ERP assay is to distinguish the effects of various cationic lipid and helper lipid components of SNALP or other lipid particles based on their relative effects on binding / uptake or fusion with / destabilization of endosomal membranes. This assay allows quantitative determination of how each component of SNALP or other lipid particles affects delivery efficiency, thereby optimizing SNALP or other lipid particles. Typically, ERP assay measures the expression of a reporter protein (e.g., luciferase, β-galactosidase, green fluorescent protein (GFP), etc.), so in some cases, SNALP formulations optimized for expression plasmids are also suitable for encapsulating interference RNA. In other cases, ERP assays can be adapted to measure the downregulation of transcription or translation of a target sequence in the presence or absence of an interfering RNA (e.g., siRNA).By comparing the ERP for each of a variety of SNALPs or other lipid particles, an optimized system can be easily determined, for example, the SNALP or other lipid particle that is most highly taken up into cells.

[0258] C. Cells for Delivery of Lipid Particles The compositions and methods of the present invention are used to treat a wide variety of cell types in vivo and in vitro. Suitable cells include, but are not limited to, hepatocytes, reticuloendothelial cells (e.g., monocytes, macrophages, etc.), fibroblasts, endothelial cells, platelet cells, other cell types infected with viruses and / or susceptible to viral infection, hematopoietic progenitor (stem) cells, keratinocytes, skeletal and smooth muscle cells, osteoblasts, neural cells, quiescent lymphocytes, terminally differentiated cells, slow-cycling or arrested primary cells, parenchymal cells, lymphocytes, epithelial cells, bone cells, etc.

[0259] In certain embodiments, an active or therapeutic agent, such as a nucleic acid (e.g., an interfering RNA), is delivered to cancer cells (e.g., cells of a solid tumor), including, but not limited to, liver cancer cells, lung cancer cells, colon cancer cells, rectal cancer cells, anal cancer cells, cholangiocarcinoma cells, small intestine cancer cells, gastric cancer cells, esophageal cancer cells, gallbladder cancer cells, pancreatic cancer cells, appendix cancer cells, breast cancer cells, ovarian cancer cells, cervical cancer cells, prostate cancer cells, renal cancer cells, cancer cells of the central nervous system, glioblastoma cells, skin cancer cells, lymphoma cells, choriocarcinoma tumor cells, head and neck cancer cells, osteogenic sarcoma cells, and blood cancer cells.

[0260] The in vivo delivery of lipid particles such as SNALP that encapsulate nucleic acid (e.g., interfering RNA) is suitable for targeting cells of any cell type.The method and composition can be used for the cells of a wide variety of vertebrates, including mammals such as dog, cat, horse, cow, sheep, goat, rodent (e.g., mouse, rat, and guinea pig), rabbit, pig, and primate (e.g., monkey, chimpanzee, and human).

[0261] D. Detection of lipid particles In some embodiments, the lipid particles (e.g., SNALP) of the present invention can be detected in a subject at about 1, 2, 3, 4, 5, 6, 7, 8 hours or more.In other embodiments, the lipid particles (e.g., SNALP) of the present invention can be detected in a subject at about 8, 12, 24, 48, 60, 72, or 96 hours or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles.The presence of the particles can be detected in cells, tissues, or other biological samples from a subject.The particles can be detected, for example, by direct detection of the particles, by detection of therapeutic nucleic acid such as interfering RNA (e.g., siRNA) sequences, by detection of target sequences of interest (i.e., by detecting expression or reduced expression of sequences of interest), or by combinations thereof.

[0262] 1. Particle detection The lipid particles of the present invention, such as SNALP, can be detected using any method known in the art. For example, labels can be directly or indirectly coupled to lipid particle components using methods well known in the art. A wide variety of labels can be used, with the label being selected according to the required sensitivity, ease of binding to lipid particle components, stability requirements, and available measurement and disposal provisions. Suitable labels include, but are not limited to, fluorescent dyes (e.g., fluorescein and derivatives such as fluorescein isothiocyanate (FITC) and Oregon Green™; rhodamine and derivatives such as Texas Red, tetrarhodamine isothiocyanate (TRITC), spectroscopic labels such as digoxigenin, biotin, phycoerythrin, AMCA, CyDye™, etc.; 3 H, 125 I, 35 S, 14 C. 32 P, 33 These include radiolabels such as P; enzymes such as horseradish peroxidase, alkaline phosphatase, and spectrocolorimetric labels such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc. The labels can be detected using any means known in the art.

[0263] 2. Nucleic Acid Detection Nucleic acid (e.g., interfering RNA) is detected and quantified herein by any of several means well known to those skilled in the art.Nucleic acid detection can be performed by well-known methods such as Southern analysis, Northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography.Additional biochemical analysis methods such as spectrometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography can also be used.

[0264] The choice of nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assay and competitive or displacement assay. Hybridization techniques are generally described, for example, in "Nucleic Acid Hybridization, A Practical Approach," Eds. Hames and Higgins, IRL Press (1985).

[0265] The sensitivity of hybridization assays can be increased by the use of nucleic acid amplification systems that increase the amount of target nucleic acid during detection. In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for producing nucleic acid fragments for subsequent subcloning are known.Examples of techniques that will adequately guide one through such in vitro amplification methods, including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicase amplification, and other RNA polymerase-mediated techniques (e.g., NASBA™), can be found in Sambrook et al., In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2000); and Ausubel et al., SHORT PROTOCOLS IN MOLECULAR BIOLOGY, eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (2002); as well as U.S. Pat. No. 4,683,202; PCR Protocols, A Guide to Methods and Applications (Innis et al. eds.) Academic Press Inc. San Diego, CA (1990); Arnheim & Levinson (October 1, 1990), C&EN 36; The Journal Of NIH Research, 3:81 (1991); Kwoh et al., Proc. Natl. Acad. Sci. USA, 86:1173 (1989); Guatelli et al., Proc. Natl. Acad. Sci. USA, 87:1874 (1990); Lomell et al., J. Clin. Chem., 35:1826 (1989); Landegren et al. al., Science, 241:1077 (1988); Van Brunt, Biotechnology, 8:291 (1990); Wu and Wallace, Gene, 4:560 (1989); Barringer et al., Gene, 89: 117 (1990); and Sooknanan and Malek, Biotechnology, 13:563 (1995).An improved method for cloning in vitro amplified nucleic acids is described in U.S. Patent No. 5,426,039. Other methods described in the art are nucleic acid sequence-based amplification (NASBA™, Cangene, Mississauga, Ontario) and the Qβ-replicase system. These systems, in which PCR or LCR primers are designed to extend or ligate only if the selected sequence is present, can be used to directly identify mutants. Alternatively, the selected sequence can be amplified, typically using, for example, non-specific PCR primers, and the amplified target region can then be probed for specific sequences that indicate mutations. The disclosures of the above references are incorporated herein by reference in their entirety for all purposes.

[0266] Nucleic acids, e.g., for use as probes in in vitro amplification methods, for use as gene probes, or as inhibitor components, are typically chemically synthesized by the solid-phase phosphoramidite triester method described by Beaucage et al., Tetrahedron Letts., 22:1859 1862 (1981), e.g., using an automated synthesizer as described in Needham VanDevanter et al., Nucleic Acids Res., 12:6159 (1984). If necessary, purification of polynucleotides is typically performed by native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al., J. Chrom., 255:137 149 (1983). The sequence of synthetic polynucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65:499.

[0267] An alternative method for measuring transcription levels is in situ hybridization. In situ hybridization assays are well known and are generally described in Angerer et al., Methods Enzymol., 152:649 (1987). In in situ hybridization assays, cells are fixed to a solid support, typically a glass slide. When searching for DNA, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at moderate temperature, which allows annealing of the labeled specific probe. The probe is preferably labeled with a radioisotope or a fluorescent reporter. EXAMPLES

[0268] IX. Working Example The present invention will be described in more detail by specific examples.The following examples are provided for illustrative purposes, but the present invention is not limited by these examples in any manner.Those skilled in the art will easily recognize various non-critical parameters that can be changed or modified to produce essentially the same results.

[0269] Example 1. Synthesis of MC3 MC3 (compound 1), having the structure shown below, was synthesized as described in Scheme 1 below. TIFF2024161074000014.tif20128TIFF2024161074000015.tif106128

[0270] Step 1: Magnesium bromide etherate (34 g, 110 mmol) and a stir bar were added to a 2000 mL round-bottom flask. The flask was sealed and flushed with nitrogen. Anhydrous diethyl ether (400 mL) was added via cannula. A solution of linolenyl mesylate (20 g, 58 mmol) in anhydrous ether (300 mL) was then added and the suspension was stirred overnight. The suspension was poured into 500 mL of cold water and transferred to a 2000-mL separatory funnel. After shaking, the organic phase was separated. The aqueous phase was then extracted with ether (2×250 mL) and all the ether phases were mixed. The ether phase was washed with water (2×250 mL), brine (250 mL) and dried over anhydrous Mg2SO4. The solution was filtered, concentrated and purified by flash chromatography. Final yield 18.9 g, 99%.

[0271] Step 2: A 1-liter RBF was charged with magnesium turnings (11.1 g, 463 mmol), anhydrous THF (65 mL), and a stir bar and flushed with nitrogen. In a separate flask, a solution of linoleyl bromide (140 g, 425 mL) in anhydrous THF (150 mL) was prepared and 20 mL of this solution was added to the magnesium. When most of the heat had dissipated, the remaining bromide was added over 15 minutes. The temperature was then maintained at 45° C. for 4 hours. The reaction was then cooled (0° C.). Using an addition funnel, a solution of ethyl formate (32.4 g, 438 mmol) in anhydrous THF (150 mL) was added over 40 minutes. The reaction was stirred at room temperature overnight. The reaction was cooled to −15° C. and 5N HCl (185 mL) was added slowly. The mixture was transferred to a 2-L separatory funnel and separated. Water (150 mL) and hexane (150 mL) were added, the mixture was washed, and the aqueous phase was removed again. The organic phase was finally washed with water (150 mL) and then concentrated to a yellow oil. The yellow oil was stirred with a mixture of EtOH (210 mL), water (30 mL) and KOH (15.8 g) at room temperature for 1.5 h. EtOH was evaporated and the residue was treated with hexane (50 mL). 5N HCl (200 mL) was added via dropping funnel. The organic phase was washed with water (2×50 mL), evaporated, dried and purified by chromatography (0-5% EtOAc in hexane, 91 g, 81%).

[0272] Step 3: Dilinoleylmethanol (7.8 g, 14.9 mmol), dimethylaminobutyric acid hydrochloride (2.99 g, 17.8 mmol) and a stir bar were added to a 500 mL RBF. The flask was flushed with nitrogen and anhydrous DCM (120 mL) was added followed by EDCI (3.6 g, 18.8 mmol), DIPEA (6.3 mL, 36.3 mmol) and DMAP (450 mg, 3.69 mmol). The reaction was stirred overnight. The reaction was diluted with DCM (300 mL) and washed with saturated NaHCO3 (200 mL), water (300 mL) and saturated NaCL (200 mL). Each aqueous wash was extracted once with DCM (50 mL). The organic phases were combined, dried (MgSO4) and concentrated to recover a yellow oil with some crystalline material. This was purified by chromatography (0-2% MeOH in CHCl3) to recover Lin-MC3 as a pale yellow oil (9.0 g, 14.1 mmol, 95%).

[0273] Example 2. Synthesis of LenMC3 and CP-LenMC3 LenMC3 (compound 4) and CP-LenMC3 (compound 5), having the structures shown below, were synthesized as described in Scheme 2 below. LenMC3 is also known as Linolenyl-MC3 and DLen-MC3. CP-LenMC3 is also known as CP-Linolenyl-MC3 and CP-DLen-MC3. TIFF2024161074000016.tif167133

[0274] Synthesis of linolenyl bromide (compound 2) TIFF2024161074000017.tif16128 Magnesium bromide etherate (34 g, 110 mmol) and a stir bar were added to a 2000 mL round bottom flask. The flask was sealed and flushed with nitrogen. Anhydrous diethyl ether (400 mL) was added via cannula. A solution of linolenyl mesylate (20 g, 58 mmol) in anhydrous ether (300 mL) was then added and the suspension was stirred overnight. The suspension was poured into 500 mL of cold water and transferred to a 2000 mL separatory funnel. After shaking, the organic phase was separated. The aqueous phase was then extracted with ether (2×250 mL) and all the ether phases were mixed. The ether phase was washed with water (2×250 mL), brine (250 mL) and dried over anhydrous Mg2SO4. The solution was filtered, concentrated and purified by flash chromatography. Final yield 19.1g, 100%.

[0275] Synthesis of dilinolenylmethanol (compound 3) TIFF2024161074000018.tif20128Magnesium turnings (2.1 g, 87 mmol), 5 iodine crystals, and a stir bar were added to a 1000 mL round bottom flask. The flask was flushed with nitrogen and a solution of linolenyl bromide (compound 2) (19.1 g, 58 mmol) in anhydrous diethyl ether (500 mL) was added via cannula. The mixture became cloudy and was refluxed overnight. The mixture was cooled to room temperature and ethyl formate (4.66 mL, 58 mmol) was added via syringe. The addition was done dropwise directly to the reaction mixture and the cloudy suspension was again stirred overnight. During this time the reaction turned bright yellow. The RM was transferred to a 2000 mL separatory funnel with ether (50 mL) and washed with 10% H2SO4 (200 mL), water (2 x 200 mL) and brine (200 mL). The organic phase was dried over anhydrous MgSO4, filtered and concentrated. The crude yield was 14.5 g. TLC showed the majority of the product to be methyl formate, which was purified by column chromatography. The purified formate (9.3 g, 16.7 mmol) was transferred to a 1000 mL round bottom flask and EtOH (600 mL) and a stir bar were added. With stirring, water (25 mL - to form a ca. 5% aqueous solution) was slowly added followed by KOH (2.0 g, 35.7 mmol). After 1 h the solution turned pale yellow. TLC showed the reaction was complete. The solution was concentrated to 50% of its volume on a rotary evaporator and then poured into 200 mL of 5% HCl. The aqueous phase was extracted with ether (3×200 mL). The ether fractions were combined, washed with water (3×200 mL), dried (MgSO4), and concentrated to recover 8.9 g (16.8 mmol, 58%) of dilinolenylmethanol.

[0276] Synthesis of Len-MC3 (compound 4) TIFF2024161074000019.tif20128 Dilinolenylmethanol (compound 3) (2.5 g, 4.76 mmol), dimethylaminobutyric acid hydrochloride (970 mg, 5.77 mmol) and a stir bar were added to a 100 mL RBF. The flask was flushed with nitrogen and anhydrous DCM (40 mL) was added followed by EDCI (FW 191.7, 1.2 g, 6.26 mmol), DIPEA (2.1 mL, 12.1 mmol) and DMAP (150 mg, 1.23 mmol). The reaction was stirred overnight, whereupon TLC showed >80% conversion. The reaction was diluted with DCM (100 mL) and washed with saturated NaHCO3 (100 mL), water (200 mL) and saturated NaCL (100 mL). The aqueous washes were combined and extracted with DCM (2 x 50 mL). The organic phases were then combined, dried (MgSO4), and concentrated to recover a yellow oil with some crystalline material, which was purified by chromatography to recover Len-MC3 as a pale yellow oil (2.3 g, 3.6 mmol, 76%).

[0277] Synthesis of CP-LenMC3 (compound 5) TIFF2024161074000020.tif241282To a 50 mL RBF was added Len-MC3 (compound 4) (1.1 g, 1.72 mmol), a stir bar, and anhydrous DCM (40 mL). The flask was flushed with N2 and cooled to 0 °C, then a 1 M solution of diethylzinc in hexanes (30 mL, 30 mmol) was added. The solution was stirred at 0 °C for 1 h, then diiodomethane (2.4 mL 30 mmol) was added, and the reaction was stirred at room temperature overnight. The reaction mixture was concentrated and then redissolved in EtOAc (50 mL). The EtOAc was washed successively with 5% HCl (2 x 50 mL), water (50 mL), NaHCO3 (50 mL), water (50 mL), and brine (50 mL). The aqueous washes were combined and extracted with DCM (2 x 50 mL). All the organic phases were combined, dried and concentrated to give crude CP-Len-MC3. 1 H-NMR showed that some olefin was still present, so the compound was treated again using the same procedure and amounts as outlined above. This time, after chromatography, 1H-NMR showed total conversion of the olefin. Final yield 1.0 g, 1.39 mmol, 81%.

[0278] Example 3. Synthesis of γ-LenMC3 and CP-γ-LenMC3 γ-LenMC3 (compound 8) and CP-γ-LenMC3 (compound 9), having the structures shown below, were synthesized as described in Scheme 3 below. γ-LenMC3 is also known as γ-linolenyl-MC3, γ-DLen-MC3, and D-γ-Len-MC3. CP-γ-LenMC3 is also known as CP-γ-linolenyl-MC3, CP-γ-DLen-MC3, and CP-D-γ-Len-MC3. TIFF2024161074000021.tif166128

[0279] Synthesis of γ-linolenyl bromide (compound 6) TIFF2024161074000022.tif11128Magnesium bromide etherate (34 g, 110 mmol) and a stir bar were added to a 2000 mL round bottom flask. The flask was sealed and flushed with nitrogen. Anhydrous diethyl ether (400 mL) was added via cannula. A solution of γ-linolenyl mesylate (20 g, 58 mmol) in anhydrous ether (300 mL) was then added and the suspension was stirred overnight. The suspension was poured into 500 mL of cold water and transferred to a 2000 mL separatory funnel. After shaking, the organic phase was separated. The aqueous phase was then extracted with ether (2×250 mL) and all the ether phases were mixed. The ether phase was washed with water (2×250 mL), brine (250 mL) and dried over anhydrous Mg2SO4. The solution was filtered, concentrated and purified by flash chromatography. Final yield 18.9g, 99%.

[0280] Synthesis of di-γ-linolenylmethanol (compound 7) TIFF2024161074000023.tif15128Magnesium turnings (2.1 g, 87 mmol), 5 iodine crystals and a stir bar were added to a 1000 mL round bottom flask. The flask was flushed with nitrogen and a solution of γ-linolenyl bromide (compound 6) (18.9 g, 57 mmol) in anhydrous diethyl ether (500 mL) was added via cannula. The mixture became cloudy and was refluxed overnight. The mixture was cooled to room temperature and ethyl formate (4.66 mL, 58 mmol) was added dropwise. The suspension was stirred overnight and it turned bright yellow. The RM was transferred to a 2000 mL separatory funnel with ether (50 mL) and washed with 10% sulfuric acid (200 mL), water (2×200 mL) and brine (200 mL). The organic phase was dried over anhydrous MgSO4, filtered and concentrated. The crude yield was 14.5 g. TLC showed the majority of the product to be methyl formate, which was purified by column chromatography. The purified formate was transferred to a 1000 mL round bottom flask and EtOH (600 mL) and a stir bar were added. With stirring, water (25 mL - forming approximately a 5% aqueous solution) was added slowly, followed by KOH (2.0 g, 35.7 mmol). After 1 h, the solution turned pale yellow. TLC showed the reaction was complete. The solution was concentrated to 50% of its volume on a rotary evaporator and then poured into 200 mL of 5% HCl. The aqueous phase was extracted with ether (3 x 200 mL). The ether fractions were combined, washed with water (3 x 200 mL), dried (MgSO4), and concentrated to recover 8.8 g of di-γ-linolenylmethanol (16.8 mmol, 58%).

[0281] Synthesis of γ-LenMC3 (compound 8) TIFF2024161074000024.tif17128 Di-γ-linolenylmethanol (compound 7) (2.5 g, 4.76 mmol), dimethylaminobutyric acid hydrochloride (970 mg, 5.77 mmol) and a stir bar were added to a 100 mL RBF. The flask was flushed with nitrogen and anhydrous DCM (40 mL) was added followed by EDCI (1.2 g, 6.26 mmol), DIPEA (2.1 mL, 12.1 mmol) and DMAP (150 mg, 1.23 mmol). The reaction was stirred overnight. The reaction was diluted with DCM (100 mL) and washed with saturated NaHCO3 (100 mL), water (200 mL) and saturated NaCL (100 mL). The aqueous washes were combined and extracted with DCM (2×50 mL). The organic phases were then combined, dried (MgSO4), and concentrated to recover a yellow oil, which was purified by chromatography to recover γ-Len-MC3 as a pale yellow oil (2.6 g, 4.1 mmol, 86%).

[0282] Synthesis of CP-γ-LenMC3 (compound 9) TIFF2024161074000025.tif201282To a 50 mL RBF was added γ-LenMC3 (compound 8) (1.28 g, 2.0 mmol), a stir bar, and anhydrous DCM (40 mL). The flask was flushed with N2 and cooled to 0 °C, then a 1 M solution of diethylzinc in hexanes (30 mL, 30 mmol, ca. 5 equiv. relative to olefin) was added. The solution was stirred at 0 °C for 1 h, then diiodomethane (2.4 mL 50 mmol) was added, and the reaction was stirred at room temperature overnight. The reaction mixture was concentrated and then redissolved in EtOAc (50 mL). The EtOAc was washed successively with 5% HCl (2 x 50 mL), water (50 mL), NaHCO3 (50 mL), water (50 mL), and brine (50 mL). The aqueous washes were combined and extracted with DCM (2 x 50 mL). All the organic phases were combined, dried and concentrated to recover crude CP-γ-LenMC3. 1 H-NMR showed that some olefin was still present, so the compound was treated again using the same procedure and amounts outlined above. This time, 1H-NMR showed total conversion of the olefin. The final yield after chromatography was 1.3 g, 1.8 mmol, 90%.

[0283] Example 4. Synthesis of MC3MC MC3MC (compound 10), having the structure shown below, was synthesized as described in Schemes 4 and 5 below. TIFF2024161074000026.tif62146

[0284] A 50 mL round bottom flask was charged with dilinoleylmethanol (3.06 g, 5.78 mmol) and a stir bar and flushed with nitrogen. Anhydrous DCM (30 mL) was added followed by diphosgene (1.75 mL, 14.46 mmol, 2.5 equiv). The reaction was stirred overnight and then concentrated on a rotary evaporator and purified by chromatography. This afforded the product as a colorless oil (2.6 g, 4.4 mmol, 76%). TIFF2024161074000027.tif40137

[0285] A 50 mL rbf containing chloroformic acid (350 mg, 0.59 mmol) and a stir bar was flushed with nitrogen and sealed. Anhydrous DCM (10 mL) and N,N,N'-trimethyl-1,3-propanediamine (580 mg, 5 mmol) were added and the reaction was stirred for 4 h. TLC showed the reaction was complete. The mixture was diluted to a volume of 40 mL with DCM and washed with saturated NaHCO3 (30 mL), water (30 mL) and brine (30 mL). The aqueous phases were combined and extracted once with DCM (20 mL). The organic phases were then combined, dried over MgSO4 and concentrated by rotary evaporation. Purification yielded the product, 350 mg, 0.52 mmol, 89%, as a pale oil.

[0286] Example 5 Synthesis of MC2MC MC2MC (compound 11), having the structure shown below, was synthesized as described in Scheme 6 below. TIFF2024161074000028.tif70144

[0287] A 50 mL round bottom flask containing chloroformic acid (400 mg, 0.68 mmol) and a stir bar was flushed with nitrogen and sealed. Anhydrous DCM (10 mL) and N,N,N'-trimethyl-1,2-ethanediamine (510 mg, 5 mmol) were added and the reaction was stirred overnight. TLC showed the reaction was complete. The mixture was concentrated by rotary evaporation and purified by column chromatography to recover the product as a pale oil (350 mg, 0.53 mmol, 78%).

[0288] Example 6. Synthesis of MC2C MC2C (compound 12), having the structure shown below, was synthesized as described in Scheme 7 below. TIFF2024161074000029.tif64141

[0289] A 50 mL round bottom flask containing chloroformic acid (400 mg, 0.68 mmol) and a stir bar was flushed with nitrogen and sealed. Anhydrous DCM (10 mL) and N,N,-dimethylethylenediamine (440 mg, 5 mmol) were added and the reaction was stirred overnight. TLC showed the reaction was complete. The mixture was concentrated by rotary evaporation and purified by column chromatography to recover the product as a pale yellow oil (350 mg, 0.54 mmol, 80%).

[0290] Example 7. Synthesis of MC3 ether The MC3 ether (compound 13), having the structure shown below, was synthesized as described in Scheme 8 below. TIFF2024161074000030.tif93128

[0291] A 50 mL RBF with a stir bar was flushed with nitrogen and anhydrous DCM (4 mL). Triflic anhydride (0.7 g, 420 μL, 2.5 mmol) was added and the flask was cooled to -15°C. Anhydrous pyridine (198 mg, 202 μL, 2.5 mmol) was added slowly, resulting in the evolution of fumes and a white precipitate. A solution of dilinoleyl methanol (1.06 g, 2 mmol) in anhydrous DCM (2 mL) was added slowly over 2 min. After stirring at approximately -15°C for 2 h, the reaction was off-white in color. TLC indicated the formation of the triflate, so water (2 mL) was added to quench the reaction. DCM (10 mL) was added and the mixture was washed with water (2 x 20 mL), dried (MgSO4), filtered, and transferred to a 25 mL round bottom flask. Proton sponge (1.07 g, 5 mmol, minimum 2.5 equiv), dimethylaminopropanol (515 mg, 5 mmol, minimum 2.5 equiv) and a stir bar were added and the vessel was flushed with nitrogen, fitted with a condenser and refluxed for 48 h. Water (10 mL) was added and stirred vigorously for several minutes before separating in a 30 mL separatory funnel. The organic phase was washed again with water (10 mL), dried over MgSO4, concentrated and purified by chromatography (MeOH / CHCl3) to recover the product as a pale yellow oil (400 mg, 33%).

[0292] Alternatively, the MC3 ether (compound 13) was synthesized starting from dilinoleylmethanol (DLinMeOH) as follows.

[0293] Synthesis of compound 14 TIFF2024161074000031.tif26128

[0294] A 50 mL RBF with a stir bar was flushed with nitrogen and DLinMeOH (1060 mg, 2 mmol), TEA (6 mmol, 834 μL) and anhydrous DCM (20 mL) were added. The flask was cooled to 0 °C and either MsCl (6 mmol) was added. The reaction was stirred overnight. The reaction was diluted to 70 mL with DCM, washed with saturated NaHCO3 (2 x 50 mL) and saturated NaCl (50 mL), dried (MgSO4), filtered, concentrated and purified by column chromatography (1-4% EtOAc in hexanes). Yield 900 mg, 75%.

[0295] Synthesis of MC3 ether A 50 mL RBF with a stir bar was flushed with nitrogen and NaH (220 mg, 9 mmol), dimethylaminopropanol (927 mg, 1.06 mL, 9 mmol) and anhydrous benzene (10 mL) were added. After the effervescence had subsided, compound 14 (440 mg, 0.75 mmol) was added and the RM was refluxed at 90 °C overnight. TLC indicated 30-50% product formation. The RM was refluxed the next night, but TLC did not appear to indicate any further reaction. The reaction was diluted to 40 mL with benzene and quenched with ethanol (25 mL). It was then washed with water (40 mL), dried and concentrated. The crude product was purified to recover the product as a pale yellow oil (157 mg, 33%).

[0296] Example 8. Synthesis of MC4 ether The MC4 ether (compound 15), having the structure shown below, was synthesized as described below. TIFF2024161074000032.tif32128

[0297] A 50 mL RBF with a stir bar was flushed with nitrogen and NaH (220 mg, 9 mmol), dimethylaminobutanol (1.05 g, 9 mmol) and anhydrous benzene (10 mL) were added. After the effervescence had subsided, compound 14 (440 mg, 0.75 mmol) was added and the RM was refluxed at 90° C. overnight. TLC showed some product formation. The reaction was diluted to 40 mL with benzene and quenched with ethanol (25 mL). It was then washed with water (40 mL), dried and concentrated. The crude product was purified to recover the product as a pale yellow oil (145 mg, 31%).

[0298] Example 9. Synthesis of MC3 amide MC3 amide (compound 16), having the structure shown below, was synthesized as described in Schemes 9-11 below. TIFF2024161074000033.tif60128

[0299] To a 500 mL RBF containing a solution of dilinoleylmethanol (10 g, 18.9 mmol) in DCM (200 mL) was added pyridinium chlorochromate (12.24 g, 56.7 mmol), anhydrous sodium carbonate (1.0 g, 9.5 mmol), and a stir bar. The resulting suspension was stirred under nitrogen at room temperature for 3 h, after which TLC showed that all SM had been consumed. Ether (300 mL) was then added to the mixture, and the resulting brown suspension was filtered through a pad of silica (300 mL), and the pad was washed with ether (3×100 mL). The ether phases were combined, concentrated, and purified to give 9.0 g (17.1 mmol, 90%) of the ketone. TIFF2024161074000034.tif29143

[0300] To a solution of dilinoleyl ketone (1.0 g, 1.9 mmol) in 2 M ammonia in ethanol (5 mL) was added titanium(IV) isopropoxide (1.15 mL, 3.8 mmol). The solution was stirred at room temperature under nitrogen for 6 h, then sodium borohydride (110 mg, 3.8 mmol) was added. The solution foamed for about 5 min, then a colorless precipitate began to form. The solution was stirred at room temperature for 16 h, quenched with 10% NH4OH (25 mL) and diluted with ethyl acetate (50 mL). The inorganic solids were filtered and the aqueous phase was washed with ethyl acetate (2 x 75 mL). The combined ethyl acetate extracts were washed with 2 M HCl (2 x 50 mL), dried over magnesium sulfate, filtered, and concentrated to dryness to give the product as a pale yellow HCl salt (1.1 g, quantitative). TIFF2024161074000035.tif36128

[0301] To a solution of dilinoleylmethylamine hydrochloride (1.1 g, 1.95 mmol), BOP (1.1 g, 2.4 mmol) and 4-(dimethylamino)butanoic acid hydrochloride (402 mg, 2.4 mmol) in anhydrous DMF (20 mL) was added diisopropylethylamine (1.4 mL, 7.8 mmol). The solution was stirred at room temperature for 16 h. The solution was concentrated to dryness in vacuo and dissolved in ethyl acetate (100 mL). The ethyl acetate was washed with brine (3×50 mL), dried over magnesium sulfate, filtered and concentrated to dryness in vacuo. The residue was purified by column chromatography (1% to 2.5% MeOH in CHCl3) to give the product as an orange oil. Decolorization through a pad of silica gel (eluted with 50% hexane-ethyl acetate to 100% ethyl acetate) gave the product as a pale yellow oil (151 mg, 12%).

[0302] Example 10. Synthesis of Pan-MC3 Phytanyl-MC3 ("Pan-MC3") (compound 17), having the structure shown below, was synthesized as described in Scheme 12 below. TIFF2024161074000036.tif137128

[0303] Synthesis of phytanyl mesylate TIFF2024161074000037.tif17128To a solution of phytanol (14.98 g, 50.2 mmol) in anhydrous dichloromethane (150 mL) was added triethylamine (7.7 mL, 55.2 mmol) under nitrogen. The solution was cooled to -10°C, then a solution of methanesulfonyl chloride (11.51 g, 100.5 mmol) in anhydrous dichloromethane (100 mL) was added dropwise over 30 minutes. Upon completion, the solution was diluted to 500 mL with dichloromethane. The solution was washed twice with saturated NaHCO3, dried over MgSO4, filtered, and concentrated to dryness to give the product as a colorless oil (18.9 g, 100%).

[0304] Synthesis of phytanyl bromide TIFF2024161074000038.tif16128To a suspension of magnesium bromide diethyl etherate (25.9 g, 100.3 mmol) in anhydrous diethyl ether (250 mL) was added dropwise over 15 min at room temperature under nitrogen to a solution of phytanyl mesylate (18.9 g, 50.2 mmol) in anhydrous diethyl ether (200 mL). The resulting slurry was stirred at room temperature for 72 h. Upon completion, the reaction mixture was cooled to 0°C and ice-cold water was added dropwise until all solids were dissolved and effervescence ceased. Diethyl ether (300 mL) was added and the organic and aqueous layers were separated. The aqueous layer was back extracted with diethyl ether (200 mL). The combined diethyl ether extracts were dried over MgSO4, filtered and concentrated. The resulting oil was purified by column chromatography (column 10"L x 2"W; eluted with 100% hexane) to give the product as a pale yellow oil (16.3 g, 90%).

[0305] Synthesis of diphytanylmethanol. TIFF2024161074000039.tif24128Magnesium turnings (1.18 g, 48.5 mmol) were heated in an oven at 250 °C for 1 h, then stirred at room temperature under nitrogen for 2 h. Anhydrous diethyl ether (300 mL) and one crystal of iodine were added, followed by a solution of phytanyl bromide (15.2 g, 42.1 mmol) in anhydrous diethyl ether (30 mL). The resulting cloudy mixture was heated at reflux overnight. The solution was cooled (0 °C) and a solution of ethyl formate (3.9 mL, 48.5 mmol) in anhydrous diethyl ether (15 mL) was added dropwise over 25 min. The resulting yellow solution was again stirred overnight. The yellow solution was cooled (0 °C) and quenched with 5 M HCl (15 mL), followed by the addition of hexane (100 mL) and water (150 mL). The aqueous and organic layers were separated and the aqueous layer was back-extracted twice with hexanes. The combined organic layers were washed with water, dried over MgSO4, filtered, and concentrated to dryness in vacuo.

[0306] The resulting pale yellow oil was dissolved in ethanol (25 mL) and transferred to a flask containing potassium hydroxide (2.2 g, 39.2 mmol) in water (5 mL). The resulting biphasic solution was stirred at 10° C. for 2.5 h. Ethanol was removed in vacuo and hexane (25 mL) and 5 M HCl (35 mL) were added. The organic and aqueous layers were separated and the organic layer was washed twice with water. The combined organic layers were dried over MgSO4, filtered and concentrated. The resulting pale yellow oil was purified by column chromatography (column 12″L×2″W; eluted with a gradient of 100% hexane→2%→4% ethyl ether in hexane) to give the product as a pale yellow oil (6.4 g, 49%).

[0307] Synthesis of phytanyl-MC3 TIFF2024161074000040.tif24128To a solution of diphytanylmethanol (6.4 g, 10.3 mmol) and 4-(dimethylamino)butyric acid hydrochloride (2.25 g, 13.4 mmol) in anhydrous dichloromethane (60 mL) was added EDC (2.77 g, 18.0 mmol), diisopropylethylamine (5.4 mL, 31.0 mmol), and 4-dimethylaminopyridine (45 mg, 0.37 mmol) at room temperature under nitrogen. After 16 h, the reaction mixture was diluted with dichloromethane (75 mL). The organic layer was washed with saturated NaHCO3, water, and brine, then dried over MgSO4, filtered, and concentrated. The resulting yellow oil was purified by column chromatography (column 10"L x 2"W; eluted with a gradient of 100% hexane → 10% → 50% ethyl acetate in hexane) to recover some phytanylmethanol (2.81 g, 44%) and to give the product as a pale yellow oil (3.53 g, 49%).

[0308] Example 11. Synthesis of Pan-MC4 Phytanyl-MC4 ("Pan-MC4") (compound 18), having the structure shown below, was synthesized as described in Scheme 13 below. TIFF2024161074000041.tif162128

[0309] Synthesis of benzyl 5-hydroxypentanoate TIFF2024161074000042.tif22128 A solution of δ-valerolactone (10 g, 100 mmol) in 1 M aqueous sodium hydroxide (100 mL) was heated at 65° C. with stirring overnight. The solution was concentrated in vacuo to dryness and any residual water was removed under high vacuum at −190° C. The resulting white powder was broken down and suspended in acetone (40 mL). Benzyl bromide (17 g, 101.4 mmol) and tetrabutylammonium bromide (0.82 g, 2.539 mmol) were added with stirring. The mixture was heated at 45° C. with stirring for 72 h, cooled, and concentrated. The resulting white oily powder was dissolved in ethyl acetate (300 mL) and washed twice each with saturated NaHCO3 and brine. The organic portion was dried over anhydrous MgSO4, filtered, and then concentrated. The result was a yellow oil, which was purified by column chromatography (column 10"L x 2"W; eluted with a gradient of 100% hexane → 30% → 50% ethyl acetate in hexane) to give the product as a pale yellow oil (3.11 g, 15%).

[0310] Synthesis of benzyl 5-(methanesulfonyl)pentanoate TIFF2024161074000043.tif23128To a solution of benzyl 5-hydroxypentanoate (2.01 g, 9.65 mmol) in anhydrous dichloromethane (30 mL) was added triethylamine (2.7 mL, 19.3 mmol) at −15° C. under nitrogen, followed by the dropwise addition of methanesulfonyl chloride solution (1.5 mL, 19.3 mmol) over 20 min. The reaction was stirred at room temperature overnight and then diluted to 75 mL with dichloromethane. The organic layer was washed three times with saturated NaHCO3 and the combined aqueous layers were back-extracted with dichloromethane. The combined organic phase was dried over MgSO4, filtered and concentrated. The resulting dark orange oil was purified by column chromatography (column 5"L x 1"W; eluted with a gradient of 100% hexanes → 10% → 20% → 25% diethyl ether in hexanes) to give the product as a pale yellow oil (1.39 g, 50%).

[0311] Synthesis of benzyl 5-(dimethylamino)pentanoate TIFF2024161074000044.tif21128 Benzyl 5-(methanesulfonyl)pentanoate (1.39 g, 4.85 mmol) was reacted in a 5.6 M solution of dimethylamine in ethanol (100 mL) for 20 hours. The solution was then concentrated in vacuo to dryness. The resulting brown oil was purified by column chromatography (column 10 "L x 1" W; eluted with a gradient of 100% dichloromethane → 2% / 0.5% → 4% / 0.5% MeOH / NH4OH in dichloromethane) to give the product as a yellow oil (0.79 g, 69%).

[0312] Synthesis of 5-(dimethylamino)pentanoic acid TIFF2024161074000045.tif201285-(Dimethylamino)benzyl pentanoate (0.79 g, 33.6 mmol) in anhydrous ethyl acetate (20 mL) was added 10% palladium on charcoal (250 mg) at room temperature under nitrogen. The solution was stirred vigorously under a hydrogen atmosphere. After 16 hours, additional palladium on charcoal (100 mg) was added to drive the reaction, and at 24 hours, hydrogen gas was bubbled into the solution. At 40 hours, the solution was filtered through Celite and concentrated in vacuo to dryness to give the product as a yellow oil (295 mg, 60.4%).

[0313] Synthesis of phytanyl-MC4 TIFF2024161074000046.tif20128 To a solution of diphytanylmethanol (0.8 g, 1.3 mmol) and 4-(dimethylamino)pentanoic acid (0.24 g, 1.7 mmol) in anhydrous dichloromethane (10 mL) was added EDC (0.347 g, 1.8 mmol), diisopropylethylamine (0.67 mL, 3.9 mmol), and 4-dimethylaminopyridine (45 mg, 0.37 mmol) at room temperature under nitrogen. After 20 hours, additional 5-(dimethylamino)pentanoic acid (0.05 g, 0.34 mmol) was added to drive the reaction. The reaction was stirred for an additional 52 hours and then diluted to 50 mL with dichloromethane. The organic phase was washed with saturated NaHCO3, water, and brine, and the combined aqueous layers were back-extracted with dichloromethane. The combined organic layers were dried over MgSO4, filtered and concentrated. The resulting yellow oil was purified by column chromatography (column 10"L x 1 1 / 4"W; eluted with a gradient of 100% hexanes → 10% → 50% ethyl acetate in hexanes) to give the product as a pale yellow oil (474 ​​mg, 51%) along with recovery of some diphytanyl methanol (348 mg, 43.5%).

[0314] Example 12. Synthesis of Pan-MC5 Phytanyl-MC5 ("Pan-MC5") (compound 19), having the structure shown below, was synthesized as described in Scheme 14 below. TIFF2024161074000047.tif180130

[0315] Synthesis of ethyl 6-(methanesulfonyl)hexanoate TIFF2024161074000048.tif20128To a solution of ethyl 6-hydroxyhexanoate (5 g, 31.2 mmol) in anhydrous dichloromethane (115 mL) was added triethylamine (8.7 mL, 62.5 mmol) at −10° C. under nitrogen, followed by the dropwise addition of methanesulfonyl chloride (4.8 mL, 62.5 mmol) over 1 h. The resulting solution was stirred at room temperature for 6 h and then diluted to 300 mL with dichloromethane. The solution was washed twice with saturated NaHCO3 and the aqueous layer was back-extracted with dichloromethane. The combined organic layers were dried over MgSO4, filtered, and concentrated. The resulting dark orange oil was purified by column chromatography (column 5″L×2″W; eluted with a gradient of 100% hexane→10%→20% ethyl acetate in hexane) to give the product as a pale yellow oil.

[0316] Synthesis of ethyl 6-(dimethylamino)hexanoate TIFF2024161074000049.tif17128 Ethyl 6-(methanesulfonyl)hexanoate was reacted in 5.6M dimethylamine-ethanol solution (100 mL) for 17 hours. The solution was then concentrated in vacuo to dryness. The resulting bright orange paste was purified by column chromatography (column 5"L x 2"W; eluted with a gradient of 100% dichloromethane → 1% / 0.25% → 2% / 0.5% MeOH / NH4OH in dichloromethane) to give the product as a yellow oil.

[0317] Synthesis of 6-(dimethylamino)hexanoic acid hydrochloride TIFF2024161074000050.tif14128To a solution of ethyl 6-(dimethylamino)hexanoate (5.85 g, 31.2 mmol) in dioxane (200 mL) was added 1 M NaOH (200 mL). The solution was stirred vigorously at room temperature for 2 h, then the dioxane was removed in vacuo. The resulting aqueous solution was made slightly acidic with concentrated HCl (15 mL). At this point, attempts were made to extract the product from the solution using dichloromethane and ether; however, all attempts failed. Instead, the water was removed under high vacuum to give the product as an off-white solid that was a mixture of approximately 35% by weight 6-(dimethylamino)hexanoic acid hydrochloride in NaCl.

[0318] Synthesis of phytanyl-MC5 TIFF2024161074000051.tif20128To a solution of diphytanylmethanol (1.5 g, 2.4 mmol) and 35% 6-(dimethylamino)hexanoic acid hydrochloride (1.79 g, 3.2 mmol) in anhydrous dichloromethane (15 mL) was added EDC (0.65 g, 3.4 mmol), diisopropylethylamine (1.26 mL, 7.2 mmol) and 4-dimethylaminopyridine (10 mg) at room temperature under nitrogen. After 48 hours, additional 35% 6-(dimethylamino)hexanoic acid (1 g, 1.8 mmol), EDC (0.32 g, 1.7 mmol) and 4-dimethylaminopyridine (15 mg) were added. After an additional 72 hours, the reaction mixture was diluted to 75 mL with dichloromethane and then washed with water, saturated NaHCO3, and brine. The combined aqueous layers were back-extracted twice with dichloromethane, and the combined organic layers were dried over MgSO4, filtered, and concentrated. The resulting yellow oil was purified by column chromatography (column 1 1 / 4"W x 10"L; eluted with a gradient of 100% hexanes → 10% → 50% ethyl acetate in hexanes) to give the product as a yellow oil (175 mg, 10%) along with recovery of some diphytanyl methanol.

[0319] Example 13. Synthesis of MC3 thioester The MC3 thioester (compound 20), having the structure shown below, was synthesized as described in Scheme 15 below. TIFF2024161074000052.tif64148

[0320] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraene-19-thiol TIFF2024161074000053.tif16128 A solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl methanesulfonate (2.0 g, 3.3 mmol) in anhydrous DMF (15 mL) was treated with NaSH·H2O (925 mg, 16.5 mmol) and heated (70 °C, 2 h). The mixture was cooled (rt), diluted with H2O, and extracted with Et2O (3x). The organic extract was washed with brine, then dried (Na2SO4), filtered, and concentrated. The crude material was chromatographed (hexanes→2% EtOAc-hexanes) to recover (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraene-19-thiol (1.31 g, 73%) as a pale yellow oil. Rf 0.9 (10% EtOAc-hexanes), FW 544.50, C 37 H 68 S.

[0321] Synthesis of S-(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4(dimethylamino)butanethioate (MC3 thioester) A solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraene-19-thiol (500 mg, 0.92 mmol) and N,N-dimethylamino-butyric acid hydrochloride (200 mg, 1.2 mmol) in anhydrous CHCl (3 mL) was treated with EDC (229 mg, 1.2 mmol), Hunig's base (481 μL, 2.8 mmol) and DMAP (18 mg). After stirring (2 h), the solution was diluted with CHCl and washed with NaHCO (sat. aq.) and brine, then dried (NaSO), filtered and concentrated. The crude material was chromatographed (CH2Cl2→3% CH3OH—CH2Cl2) to recover S-(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4(dimethylamino)butanethioate (197 mg, 33%) as a colorless oil. TIFF2024161074000055.tif43154

[0322] Example 14. Synthesis of compounds 21 to 24 (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate (compound 21), (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate (compound 22), (6Z,9Z ,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate (compound 23) and (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate (compound 24) were synthesized as described in Scheme 16 below. TIFF2024161074000056.tif215151

[0323] Synthesis of (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-one TIFF2024161074000057.tif14128To a nitrogen purged 500 mL round bottom flask was added anhydrous toluene (70 mL) followed by thin pieces of sodium metal (4.25 g, 185 mmol). Chlorotrimethylsilane (17 mL, 136.1 mmol) was slowly added and the reaction was heated to 40 °C. To this solution was added methyl linoleate (10 g, 32.4 mmol) dropwise over 45 min. The solution was refluxed for 2 h, at which point the sodium had changed from large chunks to small 1-2 mm beads (after approximately 1.5 h the reaction turned purple). The reaction was cooled to room temperature and slowly quenched with methanol (25 mL) at 0 °C for 30 min. Once the unreacted sodium metal had dissolved the reaction mixture was filtered through Celite and rinsed with ether (400 mL). The filtrate (ca. 400-500 mL) was vigorously stirred with saturated ammonium chloride (300 mL) for 16 h. Upon completion, the ether / toluene layer was separated and washed with brine (1×100 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo. The yellow oil was purified by column chromatography (gradient: 100% hexanes to 5% EtOAc in hexanes) to afford the title compound as a pale yellow oil (4.8 g, 56%).

[0324] Synthesis of (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate (compound 21) TIFF2024161074000058.tif16128To a solution of (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-one (1.0 g, 1.9 mmol), 3-(dimethylamino)propanoic acid hydrochloride (876 mg, 5.7 mmol) and EDCI (1.2 g, 6.3 mmol) in dichloromethane (20 mL), DIPEA (1.0 mL, 5.7 mmol) and DMAP (20 mg) were added. The solution was stirred at room temperature under nitrogen for 16 hours. Upon completion, the reaction was diluted with dichloromethane (50 mL) and washed with sodium bicarbonate solution (50 mL). The dichloromethane layer was dried over magnesium sulfate, filtered and concentrated in vacuo to dryness. The residue was purified by column chromatography (100% ethyl acetate) to give the title compound as a colorless oil (675 mg, 57%). TIFF2024161074000059.tif23153

[0325] Synthesis of (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate (compound 22) TIFF2024161074000060.tif17128 To a solution of (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate (450 mg, 0.72 mmol) in anhydrous methanol (20 mL) was slowly added sodium borohydride (222 mg, 5.9 mmol). The solution was stirred at room temperature for 16 h and then quenched with water (20 mL). The solution was washed with dichloromethane (3×50 mL) and the combined extracts were dried over magnesium sulfate, filtered, and concentrated in vacuo to dryness. The residue was purified by column chromatography (100% ethyl acetate) to give the title compound as a colorless oil (416 mg, 91%). TIFF2024161074000061.tif22150

[0326] Synthesis of (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate (compound 23) TIFF2024161074000062.tif13128 Using a procedure similar to that described for the synthesis of (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate, (6Z,9Z,27Z,30Z)-19-oxohexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate was obtained as a colorless oil (980 mg, 80%). TIFF2024161074000063.tif30154

[0327] Synthesis of (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate (compound 24) TIFF2024161074000064.tif13128 Using a procedure similar to that described for the synthesis of (6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 3-(dimethylamino)propanoate, 6Z,9Z,27Z,30Z)-19-hydroxyhexatriaconta-6,9,27,30-tetraen-18-yl 4-(dimethylamino)butanoate was obtained as a colorless oil (218 mg, 31%). TIFF2024161074000065.tif30154

[0328] Example 15. Synthesis of Compound 25 (6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (compound 25), having the structure shown below, was synthesized as described in Scheme 17 below. TIFF2024161074000066.tif64143

[0329] Synthesis of (6E,9E)-18-bromooctadeca-6,9-diene TIFF2024161074000067.tif8128 Using a procedure similar to that described for the synthesis of linoleyl bromide, (6E,9E)-18-bromooctadeca-6,9-diene was obtained as a colorless oil (9.1 g, 87%).

[0330] Synthesis of (10Z,13Z)-nonadeca-10,13-dienal TIFF2024161074000068.tif13128A 100 mL round bottom flask containing magnesium turnings (462 mg, 19.0 mmol) and a stir bar was dried with a high temperature heat gun for 5 min. The flask was cooled to room temperature under nitrogen and then charged with THF (25 mL). Linoleyl bromide (1.9 g, 5.76 mmol) was added dropwise and the solution was heated at 45 °C under nitrogen for 3 h. Upon completion, DMF (1.3 mL, 16.7 mmol) was added slowly and the solution was stirred at room temperature for 1 h. The solution was diluted with ether (75 mL) and washed with 5% HCl (3 x 50 mL). The ether solution was dried over magnesium sulfate, concentrated, and concentrated in vacuo to dryness. The residue was purified by column chromatography (column: 2"x10"; eluted with 2% ether / hexane) to give the title compound as a colorless oil (3.5 g, 83%).

[0331] Synthesis of (6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-ol TIFF2024161074000069.tif13128A 100 mL round bottom flask containing magnesium turnings (355 mg, 14.6 mmol) and a stir bar was dried with a high temperature heat gun for 5 min. Immediately after cooling under nitrogen, THF (6 mL) was added followed by linolaidyl bromide (6.02 g, 18.3 mmol). The mixture was heated to 45 °C and a grain of iodine was added. The reaction was refluxed for 2.5 h and then cooled to room temperature at which point a solution of (10Z,13Z)-nonadeca-10,13-dienal (3.4 g, 12.4 mmol) in THF (10 mL) was added. The solution was stirred at room temperature for 1.5 h then poured into water (150 mL) and 5% HCl (50 mL) was added. Once the magnesium was dissolved, the solution was extracted with ether (2×150 mL). The combined ether extracts were dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo. The residue was purified by column chromatography (100% hexanes) to give the title compound as a colorless oil (4.57 g, 71%).

[0332] Synthesis of (6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (compound 25) TIFF2024161074000070.tif13128 Using a procedure similar to that described for the synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, (6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate was obtained as a pale yellow oil (1.12 g, 93%). TIFF2024161074000071.tif25155

[0333] Example 16. Synthesis of compound 26 (6R,8Z,27Z,30Z)-6-hydroxyhexatriaconta-8,27,30-trien-18-yl 4-(dimethylamino)butanoate (compound 26), having the structure shown below, was synthesized as described in Scheme 18 below. TIFF2024161074000072.tif165128

[0334] Synthesis of (R,Z)-Methyl 12-(tert-butyldiphenylsilyloxy)octadec-9-enoate TIFF2024161074000073.tif13128 To a solution of methyl ricinoleate (8.0 g, 32 mmol) in anhydrous pyridine (90 mL) and anhydrous THF (45 mL) was added t-butylchlorodimethylsilane (8.5 mL, 33.3 mmol) and silver nitrate (5.65 g, 33.3 mmol). The solution was stirred at room temperature under nitrogen for 90 min. The solution was filtered through Celite and the filter cake was rinsed with THF (400 mL). The filtrate was concentrated in vacuo and the residue was dissolved in dichloromethane (300 mL) and washed with 5% HCl (150 mL). The aqueous layer was separated and washed with dichloromethane (2×200 mL). The combined dichloromethane extracts were washed with brine (350 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to dryness. The residue was purified by column chromatography (gradient: 100% hexane to 10% ethyl acetate in hexane) to give the title compound as a colorless oil (13.1 g, 93%).

[0335] Synthesis of (R,Z)-12-(tert-butyldiphenylsilyloxy)octadec-9-en-1-ol TIFF2024161074000074.tif14128To a suspension of lithium aluminum hydride (1.8 g, 47.5 mmol) in anhydrous THF (30 mL) was added a solution of (R,Z)-methyl 12-(tert-butyldiphenylsilyloxy)octadec-9-enoate (13.1 g, 23.7 mmol) in THF (30 mL) dropwise over 30 minutes. The reaction was stirred at room temperature under nitrogen for 1 hour. Upon completion, 5M NaOH (4 mL) was added dropwise at 0°C. The mixture was dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo to give the title compound as a pale yellow oil. The product (11.1 g, 89%) was used in the next step without further purification.

[0336] Synthesis of (R,Z)-12-(tert-butyldiphenylsilyloxy)octadec-9-enal TIFF2024161074000075.tif12128To a solution of (R,Z)-12-(tert-butyldiphenylsilyloxy)octadec-9-en-1-ol (11.1 g, 21.2 mmol) in anhydrous dichloromethane (160 mL) was added pyridinium chlorochromate (215.6 g, 110.3 mmol) and sodium carbonate (1.1 g, 18.4 mmol). The mixture was stirred at room temperature for 3 h and then filtered through a pad of silica (eluted with 100% ethyl acetate). The filtrate was concentrated in vacuo to dryness and the residue was purified by column chromatography (gradient: 100% hexane to 10% ethyl acetate in hexane) to give the title compound as a yellow oil (8.9 g, 81%).

[0337] Synthesis of (6R,8Z,27Z,30Z)-6-(tert-butyldiphenylsilyloxy)hexatriaconta-8,27,30-trien-18-ol TIFF2024161074000076.tif17128A 100 mL round bottom flask containing magnesium turnings (0.16 g, 6.53 mmol) and a stir bar was dried with a high temperature heat gun for 5 min. The flask was cooled to room temperature under nitrogen and then charged with THF (1.1 mL). A solution of linoleyl bromide (1.9 g, 5.76 mmol) in THF (1.9 mL) was added dropwise and the solution was heated to 55 °C under nitrogen for 2 h. Upon completion, the reaction mixture was cooled to room temperature and a solution of (R,Z)-12-(tert-butyldiphenylsilyloxy)octadec-9-enal (2.0 g, 3.84 mmol) in THF (20 mL) was added slowly over 10 min. The solution was stirred at room temperature for 1 h and then quenched with 5 M HCl (20 mL) and water (100 mL). The remaining solution was extracted with diethyl ether (3×150 mL) and the combined diethyl ether extracts were dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo. The residue was purified by column chromatography (gradient: 100% hexanes to 5% ethyl acetate-hexanes) to give the title compound as a yellow oil (1.8 g, 60%).

[0338] Synthesis of (6R,8Z,27Z,30Z)-6-(tert-butyldiphenylsilyloxy)hexatriaconta-8,27,30-trien-18-yl 4-(dimethylamino)butanoate TIFF2024161074000077.tif17128 Using a procedure similar to that described for the synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, (6R,8Z,27Z,30Z)-6-(tert-butyldiphenylsilyloxy)hexatriaconta-8,27,30-trien-18-yl 4-(dimethylamino)butanoate was obtained as a colorless oil (800 mg, 78%).

[0339] Synthesis of (6R,8Z,27Z,30Z)-6-hydroxyhexatriaconta-8,27,30-trien-18-yl 4-(dimethylamino)butanoate (compound 26) TIFF2024161074000078.tif17128(6R,8Z,27Z,30Z)-6-(tert-butyldiphenylsilyloxy)hexatriaconta-8,27,30-trien-18-yl 4-(dimethylamino)butanoate (800 mg, 0.95 mmol) in saturated HCl (g)The / MeOH (50 mL) solution was stirred for 10 min. The starting material did not dissolve so anhydrous DCM (12 mL) was added and the mixture was stirred for 30 min. Upon completion, the solution was concentrated in vacuo, saturated sodium bicarbonate (75 mL) was added and the solution was extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate extracts were washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to dryness. The residue was purified by column chromatography (100% ethyl acetate) to give the title compound as a colorless oil (0.228 g, 39%). TIFF2024161074000079.tif30157

[0340] Example 17. Synthesis of compounds 27 and 28 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl(hexyl)carbamate (compound 27) and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl((Z)-hept-4-enyl)carbamate (compound 28) having the structure shown below were synthesized as described in Scheme 19 below. TIFF2024161074000080.tif138128

[0341] Synthesis of N-hexyl-N',N'-dimethylpropane-1,3-diamine TIFF2024161074000081.tif11128A solution of n-capronaldehyde (3.79 g, 37.8 mmol) and N,N-dimethylpropane-1,3-diamine (5 mL, 39.7 mmol) in anhydrous methanol (140 mL) was stirred at room temperature for 3 h. To this solution was added sodium borohydride (2.15 g, 56.8 mmol) slowly over 5 min. The solution was stirred for 30 min, then quenched with 1 M NaOH (75 mL), diluted with water (125 mL), and extracted with ethyl acetate (3×150 mL). The combined ethyl acetate extracts were dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo. The residue was purified by column chromatography (gradient: 100% DCM to 10% MeOH in DCM with 1% NH4OH) to give the title compound as a pale yellow oil (3.79 g, 54%).

[0342] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl(hexyl)carbamate (compound 27) TIFF2024161074000082.tif16128To a solution of dilinoleylmethanol (1.0 g, 1.9 mmol) and pyridine (230 μL, 4.7 mmol) in anhydrous ether (10 mL) cooled to −15° C. under nitrogen, diphosgene (380 μL, 3.1 mmol) was added slowly. The reaction was stirred at −15° C. for 20 minutes, then N-hexyl-N′,N′-dimethylpropane-1,3-diamine (3.8 g, 20.3 mmol) was added as a solution in 4:1 ether / dichloromethane (10 mL). The solution was allowed to warm to room temperature and stirring was continued for 20 minutes. Upon completion, the solution was diluted with diethyl ether (100 mL) and washed with saturated sodium bicarbonate (2×50 mL). The ether extract was dried over magnesium sulfate, filtered, and concentrated in vacuo to dryness. The residue was purified by column chromatography (100% ethyl acetate) to give the title compound as a colorless oil (1.1 g, 76%). TIFF2024161074000083.tif23156

[0343] Synthesis of (Z)-N-(hept-4-enyl)-N',N'-dimethylpropane-1,3-diamine TIFF2024161074000084.tif10128Using a procedure similar to that described for the synthesis of N-hexyl-N',N'-dimethylpropane-1,3-diamine, (Z)-N-(hept-4-enyl)-N',N'-dimethylpropane-1,3-diamine was obtained as a pale yellow oil (5.11 g, 68%).

[0344] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl((Z)-hept-4-enyl)carbamate (compound 28) TIFF2024161074000085.tif18128 Using a procedure similar to that described for the synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl(hexyl)carbamate, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 3-(dimethylamino)propyl((Z)-hept-4-enyl)carbamate was obtained as a colorless oil (1.31 g, 92%). TIFF2024161074000086.tif23153

[0345] Example 18. Synthesis of compound 29 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 2-(dimethylamino)ethyl(ethyl)carbamate (compound 29), having the structure shown below, was synthesized as described in Scheme 20 below. TIFF2024161074000087.tif60145

[0346] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-18-yl 2-(dimethylamino)ethyl(ethyl)carbamate (compound 29) TIFF2024161074000088.tif16128To a solution of dilinoleylmethanol (1.0 g, 1.9 mmol) and pyridine (230 μL, 4.7 mmol) in anhydrous ether (10 mL) cooled to −15° C. under nitrogen, diphosgene (0.38 mL, 3.14 mmol) was added slowly. The reaction was stirred at −15° C. for 1 h, then N,N-dimethyl-N′-ethyl-ethylenediamine (2.2 mL, 14.2 mmol) was added. The solution was warmed to room temperature and stirred for 30 min. The solution was diluted with diethyl ether (50 mL) and filtered to remove urea and ammonium salts. The ether filtrate was concentrated in vacuo to dryness and the residue was purified by column chromatography (100% ethyl acetate) to give the title compound as a colorless oil (990 mg, 78%). TIFF2024161074000089.tif22152

[0347] Example 19. Synthesis of Compounds 30 and 31 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(ethyl(methyl)amino)propyl)(methyl)carbamate (compound 30) and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(diethylamino)propyl)(methyl)carbamate (compound 31), having the structure shown below, were synthesized as described in Scheme 21 below. TIFF2024161074000090.tif119128

[0348] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-hydroxypropyl)(methyl)carbamate TIFF2024161074000091.tif16128 A solution of trichloromethylchloroformate (340 μL, 2.8 mmol) in anhydrous Et2O (5 mL) was cooled (-15 °C) and treated with a solution of dilinoleylmethanol (1.0 g, 1.9 mmol) and pyridine (230 μL, 2.8 mmol) in Et2O (5 mL). After stirring (1 h), the reaction mixture was filtered through a frit and the filtrate was added dropwise to a solution of 3-methylamino-propan-1-ol (1.1 mL, 11.3 mmol) in cold Et2O (5 mL) at 0 °C. After stirring (5 min), the reaction mixture was filtered and concentrated. The crude material was chromatographed (12% to 20% EtOAc-hexanes) to recover (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-hydroxypropyl)(methyl)carbamate (960 mg, 79%) as a colorless oil. Rf 0.17 (10% EtOAc-hexanes), FW 644.07, C 42 H 77 No.3.

[0349] Synthesis of 3-((((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)carbonyl)(methyl)amino)propyl methanesulfonate TIFF2024161074000092.tif15128 A solution of alcohol (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-hydroxypropyl)(methyl)carbamate (960 mg, 1.5 mmol) and triethylamine (0.7 mL) in anhydrous CHCl (7 mL) was cooled (-15 °C) and treated with a solution of methanesulfonyl chloride (230 μL) in CHCl (5 mL) for 5 min. After stirring (45 min), the solution was diluted with CHCl, washed with NaHCO (sat. aq.) and brine, dried (NaSO), filtered and concentrated. The crude material was chromatographed (20% EtOAc-hexanes) to recover 3-((((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)carbonyl)(methyl)amino)propyl methanesulfonate (1.0 g, 95%) as a colorless oil. Rf 0.5 (CH2Cl2), FW 722.16, C 43 H 79NO5S.

[0350] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(ethyl(methyl)amino)propyl)(methyl)carbamate (compound 30) TIFF2024161074000093.tif14128 A solution of ethylmethylamine (2 mL) in EtOH (10 mL) was treated with 3-((((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)carbonyl)(methyl)amino)propyl methanesulfonate (500 mg, 0.7 mmol) in CHCl (2.5 mL). The solution was stirred (50 h), concentrated, and chromatographed (EtOAc) to recover (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(ethyl(methyl)amino)propyl)(methyl)carbamate (305 mg, 64%) as a pale yellow oil. TIFF2024161074000094.tif51155

[0351] Synthesis of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(diethylamino)propyl)(methyl)carbamate (compound 31) TIFF2024161074000095.tif18128 A solution of diethylamine (2 mL) in EtOH (10 mL) was treated with 3-((((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)carbonyl)(methyl)amino)propyl methanesulfonate (500 mg, 0.7 mmol) in CHCl (2.5 mL). The solution was stirred (50 h), concentrated, and chromatographed (EtOAc) to recover (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(3-(diethylamino)propyl)(methyl)carbamate (207 mg, 42%) as a pale yellow oil. TIFF2024161074000096.tif43156

[0352] Example 20. Synthesis of compound 32 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 2-(1H-imidazol-1-yl)acetate (compound 32), having the structure shown below, was synthesized as described in Scheme 22 below. TIFF2024161074000097.tif55147

[0353] To a solution of dilinoleylmethanol (1.5 g, 2.8 mmol), 2-(1H-imidazol-1-yl)acetic acid (1.07 g, 8.5 mmol), and EDCI hydrochloride (1.8 g, 9.4 mmol) in anhydrous dichloromethane (25 mL) was added DMAP (10 mg). The solution was refluxed under nitrogen for 16 h. Upon completion, the solution was diluted with dichloromethane (100 mL) and washed with saturated sodium bicarbonate (100 mL). The sodium bicarbonate solution was back-extracted with dichloromethane (2×100 mL). The combined dichloromethane extracts were dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo. The residue was purified by column chromatography on silica gel 60 (column: 2″×6″ L; eluted with 1:1 hexane / ethyl acetate) to give the title compound as a colorless oil (700 mg, 39%). TIFF2024161074000098.tif32157

[0354] Example 21. Synthesis of Compound 33 1-(2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)ethyl)-1H-imidazole (compound 33), having the structure shown below, was synthesized as described in Scheme 23 below. TIFF2024161074000099.tif56147

[0355] Using a procedure similar to that described for the synthesis of 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether), 1-(2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)ethyl)-1H-imidazole was obtained as a pale yellow oil (600 mg, 24%). TIFF2024161074000100.tif29157

[0356] Example 22. Synthesis of compounds 34 to 37 3-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 34), 4-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylbutan-1-amine (compound 35), Compound 35), 2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylethanamine (compound 36), and 3-((6E,9E,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 37) were synthesized as described in Scheme 24 below. TIFF2024161074000101.tif135128

[0357] Synthesis of 3-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 34) TIFF2024161074000102.tif141283-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to 3-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylpropan-1-amine (2.26 g, 54%) as a pale yellow oil. TIFF2024161074000103.tif30156

[0358] Synthesis of 4-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylbutan-1-amine (compound 35) TIFF2024161074000104.tif15128 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to 4-((3Z,6Z,9Z,28Z,31Z,34Z)-heptatriaconta-3,6,9,28,31,34-hexaen-19-yloxy)-N,N-dimethylbutan-1-amine (1.33 g, 74%) as a pale yellow oil. TIFF2024161074000105.tif24157

[0359] Synthesis of 2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylethanamine (compound 36) TIFF2024161074000106.tif121283-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to 2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylethanamine (1.30 g, 52%) as a pale yellow oil. TIFF2024161074000107.tif23160

[0360] Synthesis of 3-((6E,9E,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 37) TIFF2024161074000108.tif161283-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to 3-((6E,9E,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (0.22 g, 56%) as a colorless oil. TIFF2024161074000109.tif22157

[0361] Example 23. Synthesis of compound 38 3-((6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 38), having the structure shown below, was synthesized as described in Scheme 25 below. TIFF2024161074000110.tif80128

[0362] 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to 3-((6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (1.23 g, 50%) from (6Z,9Z,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-ol as a colorless oil. TIFF2024161074000111.tif30150

[0363] Example 24. Synthesis of compound 39 N,N-diethyl-4-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)but-2-yn-1-amine (compound 39), having the structure shown below, was synthesized as described in Scheme 26 below. TIFF2024161074000112.tif81128

[0364] 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (MC3 ether) was prepared in a similar manner to N,N-diethyl-4-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)but-2-yn-1-amine (511 mg, 48%) from di-linoleyl mesylate (1.0 g, 1.6 mmol) and 4-diethylaminobutyn-1-ol (1.2 mL, 8.2 mmol). TIFF2024161074000113.tif24155

[0365] Example 25. Synthesis of compound 40 (6E,9E,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (compound 40), having the structure shown below, was synthesized as described in Scheme 27 below. TIFF2024161074000114.tif70128

[0366] (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3) was prepared in a similar manner to (6E,9E,28E,31E)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (2.9 g, 59%) as a colorless oil. TIFF2024161074000115.tif29150

[0367] Example 26. Synthesis of compound 41 3-((7E,9Z,28Z,30E)-heptatriaconta-7,9,28,30-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 41), having the structure shown below, was synthesized as described in Scheme 28 below. TIFF2024161074000116.tif100148

[0368] Synthesis of (9Z,11E)-methyloctadeca-9,11-dienoate TIFF2024161074000117.tif11128 (9Z,11E)-methyloctadeca-9,11-dienoate was synthesized according to the procedure described in U.S. Pat. No. 5,892,074, the disclosure of which is incorporated by reference in its entirety for all purposes.

[0369] Synthesis of (9Z,11E)-octadeca-9,11-dien-1-ol TIFF2024161074000118.tif9128To a suspension of lithium aluminum hydride (1.5 g, 38.7 mmol) in anhydrous ether (50 mL) cooled to 0° C. under nitrogen, a solution of (9Z,11E)-methyloctadeca-9,11-dienoate (11.6 g, 38.7 mmol) in anhydrous diethyl ether (50 mL + 25 mL rinse) was added slowly via cannula transfer. The solution was stirred at 0° C. for 2 h, then slowly quenched with 1 M NaOH (3.5 mL). The solution was dried over magnesium sulfate, filtered, and concentrated to dryness in vacuo to give the product as a colorless oil (9.5 g, 92%).

[0370] Synthesis of (9Z,11E)-octadeca-9,11-dienyl methanesulfonate TIFF2024161074000119.tif8128 Using a procedure similar to that described for the synthesis of dilinoleyl mesylate, (9Z,11E)-octadeca-9,11-dienyl methanesulfonate was obtained as a pale yellow oil (11.8 g, 96%).

[0371] Synthesis of (7E,9Z)-18-bromooctadeca-7,9-diene TIFF2024161074000120.tif8128 Using a procedure similar to that described for the synthesis of linoleyl bromide, (7E,9Z)-18-bromooctadeca-7,9-diene was obtained as a pale yellow oil (11.0 g, 97%).

[0372] Synthesis of (7E,9Z,28Z,30E)-heptatriaconta-7,9,28,30-tetraen-19-ol TIFF2024161074000121.tif12128 Using a procedure similar to that described for the synthesis of dilinoleylmethanol, (7E,9Z,28Z,30E)-heptatriaconta-7,9,28,30-tetraen-19-ol was obtained as a pale yellow oil (4.7 g, 53%).

[0373] Synthesis of 3-((7E,9Z,28Z,30E)-heptatriaconta-7,9,28,30-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine (compound 41) TIFF2024161074000122.tif15128 Using a procedure similar to that described for the synthesis of 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine, 3-((7E,9Z,28Z,30E)-heptatriaconta-7,9,28,30-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine was obtained as a pale yellow oil (1.3 g). TIFF2024161074000123.tif23155

[0374] Example 27. Synthesis of compound 42 3-((9Z,28Z)-heptatriaconta-9,28-dien-19-yloxy)-N,N-dimethylpropan-1-amine (compound 42), having the structure shown below, was synthesized as described in Scheme 29 below. TIFF2024161074000124.tif88146

[0375] Synthesis of oleyl bromide TIFF2024161074000125.tif9128 Using a procedure similar to that described for the synthesis of linoleyl bromide, oleyl bromide was obtained as a colorless oil (70.2 g, quantitative).

[0376] Synthesis of dioleylmethanol TIFF2024161074000126.tif12128 Using a procedure similar to that described for the synthesis of dilinoleylmethanol, dioleylmethanol was obtained as a colorless oil (46.6 g, 82%).

[0377] Synthesis of dioleyl mesylate TIFF2024161074000127.tif13128 Using a procedure similar to that described for the synthesis of dilinoleyl mesylate, dioleyl mesylate was obtained as a pale yellow oil (51.7 g, 97%).

[0378] Synthesis of 3-((9Z,28Z)-heptatriaconta-9,28-dien-19-yloxy)-N,N-dimethylpropan-1-amine (compound 42) TIFF2024161074000128.tif16128Using a procedure similar to that described for the synthesis of 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-1-amine, 3-((9Z,28Z)-heptatriaconta-9,28-dien-19-yloxy)-N,N-dimethylpropan-1-amine was obtained as a colorless oil (14.7 g, 28%). TIFF2024161074000129.tif22152

[0379] Example 28. Synthesis of compound 43 1-(1-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)-1H-1,2,3-triazol-4-yl)-N,N-dimethylmethanamine (compound 43), having the structure shown below, was synthesized as described in Scheme 30 below. TIFF2024161074000130.tif48128

[0380] Synthesis of dilinoleylmethyl azide TIFF2024161074000131.tif13128 A solution of dilinoleyl mesylate (6.27 g, 10.3 mmol) in anhydrous DMF (110 mL) was treated with NaN3 (3.35 g, 51.6 mmol) followed by heating (80 °C, 18 h). DMF was then removed under reduced pressure. The residue was dissolved in CH2Cl2, washed with saturated aqueous NaHCO3 (2x) and brine, dried (Na2SO4), filtered, concentrated, and purified by column chromatography (0.5% → 1% ethyl acetate / hexanes) to recover dilinoleylmethyl azide (4.89 g, 86%) as a colorless oil. FW 553.95, C 37 H 67 N3.

[0381] Synthesis of 1-(1-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)-1H-1,2,3-triazol-4-yl)-N,N-dimethylmethanamine (compound 43) TIFF2024161074000132.tif20128A solution of dilinoleylmethyl azide (500 mg, 0.90 mmol) and 3-dimethylamino-1-propyne (75 mg, 0.90 mmol) in HO / tert-butyl alcohol (1:1, 12 mL) was treated with sodium ascorbate (0.090 mmol, 17.9 μL taken from a 1 M aqueous solution) followed by CuSO4·5HO (2.3 mg, dissolved in 30 μL water) and stirred (96 h). The solution was then diluted with HO (50 mL), extracted with CHCl2 (3×), dried (NaSO4), filtered, concentrated, and purified by column chromatography (2%→4% MeOH / CH2Cl2) to recover the title compound as a colorless oil (524 mg, 91%). TIFF2024161074000133.tif30156

[0382] Example 29. Synthesis of compound 44 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N,N-trimethylpropan-1-aminium chloride (compound 44), having the structure shown below, was synthesized as described in Scheme 31 below. TIFF2024161074000134.tif71128

[0383] To a solution of compound 13 (3.0 g, 4.9 mmol) in dichloromethane (10 mL) was added iodomethane (4.5 mL, 73.5 mmol). The solution was stirred at room temperature for 16 h under nitrogen. Upon completion, the solution was concentrated in vacuo to dryness and dissolved in dichloromethane (150 mL). The solution was transferred to a separatory funnel and washed with 1 M HCl in methanol (40 mL). To this solution was added brine (50 mL) and the mixture was shaken thoroughly. The aqueous phase was removed and the previous washing procedure was repeated four more times to complete the ion exchange process. The dichloromethane solution was dried over magnesium sulfate, filtered and concentrated in vacuo to dryness. The yellow residue was purified by column chromatography on silica gel (100% ethyl acetate to 15% MeOH in ethyl acetate) to give the title compound as a colorless oil (2.3 g, 71%). TIFF2024161074000135.tif23153

[0384] Example 30. Lipid encapsulation of siRNA All siRNA molecules used in these studies were chemically synthesized and annealed using standard procedures.

[0385] In some embodiments, siRNA molecules were encapsulated in serum-stable nucleic acid-lipid particles (SNALP) composed of the following lipids: (1) lipid conjugate PEG2000-C-DMA (3-N-[(-methoxypoly(ethylene glycol)2000)carbamoyl]-1,2-dimyristyloxypropylamine) in a molar ratio of 1.4:57.1:7.1:34.3, respectively; (2) one or more cationic lipids or salts thereof (e.g., the cationic lipid of formula I of the present invention and / or other cationic lipids described herein); (3) the phospholipid DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Avanti Polar Lipids; Alabaster, AL); and (4) synthetic cholesterol (Sigma-Aldrich Corp.; St. Louis, MO). In other words, siRNA molecules are encapsulated in SNALP in the following "1:57" formulation: 1.4% PEG2000-C-DMA; 57.1% cationic lipid; 7.1% DPPC; and 34.3% cholesterol. It should be understood that the 1:57 formulation is a targeted formulation, and the amount of lipid (both cationic and non-cationic) present in the formulation and the amount of lipid conjugate present can vary. Typically, in a 1:57 formulation, the amount of cationic lipid is 57.1 mol% ± 5 mol%, the amount of lipid conjugate is 1.4 mol% ± 0.5 mol%, and the remainder of the 1:57 formulation will be composed of non-cationic lipid (e.g., phospholipid, cholesterol, or a mixture of the two).

[0386] In other embodiments, siRNA was encapsulated in SNALP composed of the following lipids: (1) lipid conjugate PEG750-C-DMA (3-N-[(-methoxypoly(ethylene glycol)750)carbamoyl]-1,2-dimyristyloxypropylamine) in a molar ratio of 6.76:54.06:6.75:32.43, respectively; (2) one or more cationic lipids or salts thereof (e.g., cationic lipids of formula I of the invention and / or other cationic lipids described herein); (3) the phospholipid DPPC; and (4) synthetic cholesterol. In other words, siRNA was encapsulated in SNALP in the following "7:54" formulation: 6.76 mol% PEG750-C-DMA; 54.06 mol% cationic lipid; 6.75 mol% DPPC; and 32.43 mol% cholesterol. Typically in a 7:54 formulation, the amount of cationic lipid will be 54.06 mol% ± 5 mol%, the amount of lipid conjugate will be 6.76 mol% ± 1 mol%, and the remainder of the 7:54 formulation will be composed of non-cationic lipid (e.g., phospholipid, cholesterol, or a mixture of the two).

[0387] For vehicle controls, empty particles with identical lipid composition can be formed in the absence of siRNA.

[0388] Example 31. Characterization of SNALP formulations containing novel cationic lipids This example demonstrates the efficacy of 1:57 SNALP formulations containing various novel cationic lipids of formula I described herein with siRNA targeting ApoB in a mouse liver model. The ApoB siRNA sequences used in this study are provided in Table 1.

[0389] (Table 1) TIFF2024161074000136.tif20153Column 1: The numbers after "ApoB" refer to the nucleotide position of the 5' base of the sense strand relative to the human ApoB mRNA sequence NM_000384. Column 2: 2'OMe nucleotides are shown in bold and underlined. The 3'-overhangs on one or both strands of the siRNA molecule may optionally contain 1-4 deoxythymidine (dT) nucleotides, 1-4 modified and / or unmodified uridine (U) ribonucleotides, or 1-2 additional ribonucleotides having complementarity to the target sequence or its complementary strand. Column 3: The number and percentage of 2'OMe-modified nucleotides in the siRNA molecule are provided. Column 4: The number and percentage of modified nucleotides in the double-stranded (DS) region of the siRNA molecule are provided.

[0390] 1:57 SNALP formulations containing encapsulated ApoB siRNA were prepared using DLin-C2K-DMA ("C2K") or compounds 1 (DLin-M-C3-DMA ("MC3")), 4, 5, 8, 9, 10, 11, 13, 15, 17, 18, 20, 22, 23, 25, 27, 28, 29, 30, 31, 34, 35, 40, or 41, as described in Section VI above.

[0391] SNALP formulations were administered by IV injection at 0.033 mg / kg or 0.05 mg / kg to Balb / c mice (n=3 per group). To assess ApoB mRNA relative to the housekeeping gene GAPDH, hepatic ApoB mRNA levels were assessed by branched DNA assay (QuantiGene assay) 48 hours after SNALP administration.

[0392] A comparison of the hepatic ApoB mRNA knockdown activity of each of these SNALP formulations is shown in Table 2. By way of non-limiting example, Table 2 illustrates that when administered at the same dose, SNALP formulations containing compounds 1, 4, 8, 13, 15, 27, 28, or 35 unexpectedly exhibited improved ApoB silencing activity compared to SNALP formulations containing the C2K benchmark cationic lipid.

[0393] Table 2. Effect of 1:57 SNALP containing novel cationic lipids on ApoB:GAPD administered at 0.05 or 0.033 mg / kg to Balb / c mice (48 hr, n=3). TIFF2024161074000137.tif119148

[0394] It should be understood that the above specification is intended to be illustrative and not limiting. Numerous embodiments will be apparent to those skilled in the art upon review of the above specification. Therefore, the scope of the present invention should not be determined by reference to the above specification, but instead by reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. The disclosures of all articles and references, including patent applications, patents, PCT publications, and Genbank accession numbers, are incorporated herein by reference for all purposes.

[0395] Sequence information SEQUENCE LISTING <110> ARBUTUS BIOPHARMA CORPORATION <120> Novel Cationic Lipids and Methods of Use Thereof <150> US 61 / 334,104 <151> 2010-05-12 <150> US 61 / 384,050 <151> 2010-09-17 <160> 2 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> twenty one <212> RNA <213> Artificial Sequence <220> <223> synthetic ApoB siRNA ApoB-10164 <220> <221> modified_base <222> (4)...(4) <223> n = gm <220> <221> modified_base <222> (8)...(8) <223> n = um <220> <221> modified_base <222> (14)...(14) <223> n = um <400> 1 agunucanca cacngaauac c 21 <210> 2 <211> 21 <212> RNA <213> Artificial Sequence <220> <223> synthetic ApoB siRNA ApoB-10164 <220> <221> modified_base <222> (4)...(4) <223> n = um <220> <221> modified_base <222> (7)...(7) <223> n = gm <220> <221> modified_base <222> (9)...(9) <223> n = gm <220> <221> modified_base <222> (19)...(19) <223> n = um <400> 2 uauncanunu gaugacacnu g 21

Claims

1. A cationic lipid of formula I having the following structure or a salt thereof: During the ceremony: R 1 and R 2 are the same or different and independently represent hydrogen (H) or optionally substituted C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl or C 2 -C 6 alkynyl or R 1 and R 2 may be taken together to form an optionally substituted heterocycle; R 3 is absent or is hydrogen (H) or C 1 -C 6 alkyl to provide a quaternary amine; R 4 and R 5 are the same or different and independently, optionally substituted C 10 -C 24 Alkyl, C 10 -C 24 Alkenyl, C 10 -C 24 Alkynyl, or C 10 -C 24 is acyl; X is O, S, N(R 6 ), C(O), C(O)O, OC(O), C(O)N(R 6 ), N(R 6 )C(O),OC(O)N(R 6 ), N(R 6 )C(O)O, C(O)S, C(S)O, S(O), S(O)(O), C(S), or an optionally substituted heterocycle, where R 6 is hydrogen (H) or optionally substituted C 1 -C 10 Alkyl, C 2 -C 10 Alkenyl or C 2 -C 10 alkynyl; and Y is an optionally substituted or absent C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl or C 2 -C 6 It is alkynyl.

2. R 1 and R 2 The cationic lipid of claim 1, wherein: are independently selected from the group consisting of a methyl group and an ethyl group.

3. R 1 and R 2 The cationic lipid of claim 1 or 2, wherein both of are methyl groups.

4. R 1 and R 2 The cationic lipid of any one of claims 1 to 3, wherein together they form an optionally substituted heterocycle having 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof.

5. X is O, C(O)O, C(O)N(R 6 ), N(R 6 5. The cationic lipid of claim 1, wherein the cationic lipid is C(O)O, or C(O)S.

6. R 6 is hydrogen (H) and an optionally substituted methyl group, ethyl group, or C 3 -C 10 The cationic lipid according to any one of claims 1 to 5, which is selected from the group consisting of an alkyl group, an alkenyl group, or an alkynyl group.

7. The cationic lipid of any one of claims 1 to 4, wherein X is an optionally substituted heterocycle having 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof.

8. Y is (CH 2 ) n and n is 0, 1, 2, 3, 4, 5, or 6.

9. 9. The cationic lipid of claim 8, wherein n is 2, 3, or 4.

10. R 4 and R 5 The cationic lipid according to any one of claims 1 to 9, wherein at least one of said cationic lipids comprises at least one unsaturated site.

11. R 4 and R 5 11. The cationic lipid of claim 10, wherein is independently selected from the group consisting of a dodecenyl moiety, a tetradecenyl moiety, a hexadecenyl moiety, an octadecenyl moiety, and an icocenyl moiety.

12. 12. The cationic lipid of claim 11, wherein the octadecenyl moiety is an oleyl moiety.

13. R 4 and R 5 13. The cationic lipid of claim 12, wherein both of said components are oleyl moieties.

14. R 4 and R 5 The cationic lipid according to any one of claims 1 to 9, wherein at least one of said cationic lipids comprises at least two unsaturated sites.

15. R 4 and R 5 15. The cationic lipid of claim 14, wherein is independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, and an icosadienyl moiety.

16. 16. The cationic lipid of claim 15, wherein the octadecadienyl moiety is a linoleyl moiety.

17. R 4 and R 5 17. The cationic lipid of claim 16, wherein both of said components are linoleyl moieties.

18. X is C(O)O and Y is (CH 2 ) 2 or (CH 2 ) 3 and R 4 and R 5 If both are linoleyl components, R 1 and R 2 The cationic lipid of claim 1, wherein both of are not methyl groups.

19. R 4 and R 5 The cationic lipid according to any one of claims 1 to 9, wherein at least one of said cationic lipids comprises at least three unsaturated sites.

20. R 4 and R 5 20. The cationic lipid of claim 19, wherein is independently selected from the group consisting of a dodecatrienyl moiety, a tetradecatrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, and an icosatrienyl moiety.

21. 21. The cationic lipid of claim 20, wherein the octadecatrienyl moiety is a linolenyl moiety or a gamma-linolenyl moiety.

22. R 4 and R 5 The cationic lipid of claim 21, wherein both of said amino acids are linolenyl moieties or gamma-linolenyl moieties.

23. Each of the at least one, two, or three unsaturated sites is selected from the group consisting of R 4 and R 5 The cationic lipid according to any one of claims 10 to 22, wherein the cationic lipid corresponds to a cis double bond, a trans double bond, or a combination thereof at a specific position in at least one of the following:

24. R 4 and R 5 At least one of the following is substituted C 12 -C 24 10. The cationic lipid of any one of claims 1 to 9, comprising an alkyl.

25. The substituted C 12 -C 24 Alkyl has at least 1 to 6 C 1 -C 6 C with alkyl substituents 12 -C 24 25. The cationic lipid of claim 24, comprising an alkyl.

26. R 4 and R 5 26. The cationic lipid of claim 25, wherein both of said components are phytanyl moieties.

27. R 4 or R 5 The cationic lipid according to any one of claims 1 to 9, wherein one of the groups comprises at least one optionally substituted cyclic alkyl group.

28. 28. The cationic lipid of claim 27, wherein the optionally substituted cyclic alkyl group comprises an optionally substituted saturated cyclic alkyl group, an optionally substituted unsaturated cyclic alkyl group, or a combination thereof.

29. The optionally substituted saturated cyclic alkyl group is 3-8 30. The cationic lipid of claim 28, comprising a cycloalkyl group.

30. 30. The cationic lipid of claim 28 or 29, wherein the optionally substituted saturated cyclic alkyl group comprises a cyclopropyl group.

31. The optionally substituted unsaturated cyclic alkyl group is 3-8 30. The cationic lipid of claim 28, comprising a cycloalkenyl group.

32. the below described:

2. The cationic lipid of claim 1, having a structure selected from the group consisting of:

33. A lipid particle comprising the cationic lipid of any one of claims 1 to 32.

34. 34. The lipid particle of claim 33, further comprising a non-cationic lipid.

35. 35. The lipid particle of claim 34, wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol.

36. 36. The lipid particle of claim 35, wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

37. The lipid particle of claim 35, wherein the cholesterol is a cholesterol derivative.

38. The lipid particle of any one of claims 33 to 37, further comprising an associated lipid that inhibits aggregation of the particles.

39. 40. The lipid particle of claim 38, wherein the bound lipid that inhibits particle aggregation comprises a polyethylene glycol (PEG)-lipid conjugate.

40. 40. The lipid particle of claim 39, wherein the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.

41. The lipid particle of any one of claims 33 to 40, further comprising a therapeutic agent.

42. The lipid particle of claim 41 , wherein the therapeutic agent is a nucleic acid.

43. The lipid particle of claim 42, wherein the nucleic acid is an interfering RNA.

44. The lipid particle of claim 43, wherein the interfering RNA is selected from the group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), and mixtures thereof.

45. The lipid particle of claim 43 or 44, wherein the interfering RNA is a siRNA.

46. The lipid particle of any one of claims 41 to 45, wherein the therapeutic agent is not substantially degraded after incubation of the particle in serum at 37°C for 30 minutes.

47. The lipid particle of any one of claims 41 to 46, wherein the therapeutic agent is fully encapsulated in the particle.

48. 48. The lipid particle of any one of claims 41-47, having a lipid:therapeutic agent mass ratio of about 5:1 to about 15:

1.

49. The lipid particle of any one of claims 33 to 48, having a median diameter of about 30 nm to about 150 nm.

50. 50. A pharmaceutical composition comprising the lipid particle of any one of claims 33 to 49 and a pharma- ceutically acceptable carrier.

51. 49. A method for introducing a therapeutic agent into a cell, comprising the step of contacting said cell with a lipid particle according to any one of claims 41 to 48.

52. The method of claim 51 , wherein the cell is in a mammal.

53. 49. A method for in vivo delivery of a therapeutic agent, comprising administering to a mammal the lipid particle of any one of claims 41-48.

54. 54. The method of claim 53, wherein said administration is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal.

55. 55. The method of claim 53 or 54, wherein the mammal is a human.

56. 50. A method for treating a disease or disorder in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a lipid particle according to any one of claims 41 to 48.

57. 57. The method of claim 56, wherein the disease or disorder is selected from the group consisting of a viral infection, a liver disease or disorder, and cancer.

58. 58. The method of claim 56 or 57, wherein the mammal is a human.